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Background: Between 50% and 80% of people with multiple sclerosis (PwMS) experience neurogenic
bowel dysfunction (NBD) (i.e. constipation and faecal incontinence) that affects quality of life and can lead
to hospitalisation.
Objectives: To determine the clinical effectiveness and cost-effectiveness of abdominal massage plus
advice on bowel symptoms on PwMS compared with advice only. A process evaluation investigated the
factors that affected the clinical effectiveness and possible implementation of the different treatments.
Design: A randomised controlled trial with process evaluation and health economic components. Outcome
analysis was undertaken blind.
Setting: The trial took place in 12 UK hospitals.
Participants: PwMS who had ‘bothersome’ NBD.
Intervention: Following individualised training, abdominal massage was undertaken daily for 6 weeks
(intervention group). Advice on good bowel management as per the Multiple Sclerosis Society advice booklet
was provided to both groups. All participants received weekly telephone calls from the research nurse.
Main outcome measures: The primary outcome was the difference between the intervention and control
groups in change in the NBD score from baseline to week 24. Secondary outcomes were measured via a
bowel diary, adherence diary, the Constipation Scoring System, patient resource questionnaire and the
EuroQol-5 Dimensions, five-level version (EQ-5D-5L).
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Results: A total of 191 participants were finalised, 189 of whom were randomised (two participants were
finalised in error) (control group, n = 99; intervention group, n = 90) and an intention-to-treat analysis
was performed. The mean age was 52 years (standard deviation 10.83 years), 81% (n = 154) were female
and 11% (n = 21) were wheelchair dependent. Fifteen participants from the intervention group and five from
the control group were lost to follow-up. The change in NBD score by week 24 demonstrated no significant
difference between groups [mean difference total score –1.64, 95% confidence interval (CI) –3.32 to 0.04;
p = 0.0558]; there was a significant difference between groups in the change in the frequency of stool
evacuation per week (mean difference 0.62, 95% CI 0.03 to 1.21; p = 0.039) and in the number of times per
week that participants felt that they emptied their bowels completely (mean difference 1.08, 95% CI 0.41 to
1.76; p = 0.002), in favour of the intervention group. Of participant interviewees, 75% reported benefits, for
example less difficulty passing stool, more complete evacuations, less bloated, improved appetite, and 85%
continued with the massage. A cost–utility analysis conducted from a NHS and patient cost perspective found
in the imputed sample with bootstrapping a mean incremental outcome effect of the intervention relative
to usual care of –0.002 quality-adjusted life-years (QALYs) (95% CI –0.029 to 0.027 QALYs). In the same
imputed sample with bootstrapping, the mean incremental cost effect of the intervention relative to usual
care was £56.50 (95% CI –£372.62 to £415.68). No adverse events were reported. Limitations include
unequal randomisation, dropout and the possibility of ineffective massage technique.
Conclusion: The increment in the primary outcome favoured the intervention group, but it was small and
not statistically significant. The economic analysis identified that the intervention was dominated by
the control group. Given the small improvement in the primary outcome, but not in terms of QALYs,
a low-cost version of the intervention might be considered worthwhile by some patients.
Future work: Research is required to establish possible mechanisms of action and modes of massage delivery.
Trial registration: Current Controlled Trials ISRCTN85007023 and NCT03166007.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 58.
See the NIHR Journals Library website for further project information.
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Plain English summary
The symptoms of neurogenic bowel dysfunction (NBD) are constipation and/or faecal incontinence; NBDis common in people with multiple sclerosis (PwMS) and affects their quality of life. The Abdominal
Massage for Bowel Dysfunction Effectiveness Research (AMBER) study aimed to find out whether or not
abdominal massage improved the symptoms of NBD in PwMS.
In total, 191 eligible participants who felt that their constipation was ‘bothersome’ were allocated
randomly to either:
l advice on the management of NBD (control group, n = 100 participants)
l advice and abdominal massage (intervention group, n = 91 participants).
Quality-of-life questionnaires and a bowel diary were completed by all participants at the start of the
trial, at the end of 6 weeks of intervention and again at 24 weeks. To further assess the intervention,
20 participants had telephone interviews at the beginning and end of the trial.
Researchers wanted to know if participants in the intervention group had an improvement in their bowel
symptoms compared with the control group at week 24.
At the end of the study, the main symptom questionnaires showed a slight, but not statistically significant,
improvement in the intervention group (i.e. not much difference between groups) and the economic
analysis showed it was more expensive. However, at the end of the study, participants in the intervention
group did register some important findings, they:
l passed stools more frequently
l felt that they emptied their bowel more completely
l generally took fewer laxatives
l felt better.
The interviews also identified that participants liked that:
l drugs were not involved
l they could do the massage themselves
l there was a lack of adverse side effects.
Given the small improvement in the primary outcome but not in terms of cost-effectiveness, a low-cost
version of the intervention, for example as part of a self-management pathway, might be considered by
some patients.
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Scientific summary
Background
Multiple sclerosis (MS) has an increasing prevalence in the UK and is the most common neurological
condition in young adults, affecting > 100,000 people at present. It is estimated that 60% of people
with multiple sclerosis (PwMS) have problematic neurogenic bowel dysfunction (NBD). NBD is rated as one
of the most devastating scenarios affecting these people and includes symptoms of constipation, faecal
incontinence (FI), bowel evacuation difficulties or a combination of these. Constipation can lead to the
individual becoming housebound, spending hours trying to empty their bowels and limiting their ability
to work, whereas FI is often described as the most devastating event imaginable, leading to social and
emotional issues. Management of NBD in PwMS has been underexplored and lacks supporting evidence.
It is costly both in terms of carer and patient time and to the NHS. PwMS have two or three times more
admissions to hospital for bowel complications than people without MS. PwMS use laxatives, suppositories,
prolonged digital rectal stimulation and/or rectal irrigation but often these interventions have inconsistent
results. Abdominal massage is a minimally invasive modality potentially stimulating gut motility. A Cochrane
review (McClurg D, Hagen S, Dickinson L and Campbell P, Glasgow Caledonian University, 2018) reported
significant benefits in the reduction of the symptoms of constipation in several small trials with heterogeneous
populations. Abdominal massage may offer a new option in the pathway to treat NBD.
Objectives
The aim of this study was to assess the clinical effectiveness and cost-effectiveness of adding abdominal
massage to the provision of advice calls compared with advice only, with both groups being supported
by weekly telephone calls. We also aimed to identify and investigate, via a process evaluation substudy,
pilot transit and anorectal physiological substudy, the mediating factors that affected the clinical
effectiveness and possible implementation to identify possible mechanisms of action.
All outcomes were undertaken at baseline, weeks 6 and 24.
Primary outcome
The primary outcome was the difference in change between the intervention and control groups in the
Neurogenic Bowel Dysfunction Score (NBDS) from baseline to week 24.
Secondary outcomes
l Change in the Constipation Scoring System (CSS) from baseline to weeks 6 and 24.
l Information from the study trial-specific 7-day bowel diary (recorded at baseline, weekly during the
6 weeks of intervention, and during week 23).
l Bladder dysfunction, as measured by the Short Form (SF)-Qualiveen.
l Quality of life as measured by the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), and by a novel
NBD questionnaire.
l Resource use as collected by a patient resource questionnaire.
l Bowel transit and anorectal physiological tests (one centre only) undertaken pre intervention and at
week 24.
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Other outcomes recorded at each telephone conversation
l Change in medication.
l Adverse events.
Process evaluation outcomes
l Qualitative interviews with 20 participants were conducted before and after undertaking the
intervention (n = 40).
l Interviews with health-care professionals (HCPs) (n = 25) involved in the delivery of the trial were
conducted shortly after starting the study and/or at the end of the study (n = 42).
l Interviews with six key stakeholders involved with incontinence policy or services for PwMS were
conducted at only one stage of the study (n = 6).
Methods
The study was a UK-based, multicentre, pragmatic, parallel-group randomised controlled trial (RCT). There
was 1 : 1 allocation between the groups, with stratification by site and minimisation on level of disability.
Eligibility was being ‘bothered’ by bowel symptoms.
Inclusion criteria
l Males or females aged ≥ 18 years.
l A diagnosis of MS (no MS relapse in the previous 3 months).
l No major change of medication in the previous 1 month.
l Not used abdominal massage in the previous 2 months.
Exclusion criteria
l Being unable to undertake the massage themselves and did not have a carer willing to do it.
l Being unable to understand the study processes in order to give informed consent.
l Contraindications to abdominal massage, for example abdominal/pelvic cancer, hiatus, inguinal or
umbilical hernia, rectal prolapse, inflammatory bowel disease or abdominal scars, abdominal wounds or
skin disorders.
l Being pregnant.
After assessment for eligibility and completion of informed consent, each participant was scheduled for one
study visit for collection of baseline data. Details were entered into a bespoke database held at Dundee
Clinical Trials Unit, which facilitated immediate on-screen randomisation with allocation concealment. All
participants were provided with the MS Society Booklet on bowel management. Those in the intervention
group additionally received instruction in undertaking the massage (to be given by self or carer), had the
massage demonstrated on them and they or their carer were given the opportunity to ask questions and
undertake supervised practice. A digital versatile disc (DVD) showing the massage and two leaflets outlining
it were also provided. Participants were recommended to undertake the massage daily for ≈10 minutes.
Sample size for the RCT was based on the NBD score using data from a pilot study. To detect a difference
between groups of 4.21 [standard deviation (SD) 7.02] at a 5% level of significance with 90% power,
60 participants per group were needed. Thus, for a fully powered study the total sample size, allowing for
a 20% dropout rate, was 150 participants. However, in response to suggestions from the funding body,
the sample size was increased to 200 participants (100 per group), which allowed for greater attrition.
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Ethics approval for the study was granted by the West of Scotland Research Ethics Committee 4, on
11 June 2014 (reference number 14/WS/0111). A total of 11 NHS trusts/health boards granted 12 local
NHS site recruitment approvals (two different hospitals belonged to one trust). The study sponsor was
Glasgow Caledonian University (GCU) and the Abdominal Massage for Bowel Dysfunction Effectiveness
Research (AMBER) trial office was based in the Nursing, Midwifery and Allied Health Professions Research
Unit (NMAHP RU) at GCU.
Statistical analysis
Categorical data are presented using counts and percentages; continuous variables are presented using mean
(SD) and absolute differences are presented with 95% confidence intervals (CIs). Data for continuous outcome
measures (both primary and secondary) were assessed for normality before analysis. Transformations of the
outcome variables were used when necessary, if these were not normally distributed.
If data were normally distributed, outcome measures were assessed by multiple linear regression. The
primary analysis consisted of comparisons between treatment groups (bowel massage vs. no massage) at
the final visit (week 24), adjusted for site, minimisation on level of mobility (walking unaided, aided or
wheelchair bound) as well as baseline measure of the outcome and sex.
In a secondary analysis of the primary outcome, the baseline variables of age, sex, body mass index (BMI),
type of MS, number of years since diagnosis, cognitive symptoms of MS and minimisation variable on level
of mobility (walking unaided, aided or wheelchair bound) were included in the model.
When data were not normally distributed and could not be transformed into a normal distribution, data
were analysed using non-parametric methods in addition to multiple linear regression.
In addition to the comparison of baseline data with week 24 outcomes, a repeated measures analysis was
performed on the outcomes using all available visits.
Data for categorical outcome measures were assessed by logistic regression in the same way as described
for continuous outcome measures.
Statistical significance was taken as two-sided p-value of ≤ 0.05.
Results
Information about the study was given to 389 patients; of these, 273 (60.9%) patients were screened and
191 (48.1%) were randomised: 90 (47.1%) were allocated to the intervention group and 100 (51.8%)
to the control group. The number of participants per site ranged from 9 to 26 (median 16 participants).
Of the randomised participants, 22 did not complete the study. Two of these were post-randomisation
exclusions (essentially randomised in error) from whom data were not collected, leaving 189 for analysis.
Fifteen participants in the intervention group and five in the control group withdrew or were lost to
follow-up. The missingness of any data appeared to be at random with no obvious bias.
Baseline
Women constituted 81% (154/189) of participants and the mean age of all participants was 53 years
(range 26–79 years). The mean time since diagnosis of MS was 14.3 years (range 0–51 years). Demographics
and clinical symptom profiles of the two groups were evenly matched. Bowel symptoms had commenced
> 10 years previously in 37% of participants and < 1 year previously in 4% of participants. The main bowel
DOI: 10.3310/hta22580 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 58
© Queen’s Printer and Controller of HMSO 2018. This work was produced by McClurg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxv
symptoms reported by participants at baseline were feelings of incomplete emptying, straining to pass stool
and bloating.
Primary outcome
At baseline, for the intervention group, the mean total NBDS was 7.6 points (SD 5.31 points) and for
the control group it was 8.6 points (SD 5.08 points). At week 24, the mean total NBDS was 7.4 points
(SD 5.23 points) for the intervention group and 8.7 points (SD 5.70 points) for the control group. The mean
difference in change of NBDS between groups was not statistically significantly different for the total score in
our primary outcome measure at 24 weeks (–1.61 points, 95% CI –3.32 to 0.04 points; p = 0.0558).
Secondary outcomes (primary analysis)
At baseline, the intervention group had a total mean CSS score of 11.7 points (SD 4.05 points) and the
control group had a total mean CSS score of 11.5 points (SD 3.77 points). At week 24, the intervention
group had a mean CSS score of 10.1 points (SD 4.10 points) and control group had a mean CSS score of
11.1 points (SD 3.91 points). There was no significant mean difference in change of CSS score between
groups at week 24 (–0.88 points, 95% CI –2.03 to 0.27 points; p = 0.1308).
There were virtually no differences between the two groups, either at baseline or at post treatment, in the
SF-Qualiveen or in the EQ-5D-5L.
In our feasibility study on mechanistic evaluation, the low number of participants (11/23) that completed
the transit study and anorectal physiology tests make it impossible to undertake meaningful analysis on
differences between groups. However, just over 60% of all participants demonstrated slow colonic transit
at baseline.
Bowel diary
The mean frequency of stools passed per week at baseline in the intervention group was 3.9 (SD 1.68),
and for the control group it was 4.0 (SD 1.74) stools passed per week. At week 24, the frequency of
stools passed per week for the intervention group was 4.3 (SD 1.88) and for the control group it was 3.9
(SD 1.89). This was a significant mean difference in change between the groups of 0.62 stools per week
(95% CI 0.03 to 1.21 stools per week; p = 0.039).
There was no significant difference in the mean change between groups in time spent on the toilet or the
number of attempts to pass stool at week 24: –3.35 minutes (95% CI –23.1 to 16.4 minutes; p = 0.7377)
and 1.14 attempts (95% CI 0.92 to 3.19 attempts; p = 0.2770).
There was a significant difference in the mean change between groups in the number of times the
participants felt that they had successfully emptied their bowel at week 24 (1.08 times, 95% CI 0.41 to
1.76 times; p = 0.002), with the intervention group showing greater effect.
Using repeated measures analysis, statistically significant results were also found at week 6 for the number
of stools passed per week [odds ratio (OR) 0.98, 95% CI 0.36 to 1.61; p = 0.039] and the number of
times participants felt that their bowels were emptied (OR 0.56, 95% CI 0.03 to 1.10; p = 0.039), with the
intervention group showing greater effect. However, this effect decreased for both outcomes at week 24.
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There is also some evidence that the laxative use at week 24 was twice as likely to be lower in the
intervention group than the control group (OR 2.37, 95% CI 0.87 to 6.46; p = 0.092).
Other outcomes
Regression analysis indicated a greater response in the intervention group for participants walking unaided
or aided than for those using a wheelchair. Older participants and those with a higher BMI also did slightly
better. The time since diagnosis of MS did not seem to be important, but those with relapsing–remitting
MS responded better than those with primary or secondary progressive MS. Cognition severity indicated
that those with mild cognitive impairment did better than those with more severe impairment. Consistent
with other findings, the outcomes for males were significantly better than the outcomes for women
(OR –2.789, 95 % CI –5.179 to –0.399; p = 0.0226).
Serious adverse events
There were nine serious adverse events (SAEs); none was related to the trial and all were resolved.
Process evaluation
From the intervention group, 20 participants were interviewed twice: at baseline and at the end of the
intervention period. The recordings were transcribed and then supported by NVivo, version 10 (QSR
International, Warrington, UK). All 20 completed the study, with 15 reporting benefits such as increased
frequency of stools and feeling complete evacuation more often. Other benefits not recorded by trial
measures represented important improvements in quality of life for participants, including increased
appetite, greater energy, better sleep and greater control over bowel function. Participants shared their
experiences of administering the massage, including solutions that they had devised to manage any
difficulties. Comparison with change in our primary outcome measure identified inconsistencies in what
a participant was saying in the interviews and change in total score. For the five interviewees who felt
that there was no change in their bowel habits, analysis of their bowel diaries and interviews gave
some indication as to why the treatment may not have worked for them – they had an ideal stool type at
baseline and they struggled to administer the massage because of poor dexterity, fatigue and weakness.
Eighteen interview participants reported that they would continue with the massage beyond 24 weeks.
The HCP interviewees (n = 25) were involved with recruitment and had been trained in delivering the
massage intervention. Most reported that recruitment of study participants was aided by the fact that
this was a non-pharmacy intervention and could be performed by the participant themselves. The six
stakeholders identified that there was a lack of evidence-based interventions for patients with NBD and,
potentially, abdominal massage could offer a safe, non-expensive additional option for managing
bowel problems.
Economic evaluation
A cost–utility analysis was conducted from a NHS and patient cost perspective. The mean incremental cost
for the intervention group compared with the control group was £56.50 (95% CI –£372.62 to £415.68).
The incremental gain in quality-adjusted life-years (QALYs) was –0.002 QALYs (95% CI –0.029 to 0.027
QALYs). Given these results, the intervention appears to be dominated by the control group.
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Conclusions
Abdominal massage is a non-invasive, non-pharmacological intervention. Although the increment in the
primary outcome favoured the intervention group, it was small and not statistically significant, and the
economic analysis identified that the intervention was dominated by the control group. Given the small
improvement in the primary outcome, but not in terms of QALYs, a low-cost version of the intervention,
for example as part of a self-management pathway, might be considered worthwhile by some patients.
Some secondary outcomes were in favour of the intervention and reached statistical significance with
15 out of 20 interviewees reporting improvements.
Additional research is required to further establish validated outcome measures in this population,
as well as further mechanistic investigations.
Trial registration
The trial is registered as ISRCTN85007023, and on ClinicalTrials.gov as NCT03166007.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific background
The prevalence of multiple sclerosis (MS) is increasing in the UK, and MS is the most common neurological
condition in young adults (the average age at onset is 34 years), affecting > 100,000 people at present.1
It is estimated that 60% of people with multiple sclerosis (PwMS) have problematic neurogenic bowel
dysfunction (NBD);2 increased life-expectancy rates, as a result of advances in health care, present additional
challenges of the ageing bowel.3 NBD is rated as one of the most distressing scenarios affecting these
patients and includes the symptoms of constipation and faecal incontinence (FI).4 Constipation can lead to
the individual becoming housebound, spending hours trying to empty their bowels and limiting their ability
to work; whereas FI is often described as the most devastating event imaginable, leading to social and
emotional issues.5 A MS Trust report6 published in April 2017 revealed that emergency admissions (many of
which are thought to be preventable) to hospital for PwMS have increased by 12.7% over the 2 years 2015/16,
with overall admissions for bladder- and bowel-related issues, for example impaction, costing £10.4M in
2015/16.
Aetiology of neurogenic bowel dysfunction
Aetiology of NBD in PwMS is multifactorial; reduced mobility and polypharmacy may have a contributory
causative role. Coincidental pelvic nerve lesion, occurring during childbirth, could also contribute to FI in
women with MS.7 Spinal cord lesions appear to be most important in the pathogenesis of NBD symptoms
in MS.8 The pathways of neural control of defecation are not fully defined; however, cortical and pontine
centres may play a pivotal role in the regulation of sacral segments.8,9
Conduction times of central motor pathways to sphincteric sacral neurons and pelvic floor striated muscle
have been shown to be prolonged in MS.10 Impaired anorectal sensation may also contribute to the
symptoms; somatosensory-evoked potentials were delayed in PwMS compared with controls in one study.11
Loss of central modulation on spinal cord segments may lead to sympathovagal imbalance, which, in turn, can
lead to constipation, characterised by lengthened colon transit time.12 Constipation has thus been attributed to
rectal outlet obstruction, absent or incomplete puborectalis, anal canal and sphincter musculature relaxation,
and prolonged colonic transit time.10,13 Regarding FI, studies have described reduced sensation of rectal filling,
reduced rectal compliance, low anal sphincter pressures and hyper-reactivity of the rectal wall. The coexistence
of FI and constipation can be explained by inco-ordinated action of the external/internal anal sphincter
during expulsion; poor pelvic musculature relaxation may cause incomplete emptying of the rectum, which
precipitates FI when anal sphincter weakness and anorectal hyposensitivity are present.14,15
Current treatment/management options
Management of NBD in PwMS has been little explored and lacks supporting evidence.16 It is costly both in
terms of patient time and to the NHS (e.g. PwMS have two to three times more admissions to hospital for
bowel complications than non-MS patients).17 It also has an impact on the families and carers of PwMS.18
PwMS use laxatives, suppositories, prolonged digital rectal stimulation and/or rectal irrigation, but often
these interventions have inconsistent results. For example, one patient in our previous study would take
laxatives two evenings per week, but then could not leave the house the next day as he had no control
over when he would pass stool.5
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Evidence for the clinical effectiveness of abdominal massage
for constipation
A Cochrane systematic review19 has been undertaken to determine the effects of abdominal massage
for the relief of symptoms of chronic constipation in comparison with no treatment or other treatment
options. Nine randomised controlled trials (RCTs) (12 randomised comparisons) involving 427 participants
were included in the review.19 The study populations were small (with a maximum of 32 participants per
group), heterogeneous and all were rated as having a moderate or high risk of bias. Findings from two
trials suggested that abdominal massage compared with advice from a physician provided significant
additional relief of symptoms from constipation in the short term. Two trials found no significant
differences between groups. One trial, which had the three groups (aroma massage, plain massage
and control), reported that both the aroma massage group and the plain massage group had an improved
quality of life. The review concluded that there were insufficient data to allow reliable conclusions to be
drawn on the effects of abdominal massage in the management of constipation. There was some evidence
to suggest that there might be a therapeutic effect; however, larger, more rigorous trials are required to
provide evidence of both the clinical effectiveness and the cost-effectiveness of abdominal massage.
How the intervention might work
There is some evidence to suggest that abdominal massage will reduce colonic transit time and enable
predictable complete evacuation; however, the possible mechanism of action is not yet fully understood.20,21
The function of the gastrointestinal tract is influenced by, among other things, activity in the parasympathetic
division in the autonomic nervous system. Stimulation of the parasympathetic division increases the motility
of the muscles, increases the digestive secretions and relaxes sphincters in the gastrointestinal canal.22–24
Massage is thought to stimulate peristalsis in the gut by producing rectal muscular waves that stimulate the
somatoautomatic reflex and initiate bowel sensation, thereby reducing colonic transit time.25 Furthermore,
the active massaging action may result in a softening of stool consistency, allowing the stool to be passed
more easily.26
Development of the intervention
The abdominal massage intervention used within this trial was based on massage as formally taught in
physiotherapy training within the UK and used by an expert in the area in earlier studies.27–29 This expert
was involved in the development of the training materials and in the training of the clinicians undertaking
the massage. All clinicians involved with teaching the massage to participants underwent 1 half day of
training in the massage technique, as well as presentations on NBD and good bowel care. Information
provided to participants on bowel care was based on the MS Society’s handbook on bowel management.
A description of the intervention has previously been published.30 A copy of the training materials is
available in Appendix 1.
Who delivers the intervention
In previous studies, the massage was delivered by a health-care professional (HCP) with experience in
massage, a family carer or by the patient themselves. It was discovered, however, that the amount of training
and support received by participants is poorly described. In this trial, the massage was designed and taught to
be either self-massage or undertaken by a ‘carer’. Likewise, the training of the ‘trainers’ (HCPs involved in
seeing the patient and teaching the massage) was such that it was delivered in one half-day session, but also
required individuals to undertake further practice, to consolidate their training. If this limited training plus
support materials for HCPs and patients were to prove effective, then the abdominal massage could
potentially be implemented in many settings to patient populations who experience constipation.
INTRODUCTION
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Hypothesis
A 6-week intervention of abdominal massage and bowel management advice (intervention group) will
improve symptoms and quality of life in PwMS who have NBD compared with advice alone (control group).
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Chapter 2 Trial design and methods design
The Abdominal Massage for Bowel Dysfunction Effectiveness Research (AMBER) trial was designed toevaluate whether or not abdominal massage is an effective treatment in reducing the symptoms of
NBD, particularly constipation, in PwMS. This trial was a multicentre, patient-randomised, superiority trial
comparing the following in PwMS who have stated that their constipation is ‘bothersome’: an intervention
of optimised bowel care with once-daily abdominal massage for 6 weeks with the control of optimised
bowel care without massage. A description of the trial protocol has already been published.30
The main trial was supported by a process evaluation to explore the possible mediating factors that
may affect the clinical effectiveness of the intervention, how these mediating factors influence clinical
effectiveness, and whether or not the factors differ between the randomised groups. Trial processes were
evaluated to provide evidence of potential importance in the future implementation of the intervention
(see Chapter 5).
The main study objectives were to:
l establish if an optimised bowel care programme (i.e. provision of advice/information on bowel
management) with abdominal massage, compared with an optimised bowel care programme alone,
is more clinically effective and cost-effective in reducing the symptoms of NBD at week 24 in PwMS
l identify and investigate, via a process evaluation, the possible mediating factors that affect the
clinical effectiveness of the intervention (including intervention fidelity), how these mediating factors
influence clinical effectiveness and whether or not the factors differ between the randomised groups
(see Chapter 5)
l undertake a formal economic evaluation of the interventions from a NHS and a patient perspective
(see Chapter 4)
l undertake a feasibility study relating to the mechanisms of action using anal manometry and colonic
transit tests at one tertiary bowel centre where these tests are routinely undertaken
l record data to validate the responsiveness of a questionnaire to change in quality of life following
an intervention.
Ethics approval and research governance
Ethics approval for the trial was granted by the West of Scotland Research Ethics Committee (REC)
4 on 11 June 2014 (reference number 14/WS/0111). NHS approval was granted for 10 different trusts/
foundation trusts in England, and two local health boards granted approval for the two sites in Scotland.
The trial sponsor was Glasgow Caledonian University (GCU) and the AMBER trial office was based in the
Nursing, Midwifery and Allied Health Professions Research Unit (NMAHP RU) at GCU. The AMBER trial
was registered with the International Standard Randomised Controlled Trial Number (ISRCTN) registry
(ISRCTN85007023) and on ClinicalTrials.gov (NCT03166007).
Participants
The trial recruited PwMS who reported that they were ‘bothered’ (in their own judgement) by their NBD
symptoms at 12 sites across UK (n = 2 in Scotland and n = 10 in England).
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Inclusion criteria
People were eligible for the trial if they met the following inclusion criteria:
l bothered by their NBD
l aged ≥ 18 years
l diagnosis of MS (in a stable phase, i.e. no MS relapse in the previous 3 months)
l no major change of medication in the previous 1 month [e.g. introduction of disease-modifying
treatments (DMTs)]
l not used abdominal massage in the previous 2 months.
Exclusion criteria
l Being unable to undertake the massage themselves and did not have a carer willing to do it.
l Being unable to understand the trial processes in order to give informed consent.
l Contraindications to abdominal massage, which included the following: history of abdominal/pelvic
cancer, hiatus, inguinal or umbilical hernia, rectal prolapse, inflammatory bowel disease, volvulus
and pregnancy.
l Abdominal scars, abdominal wounds or skin disorders that may make abdominal massage
uncomfortable.
If a potential participant reported recent sudden and severe changes in bowel habits or rectal bleeding,
these symptoms were first discussed with the consultant at the relevant site to determine suitability.
Recruitment procedure
The research team at each trial site were responsible for identifying potential participants. Following
identification of potentially eligible individuals, a letter of introduction and an ‘expression of interest’
form was either posted or given to patients at their routine clinic appointment. Each patient approached
about the trial was allocated a unique participant identifier number. This consisted of six characters: three
letters that were an abbreviation of the site name followed by three numbers that were allocated on a
consecutive basis (e.g. 001 for first participant). This unique identifier was used throughout the trial and
was added to all participant paperwork. Once a completed ‘expression of interest’ form was returned,
a member of the research team telephoned the individual to provide further information and assess
eligibility. If eligible and willing to take part, the individual was sent a baseline appointment letter along
with a 7-day bowel diary for completion. The participant completed the bowel diary the week before the
baseline appointment. Participants were also asked to bring someone who was willing to do the massage
to this appointment, if required.
Informed consent
Informed, written consent was obtained for all participants at the baseline appointment and included
consent to any site-specific tests. The REC agreed to the completion of bowel diaries before the baseline
appointment, as the participants’ consent was implied by them willingly completing the diary. There
was no use of these data until participants had provided written informed consent; this method aided
recruitment to the trial because it meant that there was only one clinic visit required. Participants were
made aware that the treatment was allocated at random, regardless of any personal preference they had.
They had the right to withdraw from the trial at any time and for any reason; all participants were also
made aware that withdrawal would not affect their routine care.
TRIAL DESIGN AND METHODS DESIGN
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The consent form also had the option for the participant to be contacted if they were interested in taking
part in the process evaluation interviews. Chapter 5 explains the consent method followed for this part
of the study. The general practitioners (GPs) of all those who took part in the trial were informed of
their involvement.
Randomisation, concealment and blinding
Participants who provided written informed consent were randomly allocated to one of two treatment
groups during their baseline appointment: (1) advice to optimise bowel care (control group) or (2) advice to
optimise bowel care and abdominal massage (intervention group). The web-based randomisation service was
provided by the Tayside Clinical Trials Unit (CTU), a UK Clinical Research Collaboration (UKCRC)-registered
trials unit, and research staff at sites carried out the randomisation. In a few instances, the AMBER trial
central office would assist with the randomisation remotely. This took place when there may have been
issues for the staff when connecting to the web-based randomisation system (room allocation with no
computer or web connectivity issues). Group allocation was relayed by telephone to the site and copies
of the relevant randomisation paperwork were sent to all of those involved. Owing to the nature of the
intervention, it was not possible to blind the participants or site staff to the allocation. Participant group
allocation was unknown to the data analysis team. Randomisation was stratified by site and minimised on
level of disability (walking unaided, aided or wheelchair bound).
Treatment group allocation
Both trial groups
Participants in both the intervention and the control group received a 6-week intervention consisting
of one face-to-face consultation (baseline appointment) followed by weekly telephone calls to review
adherence and any changes/difficulties with their bowel management. This meant that both groups
had the same number of contacts with a HCP. Both groups received advice to optimise bowel care,
as described in the following section.
Control group (advice to optimise bowel care)
During the baseline appointment, the participants’ existing routine bowel care was reviewed and discussed
with them by a member of the site research team. Dietary and fluid advice was provided, and participants
were encouraged to be more active and to use a correct defaecation position, which was described to
them. Participants were given a copy of the bowel care advice leaflet of the MS Society that reinforced
this advice [see project web page URL: www.journalslibrary.nihr.ac.uk/programmes/hta/1212712/#/
(accessed 30 October 2017)].
Intervention group (abdominal massage and advice to optimise bowel care)
In addition to optimised bowel care as described for the control group, staff delivering the intervention
(local HCPs all fully trained in the massage technique) taught the participant and/or his or her carer how to
deliver the abdominal massage. This teaching included the following:
l Viewing a short trial-specific digital versatile disc (DVD) that demonstrated the massage techniques for
carer and self-massage (Figure 1 shows a picture captured from the training DVD).
l Provision of a study-specific abdominal massage training booklet.
l A demonstration of the massage technique on the participant.
l Practice of the various strokes by the carer or participant.
l An opportunity for the participant and carer to ask questions. Possible adaptations to accommodate a
participant’s disability were also discussed. A daily massage of 10 minutes duration was recommended.
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Participants in this group were given an information pack that consisted of the following:
l the MS Society’s bowel care advice booklet
l the massage DVD
l patient abdominal massage training information leaflets.
In order to standardise the intervention delivery across all sites, training for all site staff delivering the
intervention was provided by one individual with clinical expertise in the area. Staff attended a trial training
day and/or they were trained during the site initiation visits. Each staff member had to perform practical
demonstrations and be deemed proficient in the technique before being signed off as fully competent.
Sites were contacted after the baseline appointment of their first participant from the intervention group
to discuss how staff found delivering the massage and to answer any questions. Further training was
available at this point, but all sites felt confident in the delivery of the intervention. Any questions/feedback
from the individual sites were shared with all research site staff via monthly update teleconferences. The
weekly telephone calls to participants were done either by the staff member who delivered the massage
training, or by another member of staff on the delegation log.
Participants randomised to the control group were informed that they would be given access to the
massage training materials at the end of their follow-up (week 24). In addition, some of the sites offered
to hold training sessions with the control group participants after they had completed the study.
A description of how to perform the massage technique can be found in Appendix 1, along with the
training material given to participants as an aide memoire.
Mechanistic evaluation
One of the sites in the AMBER trial [University College Hospital (UCH), London] is a regional NBD centre
where standard anorectal physiology and colonic transit tests are routinely undertaken. AMBER trial
participants recruited at this site underwent the following tests before the intervention, and then again
at 24 weeks:
l Anorectal pressure test – this test involves the insertion of a small probe into the rectum to measure
the strength of the anal muscles.
FIGURE 1 A picture from the AMBER trial training DVD, which demonstrates the massage strokes to be used.
TRIAL DESIGN AND METHODS DESIGN
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l Anal and rectal sensation and capacity was measured by using a tiny amount of current and inflating
a small balloon within the rectum (a balloon was inserted via a tube, and sensory thresholds to
progressive distension were established. The initial tube was then removed and a different catheter
with a bipolar electrode inserted; the sensory threshold to 1 mA of current was then determined).
l Transit tests – three sets of radiopaque capsules were posted to the participant, who ingested them in
the order specified in the instructions on 3 consecutive days. Participants then attended for an abdominal
radiography 2 days after the last capsule to determine total colonic transit time (not segmental transit).
This was a small substudy in the AMBER trial to look at possible mechanisms involved in NBD in PwMS
and to look at the feasibility of undertaking such tests within this population and their compliance with
attending the repeat tests.
Data collection and management
Data were collected and recorded on study-specific paper-based case report forms (CRFs) by either site
staff or the participants (bowel diaries and patient-reported outcomes during weeks 1–6 and week 24).
Sites were trained on completion of all the paperwork before recruitment commenced and a monthly
teleconference, with all sites jointly, allowed any data issues/inconsistencies to be discussed and resolved.
The AMBER trial central office entered all data into the OpenClinica database (OpenClinica, LLC, Waltham,
MA, USA). This was set up and managed by Tayside CTU. A range of data validation checks was used to
minimise erroneous and missing data.
Baseline assessment
Demographic data and information on participants’ MS, medical history and bowel symptoms were
collected at the baseline assessment. Participants also completed a questionnaire booklet which contained
five different questionnaires (including the primary and secondary outcome measures – see Outcome
measures and Appendices 2 and 3). Information on current medication was recorded, including any
laxative use. Participants were given the bowel diaries and questionnaires, which were to be completed
during the 6-week intervention phase, at the baseline assessment, with an instruction sheet detailing how
they should be completed. Baseline anorectal physiology and colonic transit time data were collected from
the London participants using an anorectal physiology CRF.
Baseline assessments were conducted between 22 January 2015 and 19 July 2016.
Participant follow-up
The duration of follow-up was 24 weeks from the date of randomisation.
Outcomes were collected through the following documents, which were completed by participants:
l a questionnaire booklet at weeks 6 and 24 (the same as the baseline questionnaire)
l a 7-day bowel diary (control group) or bowel and massage diary (intervention group) at weeks 1 to 6
and during week 23
l patient resource-use questionnaires at weeks 1–6, and weeks 12, 18 and 24.
All information completed by the participants was returned to the AMBER trial central office by reply-paid
envelopes that were provided.
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Anorectal physiology and colonic transit time data were collected at week 24 in UCH participants only.
Site research staff telephoned all participants weekly during weeks 1 to 6 and again at week 24 to collect
additional information on any potential issues, changes in diet/exercise/fluid, adverse events (AEs) and any
changes in medication. Any potential issues with bowel management or the massage were discussed and
fed back to the AMBER trial central office if deemed necessary.
All AMBER trial follow-ups were completed by 19 January 2017.
Table 1 shows the AMBER trial matrix and data collected at each time point.
Outcome measures
Primary outcome: Neurogenic Bowel Dysfunction Score
The Neurogenic Bowel Dysfunction Score (NBDS)31 is a 10-item questionnaire covering frequency of bowel
movements (0–6 points); headache, perspiration or discomfort during defaecation (0–2 points); medication
for constipation or faecal incontinence (0–4 points each); time spent on defaecation (0–7 points); frequency
of digital stimulation or evacuation (0–6 points); frequency of faecal incontinence (0–13 points); flatus
(0–2 points); and perianal skin problems (0–3 points). The maximum score is 47 points; the higher the score,
the more severe the symptoms, with a score of ≥ 14 points rated as severe. In the AMBER trial, the primary
outcome measure was the change in the NBDS from baseline to week 24.
Secondary outcomes
Bowel symptoms
The Constipation Scoring System (CSS)32 was completed at baseline and at weeks 6 and 24 to assess
constipation symptoms. The CSS is an eight-item questionnaire with items on frequency of bowel movement,
difficulty with evacuation, feeling of incomplete evacuation, pain, length of time for evacuation, assistance
with evacuation, number of failed attempts and the duration of constipation. The maximum score is 30
points, with higher scores indicating greater severity. A 7-day bowel diary (designed for use in the AMBER
trial) was used to record information on bowel symptoms, such as frequency of bowel movement, time
spent defaecating, stool type (Bristol stool chart33), laxative use, additional interventions (such as digital
stimulation) and if there were any episodes of bowel incontinence. The diary was completed prior to
baseline, during weeks 1–6 and at week 23. In the intervention group, a 7-day massage diary was used to
record daily information on massage compliance and duration and was completed prior to baseline, during
weeks 1–6 and at week 23.
Bladder dysfunction
Bladder function was measured using the SF-Qualiveen, consisting of an eight-item questionnaire assessing
bladder dysfunction, such as leakage and signs of incomplete voiding.34 Often, if patients with MS are
suffering from constipation, they report that their bladder symptoms are worse, especially urgency and
frequency, which can lead to an increase in urinary incontinence. This outcome measure allowed the
effect of the change in bowel function on the bladder to be assessed at baseline and at weeks 6 and 24.
A higher score indicates a poorer quality of life.
Quality-of-life outcomes
To determine health status, the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), generic questionnaire
was used.35 Participants completed the EQ-5D 5L at baseline and at weeks 6 and 24.
A neurogenic bowel impact score (NBIS) questionnaire was completed at baseline and at weeks 6 and 24.
This score was developed by one of the collaborators on the AMBER trial as part of a National Institute for
Health Research (NIHR)-funded postdoctoral fellowship. The questionnaire has three subscores [(1) quality
TRIAL DESIGN AND METHODS DESIGN
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TABLE 1 The AMBER trial matrix
Item
Time point
Screen Week –1
Baseline
appointment
Telephone call Post
Telephone
call and post
Withdrawal of
data collectionWeek 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 12 Week 18 Week 24
Informed consent 7
Inclusion/exclusion 7
Medical history 7
Current
medications
7 7 7 7 7 7 7 7 7
Randomisation 7
7-day bowel diary 7 7 7 7 7 7 7 7 7 7
Process evaluation/
interviewsa
7 7
7-day bowel and
massage diarya
7 7 7 7 7 7 7 7 7
Trial questionnairesb 7 7 7 7
Physiology formsc 7 7 Visit 7
Patient resource
questionnaire
7 7 7 7 7 7 7 7 7
AEs 7 7 7 7 7 7 7 7
a Only participants in the intervention group.
b Trial questionnaires included Neurogenic Bowel Dysfunction Score; SF-Qualiveen; EuroQol-5 Dimensions, five-level version; Constipation Scoring System; and the neurogenic bowel
dysfunction patient-reported outcome measure questionnaire.
c Only participants in UCH substudy.
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of life, (2) faecal incontinence and (3) symptoms] and includes four stand-alone items. It is intended for use
with individuals with a range of conditions that result in NBD. The measure’s reliability and criterion validity
were to be evaluated.
Economic outcomes
The cost and use of NHS services were collected via a patient resource questionnaire [see project web
page URL: www.journalslibrary.nihr.ac.uk/programmes/hta/1212712/#/ (accessed 30 October 2017)]
during weeks 1–6 and at weeks 12, 18 and 24. From this information (along with the EQ-5D-5L data) the
costs and quality-adjusted life-years (QALYs) were calculated for each group. A cost–utility analysis was
conducted to calculate the incremental cost per QALY of abdominal massage compared with optimised
bowel care; this is described in detail in Chapter 4.
Change of medication
Changes of medication were recorded using a current medication form. Any changes to a participant’s
medications during their involvement in the trial were recorded. Also recorded were any reductions or
stoppage of laxatives between baseline and week 24.
Radiopaque marker transit tests
Different parameters were collected on an anorectal CRF (see Report Supplementary Material 1) for the
physiology and transit tests. The total number of markers remaining in the gut at abdominal radiography was
analysed to determine any differences between baseline and week 24, and all other data were summarised.
Adverse events
Expected AEs arising from the treatments in the AMBER trial are noted below. These are common in
individuals with constipation and thus were not collected as AEs but noted in the weekly follow-up
data collection:
l increased flatulence
l abdominal cramps
l stomach rumblings/noises
l loose stool, which in some instances may lead to faecal incontinence.
All AEs (for which a participant sought intervention from a HCP) and SAEs (including death, life-threatening
conditions, inpatient hospitalisation or prolongation of existing hospitalisation and persistent or significant
disability or incapacity) were assessed for causality, severity and expectedness, and were reported to the
relevant regulatory bodies. If a site was in doubt about whether or not an event was an AE, this was
reported and discussed before data lock. Any AE that was deemed as ongoing at the end of the trial was
reviewed and further clarification from the site was sought. If the AE was still ongoing after this (owing to
the nature of the event, but not related to the intervention), this was when the follow-up ended.
Adverse events (including SAEs) were coded with the Medical Dictionary for Regulatory Activities
(MedDRA)36 16.1 and reported by primary System Organ Class (SOC) and preferred term (PT). Participants
were counted only once when calculating the incidence of AEs. An overview table was created counting
the number of AEs by SOC and PT.
TRIAL DESIGN AND METHODS DESIGN
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Sample size
The sample size for the RCT was based on the NBDS, using data from a pilot study37 that provided the only
published data available on abdominal massage in this group of patients. That study37 found a difference
of 4.21 points in the NBDS between those receiving the intervention {mean score of 6.86 points [standard
deviation (SD) 3.8 points] at 8 weeks} and the comparison group [mean score of 11.07 points (SD 7.02
points) at 8 weeks]. Other outcomes in that study changed in favour of the intervention and participants
anecdotally reported that the massage was relaxing and that they were keen to do it themselves. Using
these data, we selected a minimum clinically important difference (MCID) of 4.21 points and selected the
higher SD of 7.02 points, found in the comparison group, as the basis for our sample size calculation.
Using these data, 60 participants per group was calculated as the necessary number of participants to
detect a difference between groups of 4.21 points (SD 7.02 points) at a 5% level of significance with
90% power. Thus, for a fully powered study, the total sample size, allowing for a 20% dropout rate,
was 150. However, in response to suggestions from the funding body, the sample size was increased to
200 participants (100 per group), which allowed for greater attrition.
Statistical analyses
Statistical methods for analysis of the main primary and secondary outcomes are detailed in the following
sections. This document was drawn up by the trial statisticians, reviewed by the Project Management
Group and formally signed off by the chief investigator and trial statistician before analysis commenced.
Analysis populations
Analysis was performed for the intention-to-treat population and is reported in accordance with
Consolidated Standards of Reporting Trials (CONSORT).38
Subgroups
Subgroup analyses were carried out by first testing for a subgroup factor by intervention interaction. If this
was significant at the 5% level, results were estimated separately by the different subgroups. This included
a secondary analysis comparing those who undertook the massage themselves with those who had a carer
massage them.
Missing data
The extent of missing data was explored in the outcomes, especially the primary outcome. Patterns of
missing data were explored and predictors of missingness examined, especially if these varied by intervention.
A table was constructed to assess differences in characteristics of those with complete data and those with
missing data for the primary analysis. Multiple imputation (MI) was implemented for the primary outcome,
assuming data were missing at random.
Summary of trial data
All continuous variables were summarised using the following descriptive statistics: non-missing sample
size, number of missing records, mean, SD, median, maximum and minimum. The frequency and
percentages (based on the non-missing sample size) of observed levels were reported for all categorical
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measures. In general, all data were listed, sorted by subject and treatment and, when appropriate, by visit
number within subject.
All summary tables were structured with a column for each treatment group and an additional column for
the total population relevant to that table/treatment, including any missing observations.
Demographic and baseline variables
The baseline characteristics of participants that were recorded comprised age, sex, body mass index (BMI),
type of MS, site, number of years since diagnosis, cognitive symptoms of MS and level of mobility (walking
unaided, aided or wheelchair bound).
Prior and current medications
Prior medications were all medications that were being taken by a participant before the trial started.
Concomitant medications were all medications commenced during the trial and all changes to the dosing
of prior medications. Prior medications were listed but not analysed. Concomitant medications were
analysed by number of medications taken.
Treatment adherence
Treatment adherence was calculated from the weekly bowel diaries. The number of times the bowel
massage was done per week was used in the main analysis. For the control group, this number was set to 0.
Efficacy analyses
Data for continuous outcome measures (both primary and secondary) were assessed for normality
before analysis. Transformations of the outcome variables were used when necessary, if these were not
normally distributed.
If data were normally distributed, outcome measures were assessed by multiple linear mixed-model
regression. The primary analysis consisted of comparisons between treatment groups (bowel massage
vs. no massage) at the final visit (week 24), adjusted for site, minimisation variable level of mobility
(walking unaided, aided or wheelchair bound), as well as baseline measure of the outcome and sex.
In a secondary analysis of the primary outcome, additional baseline variables (age, sex, BMI, type of MS,
number of years since diagnosis and cognitive symptoms of MS) were included in the model.
When data were not normally distributed and could not be transformed into a normal distribution,
they were analysed using non-parametric methods in addition to multiple linear regression.
In addition to the comparison of baseline with week 24, a repeated measures mixed-model analysis was
performed on the outcomes using all available visits.
Data for categorical outcome measures were assessed by logistic regression in the same way as described
for continuous outcome measures.
TRIAL DESIGN AND METHODS DESIGN
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Primary efficacy analysis
The primary outcome measure was the between-group difference in the change of NBDS at week 24 with
the analysis adjusted, as described above.
Secondary efficacy analyses
Bowel outcomes
l Between-group difference in change in constipation symptoms. Analysis variable is the total
constipation score.
l Bowel symptoms (7-day bowel diary). The percentage of normal stools per week was calculated and
used for analysis. In addition, the number of days that a stool was passed and time spent passing
stools was analysed.
l Radiopaque marker transit tests. The number of total markers was used for the analysis.
l Adherence to massage schedule (massage diary). As this is only available for the intervention treatment
group, data are summarised in the descriptive statistics. No formal testing was done.
Urinary outcomes
l Between-group difference in change in total score of bladder function (SF-Qualiveen).
Quality-of-life outcomes
l Between-group difference in change in health-related quality of life, measured by the EQ- 5D-5L using
both the EuroQol Visual Analogue Scale (EQ-VAS) and the index score.
l Between-group difference in change of patient-reported quality of life. This consists of four scores
derived from the NBD patient-reported outcomes tool.
l Between-group difference in change in medication, analysed as all patients who stopped using
laxatives at week 24. This was determined from the concomitant medication page.
l Between-group difference in change in medication, analysed as the number of changes in usual
laxative use at week 24. This was taken from the bowel diary as the number of changes from usual
laxative use to use of fewer laxatives at week 24.
l Between-group changes in the regular use of medications to counter constipation were assessed at
weeks 6 and 24.
Reporting conventions
Values of ≥ 0.001 are reported to three decimal places; p-values of < 0.001 are reported as < 0.001.
The mean, SD and any other statistics, other than quantiles, are reported to one decimal place greater
than the original data. Quantiles, such as median or minimum and maximum, use the same number of
decimal places as the original data. Estimated parameters not on the same scale as raw observations
(e.g. regression coefficients) are reported to three significant figures.
All analyses were performed using SAS® 9.3 (SAS Institute Inc., Cary, NC, USA. SAS and all other SAS
Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the
USA and other countries. ® indicates USA registration.) All data, analysis programs and output were kept
on the Mackenzie Server and backed up according to the internal Tayside Clinical Trials Unit (TCTU)
information technology standard operating procedures.
Analysis programs were required to run without errors or warnings. The analysis programs for outcomes
were reviewed by a second statistician and any irregularities in the programs were investigated and fixed,
and the date of finalised analysis programs was signed and recorded.
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Economic analysis
The cost of abdominal massage and optimised bowel care relative to optimised bowel care alone in PwMS
who have NBD was considered from NHS and patient perspectives. Health-care resource use by patients
in both trial groups was collected at each of the follow-up time periods (weeks 1–6, 12, 18 and 24). This
included contact with health professionals and medications prescribed. These were costed using NHS pay
and prices or, when appropriate, other (e.g. market-based) sources. The economic analysis (including the
methods used) is detailed in Chapter 4.
Important changes to protocol after trial commencement
All sites used protocol version 2, dated 18 November 2014, throughout the trial duration. The London
site used an additional patient information leaflet (PIL) to describe the additional tests carried out at this site.
After original approval of the PIL, one of the tests was no longer completed routinely at the London site,
so this information was removed and the amended PIL was approved by all relevant regulatory bodies.
This change was carried out before any patients were recruited at the site.
Another substantial amendment was to incorporate a substudy, entitled SWAT (study within a trial) 24, in
the AMBER trial. Participants were randomised to receive either the original cover letter or an enhanced
cover letter (sent with the questionnaire at week 24) to evaluate whether or not the wording used would
increase return rates of the questionnaires.
Data from the substudy will contribute to the Trial Forge39 initiative to improve trial efficiency and to the
Cochrane review of strategies to improve trial retention.40
The results of the Trial Forge39 project will help to increase the evidence base on the retention of
participants to trials. The only change to the AMBER trial was the way that the cover letter sent with
questionnaires was written (no protocol change).
Other non-substantial changes included the:
l addition of new sites as the trial progressed (original target was 10 sites but final total was 12 sites)
l set-up of two patient-identifying centres to assist two sites with recruitment
l sites collecting the NBDS during the telephone call with participants at week 24 to maximise the
primary outcome data in the study.
Trial oversight
The trial was led by the chief investigator who, along with the trial management team members
(consisting of a trial manager, a data co-ordinator and a process evaluation researcher), were employed
by NMAHP RU.
The trial was overseen by a Project Management Group (PMG), a Trial Steering Committee (TSC) and a
Data Monitoring and Ethics Committee (DMEC).
The PMG had a teleconference approximately every 4–6 weeks during the recruitment period and then
bimonthly after this. The group’s role was to support any decision-making that the trial management team
needed further advice on.
TRIAL DESIGN AND METHODS DESIGN
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The TSC had both an independent chairperson and members but also consisted of the trial collaborators.
The TSC had four meetings over the course of the trial, with additional updates on recruitment when
requested. The TSC commended the team on recruiting to target and on time.
An independent DMEC, chaired by a statistician, had three meetings over the course of the study, and
additional updates were provided when requested. All statistical reports to the DMEC were prepared by
a statistician from the TCTU. The DMEC had no issues with the trial continuing at any time point and
commended the team on the recruitment and management of the study. The DMEC charter can be
reviewed in Appendix 2.
Patient and public involvement
The AMBER trial has had active participation with a group of PwMS (hereafter referred to as the MS focus
group). Some of the MS focus group were involved with the development of the grant application, providing
feedback on the lay summary, trial design and appropriate outcome measures and questionnaires. Several
additional PwMS became involved during the very early stages of the trial and throughout implementation
and dissemination of results. The MS focus group included males and females, with various levels of
disability and of various ages, some with and some without NBD. Approximately 10 members of the MS
focus group attended each of the meetings. Material to review was sent electronically before the meetings
and was available in hard copy at the meetings; very helpful feedback and discussions took place. One of the
members of the MS focus group has also attended each TSC meeting as a lay representative and has actively
engaged in the conversations and discussions at each meeting. Before recruiting any participants to the trial,
the MS focus group reviewed the massage training DVD and the massage training material that would be
given to the participant to take home with them, and their input to this was extremely influential. The
group’s opinion of the initial version of the training DVD was that the visual was excellent but the language
used was ‘too clinical’. This was overcome by the chief investigator of the trial doing a voice-over on the
DVD; the group reviewed this again and it was deemed much more acceptable and user friendly. Many of
the trial participants subsequently commented that they thought the video was extremely useful and easy
to follow.
We initially had two different training documents and we asked the group which would be better used as
an aide memoire. The MS focus group had very mixed opinions on their preferences, and discussed the
style, language and diagrams used. It was therefore concluded that both of these additional training
materials would be provided to all participants in the intervention arm and they could decide which
material they felt was better for them. However, there is the possibility of combining the information
into one single training document if the intervention is rolled out to clinical care.
Participants in the AMBER trial were given quite a lot of information to take away with them at the
baseline appointment, in the form of a ‘follow-up pack’. This pack included all the questionnaires and
bowel diaries and study instructions on what they had to complete over the 6-week intervention period,
and also the massage training DVD and reading materials (only if the participant was in the intervention
group). The MS focus group reviewed this pack and thought that it was logical and clear and some further
feedback from site staff implied that the participants ‘liked’ having this pack to take away with them.
We kept in touch with the MS focus group throughout the study, giving updates on recruitment, and
there were discussions on dissemination plans. A dissemination day was held on 23 January 2018 in
Glasgow Caledonian University, to which all the research staff involved in the study, and local participants,
were invited. Representatives of the MS focus group also attended.
Throughout the active recruitment of the study, local and national MS charities were aware of our research
and promoted the study where regulations allowed.
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Chapter 3 Results
Trial recruitment
Recruitment overall was considered very successful; Figure 2 shows how well the actual recruitment met
the expected monthly targets over the 18 months of active recruitment. The trial oversight committees
agreed to stop recruitment on time at 191 participants after reviewing attrition information. Twelve sites
recruited participants from 22 January 2015 to 19 July 2016 and each site recruited between 9 and
26 participants (see Appendix 3).
The CONSORT flow diagram (Figure 3) shows the movement of participants through the AMBER trial.
There were 237 PwMS and possible bowel problems screened (≈61% of the 389 PwMS approached by
the research staff) and 191 PwMS (81% of those screened; 49% of those approached) were randomised.
The near 50% uptake on those approached versus those randomised was in accordance with the estimate
of uptake stated in the protocol.
Of the randomised participants, 22 did not complete the study. Two of these were post-randomisation
exclusions (essentially randomised in error) and data were not collected from these two participants.
Thus, the analysis was based on 189 participants: 90 in the intervention group (abdominal massage plus
advice on optimised bowel care) and 99 in the control group (only advice on optimised bowel care).
The inequality in the number of participants per group was attributable to minimisation at site level.
For the 20 correctly randomised participants (intervention group, n = 15; control group, n = 5) who did not
complete the study, baseline data were successfully collected and all participants agreed that their existing
data could be used. Participants either withdrew (intervention group, n = 11; control group, n = 3) or were
lost to follow-up (intervention group, n = 4; control group, n = 2). In some instances, if the data were not
returned, then the week-6 and week-24 follow-up data collection was completed by the researcher during
a telephone call. This explains the differing numbers for the NBDS in the CONSORT flow diagram at weeks 6
and 24 in relation to reported withdrawals or loss to follow-up.
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FIGURE 2 Predicted recruitment vs. actual recruitment.
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• Received allocated intervention, n = 90 (47.1%)
• Did not receive intervention,c n = 1
Information given about the study
(n = 389)
Did not reach eligibility screening
• Declined participation, n = 52 (13.4%)
• Did not respond to initial invitation,
   n = 100 (25.7%)
Excluded
• Not meeting inclusion criteria, n = 29 (7.5%)
• Eligible but not randomised,b n = 17 (4.4%)
Assessed for eligibility
(n = 237; 60.9%)
Randomised
(n = 191; 49.1% of those approached about study)
• Baseline NBD Qu for analysis, n = 86 (95.6%)
• Baseline NBD Qu missing information, n = 4 (4.4%)
• 6-week NBD Qu for analysis, n = 62 (68.9%)
• 6-week NBD Qu missing information, n = 2 (2.2%)
Participant withdrawals
(n = 9)
Lost to follow-up
(n = 0)
Participant withdrawals
(n = 2)
Lost to follow-up
(n = 4)
• 24-week NBD Qu for analysis, n = 69 (76.7%)
• 24-week NBD Qu missing information, n = 3 (3.3%)
Minimisation criteria (n = 90): walking unaided (n = 37),
aided walking (n = 43) and wheelchair bound (n = 10)
• Received allocated intervention, n = 99 (51.8%)
• Did not receive intervention,c n = 1
• Baseline NBD Qu for analysis, n = 94 (94.9%)
• Baseline NBD Qu missing information, n = 5 (5.1%)
• 6-week NBD Qu for analysis, n = 83 (83.8%)
• 6-week NBD Qu missing information, n = 7 (7.1%)
Participant withdrawals
(n = 2)
Lost to follow-up
(n = 0)
Participant withdrawals
(n = 1)
Lost to follow-up
(n = 2)
• 24-week NBD Qu for analysis, n = 84 (84.8%)
• 24-week NBD Qu missing information, n = 6 (6.7%)
Minimisation criteria (n = 99): walking unaided (n = 42),
aided walking (n = 46) and wheelchair bound (n = 11)
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(n = 91)
Allocated to standard care
(n = 100)
Baseline NBD Qu received
(n = 90; 100%)
Baseline NBD Qu received
(n = 99; 100%)
6-week NBD Qu received
(n = 64; 71.1%)
6-week NBD Qu received
(n = 90; 90.9%)
24-week NBD Qu received
(n = 72; 80%)
24-week NBD Qu received
(n = 90; 90.9%)
FIGURE 3 The CONSORT flow diagram. Qu, questionnaire. a, In the enrolment and screening information,
all percentages are calculated from the number of people approached about the study (n= 389); b, reasons for
those who were eligible but did not take part vary from a patient’s personal circumstances changing to baseline
appointments being made for a patient but he/she not attending; c, in each group, one participant was randomised
and subsequently deemed ineligible for the trial when eligibility was reassessed. No data were collected for these
two participants; and d, these sections show the breakdown for the primary outcome measure (NBDS) at each stage
of data collection: baseline, week 6 and week 24. All percentages calculated are from n= 90 (intervention group)
and n= 99 (control group).
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Quality of participant-completed outcome data
Participant-completed outcomes were returned by post at weeks 6 and 24. Questionnaire and bowel diary
data were checked for completeness and every effort was made to collect any missing information when
acceptable to do so.
The CONSORT flow diagram (see Figure 3) shows the numbers available for the primary outcome analysis
at baseline and weeks 6 and 24 (NBDS). During monitoring of the study attrition rates and primary and
secondary outcome data received, it was evident that some participants were stating that they had
returned their outcome measures by post but these were not received in the AMBER trial office. Thus, in
order to maximise our available primary outcome data for analysis, from 22 March 2016 onwards, the
research staff at each site completed the NBDS (10 questions) during the telephone call at week 24. This
increased our available data for primary outcome analyses at 24 weeks, compared with 6 weeks, in both
study groups (intervention group, 76.7%; control group, 84.8%).
There was a greater number of withdrawals/losses to follow-up in the intervention group (15/90) than in
the control group (5/99).
For all outcome data, the numbers available for analysis and any reasons for missing data will be reported
when discussing each outcome below.
Reasons for withdrawal/losses to follow-up
There were two randomisation failures and 20 participants who withdrew and were lost to follow-up
(n = 14 intervention group, n = 16 control group; none withdrew consent for use of existing data).
We have undertaken an analysis of the missing data (see Appendix 4) and it would seem that they do not
suggest any major biases in the primary analysis. The reasons for withdrawal in the intervention group
were varied and included change in diagnosis of MS, family circumstances, worsening of condition and
too much paperwork. There is also the possibility that those in the control group remained in the study
so that they would receive the training in the abdominal massage and had not yet experienced the
potential disappointment of the intervention not working for them, which might increase the likelihood of
withdrawing from the study. Interestingly, of those who took part in the interview study, none withdrew
or were lost to follow-up, which may indicate that this was a more motivated group or that taking part in
the interviews facilitated retention.
Missing primary outcome data
The missingness of the primary outcome data appeared to be relatively unrelated to baseline characteristics,
apart from the following: trial group (more missing data in the intervention group), more missing data in
those not wheelchair bound, slightly more missing data for women and for younger participants, and more
missing data in some centres (see Appendix 4 and Chapter 6 for possible reasons for all of the above).
However, using the characteristics at baseline to impute missing data, MI was carried out for the primary
outcome and the primary analysis was repeated as a sensitivity analysis. This approach assumes that data
are missing at random; this is discussed further in Chapter 6.
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Baseline data
The mean age of participants was 53 years (SD 10.4 years) and 81% (154/189) were female. Mean time
since diagnosis of MS was 14.3 years (SD 9.1 years). Baseline demographics and clinical data are summarised
in Table 2. Demographics and symptom characteristics of the two groups were comparable at baseline.
TABLE 2 Characteristics of participants at study entry
Characteristic
Trial group
Intervention (N= 90) Control (N= 99)
Clinical characteristics
Minimisation variable: walking aids, n (%)
Walking unaided 37 (41.1) 42 (42.4)
Aided walking 43 (47.8) 46 (46.5)
Wheelchair bound 10 (11.1) 11 (11.1)
Age (years), mean (SD) 53.5 (11.32) 51.3 (10.32)
Sex, n (%)
Male 14 (15.6) 21 (21.2)
Female 76 (84.4) 78 (78.8)
BMI (kg/m2), mean (SD) 27.4 (6.207) 26.22 (5.525)
Time since diagnosis of MS (years), mean (SD) 14.8 (9.76) 13.9 (8.64)
Type of MS, n (%)
Benign 0 (0.0) 2 (2.0)
Relapsing–remitting 45 (50.0) 61 (61.6)
Secondary progressive 36 (40.0) 23 (23.2)
Primary progressive 9 (10.0) 13 (13.1)
Severity of symptoms, n (%)
Cognitive
None 39 (43.3) 35 (35.4)
Moderate 50 (55.5) 61 (62.6)
Severe 1 (1.1) 3 (3.0)
Pain
None 41 (46.6) 46 (46.5)
Moderate 43 (47.8) 52 (52.5)
Severe 6 (7.6) 1 (1.0)
Spasm
None 33 (36.7) 31 (31.3)
Moderate 58 (64.4) 63 (64.7)
Severe 17 (12.2) 11 (11.1)
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Bowel symptoms
To be eligible to participate in the trial, participants had to be ‘bothered’ by their constipation. Bowel
symptoms had commenced > 10 years ago in 37% of participants and < 1 year ago in 4% of participants.
The main bowel symptoms reported by participants at baseline were a feeling of incomplete emptying,
straining to pass stool and bloating (Table 3).
TABLE 2 Characteristics of participants at study entry (continued )
Characteristic
Trial group
Intervention (N= 90) Control (N= 99)
Depression
None 41 (45.6) 52 (52.5)
Moderate 45 (50.0) 42 (43.5)
Severe 4 (4.4) 4 (4.0)
Fatigue
None 8 (8.9) 5 (5.1)
Moderate 58 (64.5) 68 (68.7)
Severe 24 (26.7) 26 (26.3)
Bladder
None 12 (13.3) 15 (15.2)
Moderate 57 (63.4) 59 (59.6)
Severe 29 (32.2) 29 (29.3)
TABLE 3 Bowel symptoms reported in CRF
Bowel symptoms
Trial group
Intervention (N= 90) Control (N= 99)
Pain: yes, n (%) 59 (65.6) 60 (60.6)
Bloating: yes, n (%) 76 (84.4) 86 (86.9)
Faecal incontinence: yes, n (%) 39 (43.0) 60 (60.6)
Successful opening of bowels 2–4 times a week, n (%) 59 (65.6) 53 (53.5)
Type of stool (Bristol stool chart) over the last week (%)
Types 1 and 2 21.8 19.4
Types 3 and 4 20.2 23.6
Types 5, 6 and 7 16.1 14.6
No stool 39.8 38.8
Missing 2.3 2.4
Constipated (no stool + types 1 and 2) 61.6 58.2
Straining to pass stool: yes, ≥ 25% of the time, n (%) 80 (88.9) 74 (74.8)
Digital stimulation: yes, ≥ 25% of the time, n (%) 28 (31.1) 29 (29.3)
Feeling of incomplete emptying: yes, ≥ 25% of the time, n (%) 83 (92.8) 94 (94.9)
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Primary analyses
The primary analysis is the comparison between treatment groups (bowel massage vs. no massage) at
the final visit (24 weeks), adjusted for site and minimisation variable level of mobility (walking unaided,
walking aided, or wheelchair bound), as well as baseline measure of the outcome and sex.
Primary outcome measure
Neurogenic Bowel Dysfunction Score
At baseline, the mean score for the intervention group was 7.6 points (SD 5.31 points) and the median
was 6.0 points (range 0–21 points). For the control group at baseline, the mean NBDS was 8.6 points
(SD 5.08 points) and the median was 9.0 points (range 0–22 points) (Table 4). These scores indicate that
the NBD symptoms were having a minor impact on most participants. Scores of 7–11 points indicate minor
impact and scores of ≥ 14 points indicate severe impact. The mean NBDS at week 24 was 7.4 points
(SD 5.23 points) and the median was 7.0 points (range 0–24 points) for the intervention group; the mean
NBDS was 8.7 points (SD 5.70 points) and the median was 7.5 points (range 0–24 points) for the control
group at week 24. The mean adjusted difference in change between randomised groups from baseline
to week 24 was not statistically significantly different [mean difference between groups (intervention –
control): –1.6, 95% confidence interval (CI) –3.32 to 0.04; p = 0.0558; Table 5]. Figures 4 and 5 visually
show the change over time within the two groups.
TABLE 4 Summary of primary and secondary outcomes at baseline, week 6 and week 24
Score
Trial group
Intervention (N= 90) Control (N= 99)
Mean (SD) n Median (range) Mean (SD) n Median (range)
Primary outcome measure – symptom severity
NBD score (points)a
Baseline 7.6 (5.3) 86 6 (0–21) 8.6 (5.1) 94 9 (0–22)
Week 6 8.4 (6.2) 62 7 (0–25) 9.1 (5.7) 83 8 (0–34)
Week 24 7.4 (5.2) 69 7 (0–24) 8.7 (5.7) 84 7.5 (0–24)
Secondary outcome measure – symptom severity
Constipation score (points)b
Baseline 11.7 (4.1) 88 12 (1–25) 11.5 (3.8) 97 11 (3–21)
Week 6 10.6 (4.3) 58 11 (1–22) 10.8 (4.0) 83 11 (1–22)
Week 24 10.1 (4.1) 57 10 (2–22) 11.1 (3.9) 81 11 (3–27)
Bowel diary data
Time spent on toilet (minutes per week)
Baseline 75.6 (69.6) 80 57.5 (3–330) 75.8 (74.4) 87 55.0 (3–370)
Week 6 77.9 (73.3) 66 55.0 (5–315) 85.0 (88.5) 85 50.0 (2–400)
Week 24 78.2 (92.4) 53 45.0 (3–550) 77.0 (68.5) 78 56.5 (1–295)
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TABLE 4 Summary of primary and secondary outcomes at baseline, week 6 and week 24 (continued )
Score
Trial group
Intervention (N= 90) Control (N= 99)
Mean (SD) n Median (range) Mean (SD) n Median (range)
Number of attempts per week to empty the bowels
Baseline 10.4 (6.7) 86 9 (0–35) 8.6 (5.2) 91 8 (0–32)
Week 6 11.3 (7.1) 65 9 (2–32) 8.9 (6.0) 88 8 (1–32)
Week 24 10.7 (7.2) 53 10 (1–43) 8.3 (5.1) 77 7 (1–23)
Number of stools passed per week
Baseline 3.9 (1.7) 88 4.0 (0–7) 4.0 (1.7) 98 4 (0–7)
Week 6 4.3 (1.9) 68 4.5 (1–7) 3.9 (1.8) 89 3 (0–7)
Week 24 4.3 (1.9) 57 4.0 (0–7) 3.9 (1.9) 81 4 (0–7)
Bladder symptom severity
SF-Qualiveen total bladder scorec
Baseline 1.8 (1.10) 90 1.8 (0–4) 2.0 (1.20) 99 1.8 (0–4)
Week 6 1.7 (1.13) 61 1.6 (0–4) 2.1 (1.15) 85 2.1 (0–4)
Week 24 1.7 (1.10) 57 1.8 (0–4) 2.1 (1.12) 81 2.0 (0–4)
QoL
EQ-5D-5L VAS scored (maximum score of 100)
Baseline 60.6 (21.1) 89 60 (3–100) 55.7 (20.6) 98 60 (3–100)
Week 6 59.4 (24.0) 59 65 (5–97) 55.4 (20.8) 86 60 (5–100)
Week 24 59.8 (22.6) 58 62.5 (10–95) 51.3 (20.3) 83 50 (10–90)
EQ-5D-5L health index scoree (maximum score of 1)
Baseline 0.50 (0.25) 95 0.6 (–0–1) 0.50 (0.28) 99 0.6 (–0–1)
Week 6 0.50 (0.29) 60 0.6 (–0–1) 0.50 (0.27) 84 0.5 (–0–1)
Week 24 0.50 (0.28) 58 0.6 (–0–1) 0.50 (0.28) 83 0.5 (–0–1)
New QoL measure for validation (NBIS)
NBISf (total score maximum of 52)
Baseline 20.2 (8.5) 86 20 (6–41) 20.8 (7.4) 98 21 (5–38)
Week 6 19.9 (8.2) 56 19 (5–42) 21.4 (7.0) 82 21 (3–42)
Week 24 19.0 (8.4) 56 18 (5–50) 20.9 (7.4) 77 21 (1–40)
NBIS QoL (maximum score of 24)
Baseline 9.6 (5.1) 88 9 (0–22) 10.7 (4.7) 99 11 (1–22)
Week 6 9.9 (4.9) 56 10 (0–21) 10.7 (4.3) 83 11 (1–23)
Week 24 9.2 (4.8) 58 8.5 (2–23) 10.7 (4.7) 80 11 (0–24)
NBIS faecal incontinence score (maximum score of 12)
Baseline 3.7 (2.4) 90 3 (0–10) 3.7 (2.0) 99 3 (0–9)
Week 6 3.6 (2.3) 61 3 (0–9) 4.1 (2.1) 87 4 (0–11)
Week 24 3.8 (2.5) 57 4 (0–12) 4.1 (1.8) 82 4 (0–9)
continued
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TABLE 4 Summary of primary and secondary outcomes at baseline, week 6 and week 24 (continued )
Score
Trial group
Intervention (N= 90) Control (N= 99)
Mean (SD) n Median (range) Mean (SD) n Median (range)
NBIS symptom score (maximum score of 16)
Baseline 6.9 (2.9) 88 7 (0–16) 6.4 (3.1) 98 6 (1–13)
Week 6 6.4 (3.2) 60 6 (1–14) 6.6 (2.5) 84 6 (1–14)
Week 24 6.0 (2.8) 57 6 (1–15) 6.2 (2.8) 80 6 (0–14)
QoL, quality of life; VAS, visual analogue scale.
a NBDS range: 0–47 points; a score of ≥ 14 points indicates severe NBD.
b Constipation Scoring Symptom range: 0–30 points; a score of 30 points indicates severe constipation symptoms.
c SF-Qualiveen total bladder score range: 0–4; a higher score indicates worse bladder dysfunction.
d EQ-5D-5L VAS: maximum score of 100. A higher score indicates better QoL.
e EQ-5D-5L health index: maximum score of 1, which indicates best health.
f NBIS: higher scores for all subscales indicate greater improvement in NBD.
TABLE 5 Analysis of change from baseline of the NBDS
Time point
Trial group Mean difference in
change between groups
(intervention–control),
mixed modelsIntervention (N= 90) Control (N= 99)
n
Mean change
(95% CI) n
Mean change
(95% CI) Adjusteda (95% CI) p-value
Baseline to week 6 61 0.6 (–0.73 to 1.98) 80 0.9 (–0.5 to 2.22) –0.58 (–2.38 to 1.22) 0.5236
Baseline to week 24 66 –0.6 (–2.11 to 0.93) 80 0.5 (–0.78 to 1.83) –1.64 (–3.32 to 0.04) 0.0558
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
entered as a random factor.
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FIGURE 4 Change in NBDS over time.
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Secondary outcomes
Constipation Scoring System
At baseline, the intervention group had a mean CSS score of 11.7 points (SD 4.05 points), and the control
group had a mean CSS score of 11.5 points (SD 3.77 points). At week 24, the intervention group had a
mean CSS score of 10.1 points (SD 4.10 points), and the control group had a mean CSS score of 11.1
points (SD 3.91 points). Figure 6 is a line graph showing the change over time in the two groups. There
was no significant mean difference between the groups in change in the total CSS score between baseline
and either time point (Table 6).
Short Form Qualiveen Bladder Questionnaire
At baseline, both groups demonstrated moderate effects of bladder dysfunction on their overall quality of
life with a total SF-Qualiveen score in the intervention group of 1.8 points (SD 1.10 points) and the control
group of 2.0 points (SD 1.20 points). The results in all four domains of the SF-Qualiveen, that is (1) bother
with limitations, (2) frequency of limitations, (3) fears and (4) feelings related to urinary problems, were
also similar in both groups There were no significant differences between groups in the change from
baseline to weeks 6 or 24 in the SF-Qualiveen score (Table 7).
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FIGURE 6 Change in total CSS score over time.
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EuroQol-5 Dimensions, five-level version: quality-of-life outcomes
All the results of the EQ-5D-5L are summarised in Chapter 4.
Neurogenic bowel dysfunction patient-reported outcome measure
There were no significant changes in any of the outcomes from the NBIS. All results are summarised in
Table 8.
Bowel diary data
Within the statistical analysis plan (SAP), we identified the most important data to be analysed in the
bowel diary. These were the number of days passing stools, time spent on the toilet and percentage of
normal stools.
Each participant was required to complete 8 weeks of bowel diaries (at baseline, weeks 1–6 and week 24).
Overall, these were well completed and compliance was high. For example, frequency of passing of stool
was completed by 88 out of 90 (97.7%) participants and 98 out of 99 (98.9%) participants at baseline;
by 68 out of 90 (75.5%) and 89 out of 99 (89.8%) participants at 6 weeks; and by 57 out of 90 (63%)
and 81 out of 99 (81%) participants at week 24 for the intervention and control groups, respectively.
TABLE 7 Analysis of change from baseline in SF-Qualiveen score
Time point
Trial group Mean difference in change
between groups, mixed
modelsIntervention (N= 90) Control (N= 99)
n Mean change (95% CI) n Mean change (95% CI) Adjusteda (95% CI) p-value
Baseline to week 6 61 0.8 (–0.74 to 2.38) 85 1.4 (0.26 to 2.48) –1.09 (–2.89 to 0.70) 0.2306
Baseline to week 24 57 0.6 (–1.2 to 2.43) 81 0.5 (–0.89 to 1.96) –0.58 (–2.74 to 1.58) 0.5968
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
used as a random factor.
TABLE 6 Analysis of change in CSS score from baseline
Time point
Trial group Mean difference in change
between groups, mixed
modelsIntervention (N= 90) Control (N= 99)
n Mean change (95% CI) n Mean change (95% CI) Adjusteda (95% CI) p-value
Baseline to week 6 57 –1.2 (–2.11 to –0.33) 82 –0.3 (–1.05 to 0.48) –0.89 (–2.03 to 0.26) 0.1273
Baseline to week 24 56 –1.1 (–2.15 to –0.1) 81 –0.3 (–1.08 to 0.45) –0.88 (–2.03 to 0.27) 0.1308
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
used as a random factor.
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Stools passed per week
The mean frequency of stools passed per week at baseline was 3.9 (SD 1.68 stools passed per week) in
the intervention group and 4.0 (SD 1.74 stools passed per week) in the control group. At week 6, this
increased to 4.3 stools passed per week (SD 1.87) in the intervention group and decreased to 3.9 stools
passed per week (SD 1.81) in the control group; at week 24, there was no change from week 6 in either
group [i.e. mean frequency of stools passed per week was 4.3 (SD 1.88) in the intervention group and
3.9 (SD 1.89) in the control group]. Figure 7 is a line graph visually showing the change over time within
the two groups.
There was a statistically significant difference between trial groups in the change in number of stools
passed from baseline to week 24 (Table 9). The difference between the trial groups was 0.62 (95% CI
0.03 to 1.21; p = 0.039). As there was some inconsistency in completion of the diaries, the analyses of
change values were derived from a combination of two questions [(1) how often did you pass a stool?
and (2) type of stool] to give one answer on frequency. If one or the other question was answered, this
was taken as having passed a stool; if neither question was answered, this was taken as no stool passed.
Figure 8 highlights very little change in the first 5 weeks.
TABLE 8 Summary of NBIS data
NBIS
Trial group
Mean difference in change
between groups, mixed modelsIntervention (N= 90) Control (N= 99)
n Mean change (95% CI) n Mean change (95% CI) Adjusteda (95% CI) p-value
Total score
Week 6 53 0.3 (–1.34 to 1.9) 82 1.0 (–0.8 to 2.01) –1.04 (–2.72 to 0.64) 0.2216
Week 24 53 –0.8 (–2.62 to 1.04) 77 0.3 (–0.85 to 1.47) –1.46 (–3.43 to 0.52) 0.1468
Quality-of-life score
Week 6 54 0.6 (–0.21 to 1.47) 83 0.4 (–0.22 to 1.01) 0.04 (–0.93 to 1.01) 0.9387
Week 24 56 –0.2 (–1.17 to 0.81) 80 0.3 (–0.45 to 0.97) –0.70 (–1.82 to 0.43) 0.2239
Faecal incontinence score
Week 6 61 0.0 (–0.51 to 0.48) 87 0.3 (–0.03 to 0.68) –0.49 (–1.03 to 0.05) 0.0768
Week 24 57 –0.1 (–0.69 to 0.52) 82 0.4 (–0.05 to 0.78) –0.39 (–1.01 to 0.23) 0.2117
Symptom score
Week 6 59 –0.2 (–0.89 to 0.45) 84 0.2 (–0.2 to 0.68) –0.42 (–1.12 to 0.29) 0.2469
Week 24 56 –0.4 (–1.04 to 0.22) 80 –0.2 (–0.66 to 0.31) –0.26 (–0.97 to 0.46) 0.4779
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
used as a random factor.
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FIGURE 7 Change in the mean number of stools passed per week.
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Time spent on the toilet
At baseline, those in the intervention group spent a mean of 75.6 minutes (SD 69.60 minutes) per week
on the toilet and those in the control group spent a mean of 75.8 minutes (SD 74.36 minutes) per week
on the toilet. At week 6, this time was 77.9 minutes (SD 73.26 minutes) per week for the intervention
group and 85.0 minutes (SD 88.52 minutes) per week for the control group. At week 24, these times were
78.2 minutes (SD 92.43 minutes) and 77.0 minutes (SD 68.51 minutes) per week for the intervention and
control groups, respectively. There was no statistically significant difference between groups in the mean
change in time spent going to the toilet between baseline and either time point (Table 10).
TABLE 9 Analysis of change from baseline in the number of stools passed per week
Time point
Trial group Mean difference in change
between groups, mixed
modelsIntervention (N= 90) Control (N= 99)
n
Mean change
(95% CI) n
Mean change
(95% CI) Adjusteda (95% CI) p-value
Stools passed per week (adjusted to combine number and type of stool if data inconsistent)
Baseline to week 6 67 0.4 (0.07 to 0.68) 88 0.0 (–0.34 to 0.39) 0.38 (–0.08 to 0.85) 0.1036
Baseline to week 24 56 0.1 (–0.34 to 0.51) 80 –0.5 (–0.88 to 0.02) 0.62 (0.03 to 1.21) 0.039
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
used as a random factor.
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FIGURE 8 Box-and-whisker plot of number of stools passed per week.
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Type of stool
For each stool passed, participants were asked to indicate the type of the stool, as per the Bristol stool chart.33
Using types 3 and 4 as normal, and types 1 and 2 and no stool per week as constipated, there was a
reduction in the percentage of participants who were constipated in the intervention group (from 61.6% at
baseline to 55.4% at week 24) and in the control group (from 59.0% to 58.9% at week 24). The percentage
passing normal stools (types 3 and 4) was 20.2% in the intervention group and 17.5% in the control group
at baseline; at week 24 this percentage was 23.9% in the intervention group and 22.8% in the control
group (see Appendix 5).
Medications used in the AMBER trial for bowel management (information
from medication form)
At baseline, 67 (74%) participants in the intervention group and 80 (80%) participants in the control
group were on at least one medication, with numbers of medications ranging from 1 to 35. The number
of participants on medication for management of their bowel symptoms was 44 (i.e. 44/67; 66%) in the
intervention group and 54 (i.e. 54/80; 68%) in the control group. Laxido Orange (Almac Pharma Services
Ltd, Craigavon, UK), Movicol (Norgrine Ltd, Hengoed, UK) and docusate sodium appeared to be the most
popular medications used in both groups, with suppositories being used by approximately only 9% of
participants in each group.
At the start of the trial, 44 participants were on zero medications (24 participants in the intervention group
and 20 in the control group).
During the course of the study, 32 participants in the intervention group and 44 participants in the control
group started new medications, with nearly twice as many new medication entries recorded in the control
group compared with the intervention group (69 vs. 135). Thirteen participants in the intervention group
had taken at least one additional medication for bowel management, with 19 different entries recorded in
total (e.g. one participant had five entries for four different laxatives). In the control group, 12 participants
started new medications for their bowels, with 33 different entries (several participants reported three or
four additional bowel medications; one had 12 entries, eight for different bowel medications and four for
glycerine suppositories).
At the end of the study, 15 participants in the intervention group (18 entries in total) and 13 participants
in the control group (35 entries) had stopped taking some of their bowel management medications.
There were still 38 participants who were not on any form of medication (intervention group, n = 20;
control group, n = 18) at the end of the study.
TABLE 10 Analysis of change in time spent on the toilet from baseline
Time point
Trial group
Mean difference in change
between groups, mixed modelsIntervention (N= 90) Control (N= 99)
n
Mean change
from baseline
(95% CI) n
Mean change from
baseline (95% CI) Adjusteda (95% CI) p-value
Time spent on the toilet (minutes per week)
Baseline to week 6 60 –0.7 (–15.7 to 14.39) 80 9.8 (–5.28 to 24.95) –7.92 (–29.0 to 13.17) 0.4588
Baseline to week 24 50 –6.5 (–21.86 to 8.78) 71 –3.8 (–19.71 to 12.17) –3.35 (–23.1 to 16.4) 0.7377
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
used as a random factor.
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Anorectal physiology and transit test results
University College Hospital, London, was the only site in the AMBER trial to recruit participants to a pilot
substudy, to determine if any information about the mechanism of action of abdominal massage could be
gleaned through anorectal physiology and colonic transit tests, which are routinely undertaken at this site.
Participants had a test at baseline and a repeat test at week 24. All participants from UCH took part in
the substudy.
A total of 26 participants were randomised at UCH; however, two post-randomisation exclusions occurred.
All baseline outcomes for the main study were completed by 24 participants. Of these, 23 participants
underwent baseline transit tests; the 23 participants comprised two male (8.7%) and 21 female (91.3%)
participants, 11 from the intervention group and 12 from the control group, with a mean age of 53.5 years
(SD 12.59 years). There were no baseline transit test data for one of the 24 participants. Three participants
withdrew from the study during the 6 weeks of intervention and a further participant was lost to follow-up
(could not be contacted for the week-24 follow-up and did not return any patient-reported outcomes).
A further eight participants withdrew from having the repeat tests at week 24, leaving 12 participants with
week-24 transit and physiology results. One of these participants had no baseline transit data; thus, 11 sets
of baseline and week 24 transit test data were available for analysis.
There was no difference between the groups with respect to changes in the duration of bowel symptoms,
faecal incontinence, infrequent emptying, pain or bloating (see Report Supplementary Material 1). The
baseline data indicated that 65.2% (15/23) of the participants who underwent the transit test had slow
transit, six (54.5%) in the intervention group and nine (75%) in the control group.
Table 11 shows that there was no significant difference in the change in the number of total markers
between the groups; although there was a possibility that the groups were not well matched at baseline
with a median number of markers of 17 (range 0–54) in the intervention group, while in the control
group the median number of markers was 47 (range 0–60). The CI is wide because of the small number
of participants. The markers in the rectosigmoid were relatively well matched at baseline, median 10
(range 0–46) in the intervention group and a median 12.5 (range 0–35) in the control group.
Notwithstanding the substantial number of participants who failed to complete the test at week 24 (five in
the intervention group and six in the control group), the change between pre treatment and week 24 was
16 (range –6 to 32) in the intervention group and –5.0 (range –13 to 17) in the control group. This may be
explained by the fact that, in the intervention group, the massage was moving content to the distal colon,
if not necessarily triggering evacuation.
The difference at baseline for the total markers and markers in the left and right colon, that is, groups not
matched at baseline for these outcomes, as well as the numbers not completing the test at week 24, make
it impossible to differentiate between changes as a result of regression to the mean and actual changes.
TABLE 11 Radiopaque marker transit test, total number of markers data summary
Time point
Trial group
Mean difference in change
between groups, mixed modelsIntervention Control
n
Mean change from
baseline in the number
of markers (95% CI) n
Mean change from
baseline in the number
of markers (95% CI) Adjusteda (95% CI) p-value
24 weeks 5 13.2 (–20.04 to 46.44) 6 –7.8 (–20.29 to 4.63) 15.7 (–37.69 to 69.01) 0.4846
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided, wheelchair bound) and sex. Centre was
used as a random factor.
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Anorectal pressure tests and anal and rectal sensation and capacity
The small number of participants who completed the tests at week 24 mean that the sample size is too
small to draw conclusions.
Adverse events
A total of 84 AEs were noted in the trial: 28 in the intervention group and 56 in the control group.
Table 12 summarises this information, along with the numbers of participants affected in each group.
Appendix 6 is a summary of all the AEs. Five AEs were reported as being possibly related to the
intervention; however, two of these were reported in the control group [urinary tract infection (UTI) and
diarrhoea]; as they had no intervention, the fact that there were two AEs in this group that were classed as
possibly related to the intervention is deemed as an error on the part of the site reporting the AE. For the
three possibly related AEs reported in the intervention group, two were for one participant who had two
UTIs, both of which resolved within 1 week, and one participant had reflux and went to accident and
emergency (A&E) but was not admitted. Both of these participants were still continuing with the massage
at 24 weeks despite these reported AEs.
Additional information on all AEs (reported by primary SOC and PT) can be found in Report Supplementary
Material 1.
Summary of serious adverse events
From the 84 reported AEs, nine were classified as a SAE. A summary of the SAEs reported is in Appendix 6.
Two of these SAEs were a hospitalisation as a result of a MS relapse (one in each study group) and one was
a fall, but, considering the study cohort, these are not surprising events. None was related to the trial and all
were resolved.
Secondary analysis
In a secondary analysis of the primary outcome, using MI for the missing data, the following baseline
variables were included in the model: age, sex, BMI, type of MS, number of years since diagnosis, cognitive
symptoms of MS and minimisation variable level of mobility (walking unaided, walking aided or wheelchair
bound). Table 13 shows the results adjusted for all variables; this indicated a similar result as found in the
primary analysis, with no significant difference between the intervention and control groups. For assessing
if changes in symptoms were dependent on site, with Edinburgh taken as the reference site, there was
no statistically significant difference between the sites (p = 0.8326), although slightly better results were
reported at sites in Sheffield, Salford, Lincoln, Leeds and the John Radcliffe Hospital than in Edinburgh.
TABLE 12 Adverse events reported
Category
Trial group (n)
Total (n)Intervention Control group
All participants 91 100 191
Participants with AEs 19 30 49
AEs 28 56 84
Of which, SAEs 3 6 9
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Regression analysis also indicated that there is more likely to be a benefit in the intervention group for
those walking unaided or aided, as they responded better than wheelchair-bound participants, while those
of greater age and higher BMI also did slightly better. The time since diagnosis of MS did not seem to be
important, but those with relapsing–remitting MS responded more positively than those with primary
progressive MS. Cognition severity indicated that those with mild or no impairment did better than those
with severe impairment. Consistent with other findings, males responded significantly better (mean
difference –2.789, 95% CI –5.179 to –0.399; p = 0.0226).
TABLE 13 Secondary analysis: primary outcome NBDS adjusted for all baseline variables
Variable Estimate 95% CI p-value
Intervention vs. control –1.060 –2.976 to 0.855 0.2751
Centre vs. Edinburgh 0.8326
Southern General Hospital, Glasgow 0.135 –4.334 to 4.604
Royal Victoria Hospital, Newcastle upon Tyne 2.411 –2.397 to 7.218
UCH, London 0.997 –3.614 to 5.608
Royal Preston Hospital, Preston 1.868 –2.996 to 6.732
The Walton Centre, Liverpool 1.411 –3.704 to 6.526
John Radcliffe Hospital, Oxford –0.257 –4.901 to 4.387
Leeds Community Healthcare NHS Trust –0.326 –5.321 to 4.668
United Lincolnshire Hospitals NHS Trust –0.034 –4.845 to 4.778
Salford Royal Hospital NHS Trust –0.687 –5.481 to 4.107
Sheffield Teaching Hospitals NHS Trust –1.594 –6.223 to 3.034
Northampton General Hospital, Northampton 1.893 –3.560 to 7.347
Baseline NBDS (+ 1 unit) 0.327 0.137 to 0.516 0.0009
Minimisation variable: mobility vs. wheelchair bound 0.9560
Walking unaided –0.218 –3.476 to 3.040
Walking aided –0.425 –3.525 to 2.674
Age (+ 1 year) –0.097 –0.211 to 0.018 0.0972
BMI (+ 1 kg/m2) –0.042 –0.207 to 0.124 0.6171
Male vs. female –2.789 –5.179 to –0.399 0.0226
Time since diagnosis of MS (+ 1 years since diagnosis) 0.046 –0.069 to 0.160 0.4309
Cognitive status vs. severe 0.7719
None –0.754 –6.832 to 5.323
Mild –1.720 –7.722 to 4.282
Moderate –0.709 –6.833 to 5.415
Type of MS vs. primary progressive 0.5537
Type of MS: benign –1.515 –10.071 to 7.041
Type of MS: relapsing–remitting –2.525 –6.031 to 0.980
Type of MS: secondary progressive –1.749 –5.325 to 1.826
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Sensitivity analysis
A sensitivity analysis was carried out using MI of the primary outcome NBDS, and a similar result to the
primary analysis was found (difference in change between the intervention and control group: –1.266,
95% CI –2.936 to 0.403; p = 0.1371) (Table 14). Males, however, again demonstrated a greater beneficial
effect (males vs. females: –2.280, 95% CI –4.478 to –0.083; p = 0.0419).
The repeated-measures analysis (Table 15) was not significant for the primary outcome or all other outcomes,
except for the increased number of times that participants felt that their bowel was emptied and the number
of stools passed per week, which were in favour of the intervention. Between baseline and week 6, the mean
difference in the number of stools for the intervention group was 0.98 (95% CI 0.36 to 1.61; p = 0.03902)
and for the control group it was 0.56 (95% CI 0.03 to 1.10; p = 0.039). This effect was decreased for both
outcomes at week 24, but was still statistically significant over all time periods.
Change in laxative use
At week 6, the outcome for the regular use of laxatives or drops at week 6 compared with no use of
laxatives or drops had an odds ratio (OR) of 2.37 (95% CI 0.87 to 6.46; p = 0.092), using ordinal regression
adjusted for all baseline variables (baseline use, centre, age, sex, mobility, BMI, time since diagnosis of MS,
type of MS and cognitive status). At week 24, the OR for the same outcome was 1.62 (95% CI 0.74 to
3.55; p = 0.229) using ordinal regression adjusted for all the same baseline variables. Although the ORs
were not significant, there is some evidence that the intervention group were twice as likely to achieve a
lower level of laxative use than the control group (Table 16).
TABLE 14 Sensitivity analysis of the primary analysis with MI of primary outcome NBDS
Parameter Estimate SE 95% CI p-value
Intervention group vs. control group –1.266 0.852 –2.936 to 0.403 0.1371
Centre
John Radcliffe Hospital, Oxford –0.084 2.289 –4.570 to 4.402 0.9708
Leeds Community Healthcare NHS Trust –0.012 2.434 –4.784 to 4.759 0.9959
Northampton General Hospital, Northampton 0.847 2.368 –3.794 to 5.488 0.7206
Royal Preston Hospital, Preston 1.062 2.233 –3.315 to 5.438 0.6345
Royal Victoria Hospital, Newcastle upon Tyne 1.225 2.290 –3.263 to 5.712 0.5927
Salford Royal Hospital NHS Trust 0.090 2.254 –4.328 to 4.508 0.9682
Sheffield Teaching Hospitals NHS Trust –1.622 2.247 –6.026 to 2.783 0.4706
Southern General Hospital, Glasgow –0.083 2.159 –4.313 to 4.148 0.9694
The Walton Centre, Liverpool 1.039 2.487 –3.835 to 5.914 0.6760
United Lincolnshire Hospitals NHS Trust –0.468 2.304 –4.984 to 4.048 0.8391
UCH, London 0.168 2.148 –4.042 to 4.378 0.9377
NBD total score at baseline 0.356 0.090 0.181 to 0.532 < 0.0001
Minimisation variable: mobility vs. wheelchair bound
Walking unaided 0.320 1.449 –2.521 to 3.161 0.8251
Walking aided –0.192 1.420 –2.975 to 2.591 0.8924
Male vs. female –2.280 1.121 –4.478 to –0.083 0.0419
SE, standard error.
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TABLE 16 Secondary analysis of NBDS for regular use of laxative drops or tablets at all time points
Variable
Trial group, n (%)
Total, n (%)Intervention Control
Pre intervention
Missing 0 (0.0) 0 (0.0) 0 (0.0)
No regular use 41 (45.6) 48 (48.5) 89 (47.1)
Regular use of laxative drops or tablets 43 (47.8) 47 (47.5) 90 (47.6)
Regular use of both laxative drops and tablets 6 (6.7) 4 (4.0) 10 (5.3)
Total 90 (100.0) 99 (100.0) 189 (100.0)
Week 6
Missing 0 (0.0) 1 (1.1) 1 (0.6)
No regular use 34 (53.1) 48 (53.3) 82 (53.2)
Regular use of laxative drops or tablets 27 (42.2) 37 (41.1) 64 (41.6)
Regular use of both laxative drops and tablets 3 (4.7) 4 (4.4) 7 (4.5)
Total 64 (100.0) 90 (100.0) 154 (100.0)
Week 24
Missing 0 (0.0) 0 (0.0) 0 (0.0)
No regular use 43 (59.7) 51 (56.7) 94 (58.0)
Regular use of laxative drops or tablets 26 (36.1) 35 (38.9) 61 (37.7)
Regular use of both laxative drops and tablets 3 (4.2) 4 (4.4) 7 (4.3)
Total 72 (100.0) 90 (100.0) 162 (100.0)
TABLE 15 Summary of repeated-measures analysis of primary and secondary outcomes
Outcome
Intervention – control
Overall
p-valuea
Week 6 Week 24
LS mean (95% CI)a p-valuea LS mean (95% CI)a p-valuea
NBDS –1.16 (–2.84 to 0.53) 0.179 –0.54 (–2.26 to 1.17) 0.535 0.254
Constipation score –0.88 (–1.99 to 0.23) 0.121 –0.53 (–1.64 to 0.58) 0.349 0.157
Time spent on toilet –0.42 (–21.5 to 20.6) 0.969 –9.70 (–29.3 to 9.9) 0.331 0.545
No attempts per week 1.31 (–0.66 to 3.29) 0.192 1.01 (–0.83 to 2.86) 0.281 0.138
Did not empty bowels 0.98 (0.36 to 1.61) 0.002 0.48 (–0.11 to 1.07) 0.108 0.007
No stools per week 0.56 (0.03 to 1.10) 0.039 0.32 (–0.18 to 0.82) 0.215 0.026
SF-Qualiveen score –0.24 (–2.17 to 1.69) 0.809 –0.87 (–2.76 to 1.01) 0.363 0.498
EQ-5D-5L VAS score 4.30 (–2.05 to 10.65) 0.184 0.67 (–5.59 to 6.92) 0.834 0.374
EQ-5D-5L UK Health Index score 0.003 (–0.05 to 0.065) 0.916 0.004 (–0.056 to 0.065) 0.885 0.888
NBIS
Faecal score –0.37 (–0.95 to 0.20) 0.203 –0.43 (–0.99 to 0.13) 0.136 0.107
QoL –0.67 (–1.68 to 0.34) 0.192 –0.06 (–1.07 to 0.95) 0.907 0.403
Symptom score –0.29 (–0.99 to 0.41) 0.415 –0.43 (–1.12 to 0.25) 0.214 0.226
Total score –1.40 (–3.15 to 0.35) 0.117 –1.05 (–2.79 to 0.68) 0.234 0.106
LS, least squares; QoL, quality of life; VAS, visual analogue scale.
a Mixed-model, repeated-measures, least squares estimates.
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Post hoc analysis
The following descriptive analysis (and, when indicated, further statistical analysis) focuses on questions
within questionnaires and on further bowel diary data on symptoms that were identified as being important
to participants and/or were identified in other analyses as significantly changed between the two groups.
Neurogenic Bowel Dysfunction Score: those with constipation at baseline
(i.e. with a score of ≥ 11 points)
As the overall level of constipation at baseline was rated as mild in both groups according to the NBDS
[at baseline the total mean score for the intervention group was 7.6 points (SD 5.31 points) and the median
was 6.0 points (range 0–21 points), whereas in the control group, the mean was 8.6 points (SD 5.08 points)
and the median was 9.0 points (range 0–22 points)], the analysis was repeated for only those participants
with a NBDS at baseline of ≥ 11 points. The results are presented in Table 17.
The univariate analysis and linear regression analysis can be reviewed in Report Supplementary Material 1.
The numbers in both groups were reduced and the only evidence of any effect was at week 6 for those
with a longer time since diagnosis of MS (F4,30, p = 0.043, estimate 0.153, t-test value 2.07, p = 0.0437,
95% CI 0.004 to 0.302).
Frequency of defaecation as per question 1 in the Neurogenic Bowel
Dysfunction Score
There was an increase in the number of participants passing stools daily from baseline to week 24 in the
intervention group (12.2% to 23.6%), with a smaller increase in the control group (16.2% to 20.0%).
The intervention group had a small decrease in the percentage passing stools fewer times than once per
week (6.7% to 5.6%), compared with an increase in the control group (7.1% to 12.2%).
Frequency of defaecation as per the question in the Constipation
Scoring System
The percentage of participants in the intervention group who were passing stool two or more times per
week by week 6 was 92.1% and in the control group it was 88.6%; at week 6, 6.6% in the intervention
group and 10.1% in the control group were passing stool fewer times than once a week. At week 24,
the percentage of participants passing stools more than two times per week had increased to 94.9% in
the intervention group and had decreased in the control group to 80.7%; 3.4% of the intervention group
were now passing stools fewer times than once per week, whereas in the control group this percentage
had increased to 16.8%.
Feeling of incomplete evacuation as per the question in the Constipation
Scoring System
At baseline, the percentage of participants who ‘never felt incomplete evacuation’ was 6.7% in the
intervention group and 9.1% in the control group; at week 24, this increased to 15.5% in the intervention
group and decreased to 8.4% in the control group. At baseline, 21.3% of participants in the intervention
group and 20.3% in the control group ‘always felt incomplete evacuation’; at week 24 this decreased to
3.4% in the intervention group and 10.8% in the control group.
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TABLE 17 The NBDS for patients with a NBDS at baseline of ≥ 11 points
Time point
Trial group
Intervention Control
n Mean SD First quartile Median Third quartile 95% CI n Mean SD First quartile Median Third quartile 95% CI
Intervention 20 12.3 7.0 13.0 18.5 9.3 to 15.2 28 10.7 7.5 10.5 13.5 8.9 to 12.5
6 weeks 6.4 4.7
Intervention 22 9.0 4.0 9.5 12.0 6.2 to 11.8 28 9.9 6.0 9.5 13.0 7.8 to 12.2
24 weeks 6.3 5.4
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Bowel diary data
Attempts to pass stool
At baseline, the mean number of attempts to pass stool in the intervention group was 10.4 (SD 6.73
attempts), whereas for the control group this mean was 8.6 (SD 5.22 attempts). At week 6, the mean
number of attempts was 11.3 (SD 7.31 attempts) for the intervention group and 8.9 (SD 6.00 attempts)
for the control group; and at week 24 the mean number of attempts to pass stool was 10.7 (SD 7.16
attempts) and 8.3 (SD 5.09 attempts) for the intervention and control groups, respectively.
As can be seen in Table 18 and Figure 9, the mean changes between baseline and weeks 6 and 24 for
attempts to empty the bowel were not statistically significant between groups.
At baseline, the number of times per week that the participants felt that they had a complete evacuation
was 1.9 (SD 2.2 times) and 1.8 (SD 1.73 times) for the intervention and control groups, respectively.
At week 6, this was 2.6 times (SD 2.2 times) and 2.2 times (SD 2.0 times) for the intervention and control
groups, respectively, and at week 24 this number was 3.0 times (SD 2.16) and 2.2 times (SD 2.14 times)
for the intervention and control groups, respectively.
There was a statistically significant difference between groups in the change in number of complete
evacuations per week from baseline to week 24 (p = 0.002) (Table 19). The intervention group had, on
average, increased the number of complete evacuations per week by 1.08 more than the control group,
although this was a post hoc analysis.
TABLE 18 Attempts to pass stool per week
Time point
Trial group
Mean difference in change
between groups, mixed modelsIntervention (N= 90) Control (N= 99)
n
Mean change
from baseline
(95% CI) n
Mean change
from baseline
(95% CI) Adjusteda (95% CI) p-value
6 weeks 62 0.2 (–1.49 to 1.84) 84 0.4 (–0.83 to 1.66) 1.08 (–0.81 to 2.96) 0.2608
24 weeks 52 –0.9 (–2.82 to 1.02) 75 –0.5 (–1.96 to 1.0) 1.14 (–0.92 to 3.19) 0.2770
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
used as a random factor.
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FIGURE 9 Frequency of feeling of successful evacuation.
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Other diary data
Analysis of other data provided by the self-completed bowel diary was not statistically tested as per the
SAP (e.g. frequency of faecal incontinence, use of digital stimulation, type of stool) and no change was
identified between groups to warrant post hoc analysis. The bowel diary question on laxative use asked if
laxative use was the same, less or more. This was difficult to analyse as it was not being compared with
baseline but with the previous week.
Adherence to the intervention (massage diary and nurse weekly
telephone calls)
All participants received weekly telephone calls from the research nurse during the 6 weeks of intervention
and again at week 24. The aim of the calls was to support fidelity to the trial protocol. There was good
response to the follow-up telephone calls made by research staff at sites; 81% of participants in the
intervention group and 86% in the control group were reached at week 24 and data were collected
during the telephone calls.
According to information collected during the follow-up calls, 72.6% to 83.3% of participants in the
intervention group administered the massage themselves throughout the 6 weeks of intervention; for
10.3% to 14.1% of participants, a carer undertook the massage. Some data were missing or massage
was not undertaken in 2.6% of cases.
According to the bowel diary records, which also recorded when the massage was undertaken in the
intervention group, the mean number of days on which massage was performed per week was 5.2 (SD 1.88).
This varied little over the 6 weeks of intervention [at week 6, the mean was 5.4 days (SD 1.75)]. At week 24
those still doing the massage (n = 57, 82%) were undertaking it on average 3.2 times per week (SD 2.83
times per week). Mean time spent on the massage during weeks 1–6 was 72.5 minutes (SD 4.0 minutes) and
at week 24 it was 55.8 minutes (SD 40.0 minutes).
Participants were shown how to perform the massage lying down, semi-lying down or sitting up. Information
on the choice of position utilised, in addition to the time of day the massage was performed, was collected
during the 6 weeks of the intervention. During weeks 1–6, 58–64% of participants performed the massage
lying down, 16–24% semi-lying down and 1–4% sitting up.
Morning massage administration seemed to be the preferred time (for 46–56% of all participants), then
evening (26–31%), with afternoon administration being least common (4–6%).
TABLE 19 Number of times a complete evacuation per week was reported
Time point
Trial group
Mean difference in change
between groups, mixed modelsIntervention (N= 90) Control (N= 99)
n
Mean change
from baseline
(95% CI) n
Mean change
from baseline
(95% CI) Adjusteda (95% CI) p-value
6 weeks 62 0.8 (0.4 to 1.2) 84 0.2 (–0.2 to 0.6) 0.48 (–0.10 to 1.06) 0.104
24 weeks 52 1.2 (0.6 to 1.8) 75 0.3 (–0.1 to 0.7) 1.08 (0.41 to 1.76) 0.002
a Adjusted for baseline value, centre, mobility (walking unaided, walking aided or wheelchair bound) and sex. Centre was
used as a random factor.
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Information from nurse weekly telephone calls
Reasons for discontinuing the intervention, as reported in the final week 24 telephone call with the
research nurse (n = 77 interviews; 20 discontinued), included no benefit (n = 8; 10%), burden on carer
(n = 1; 1.3%) and too difficult (n = 5; 6.5%); the rest gave no reason or data were missing.
Adherence to lifestyle
In the intervention and control groups, 20% and 30% of participants, respectively, stated that they made
at least one change to their lifestyle as part of the optimised bowel care information. More participants in
the control group than the intervention group changed their diet during weeks 1–4 but did not seem to
continue with this; however, they did continue to alter their fluid intake and do more exercise. The number
who changed their position for defaecation was similar in both groups.
Approximately 50% of participants in the intervention group reported a change in their bowel habits
compared with 38% in the control group at week 1, and this difference was mirrored at week 24 with
approximately 43% in the intervention group versus 31% in the control group reporting a change in
bowel habits. Changes reported more frequently in the intervention group were more frequent bowel
movements, less time spent on the toilet and softer stools than the control group at weeks 1 and 24.
For the AMBER trial full set of descriptive statistics, see Report Supplementary Material 1.
Neurogenic bowel impact score
Analysis of the new NBD symptom score was undertaken for further validation; the analysis carried out is
in Report Supplementary Material 1.
The new neurogenic bowel patient-reported outcome measure (NBIS) showed only moderate repeatability
in the control group for the AMBER trial. However, this was over a longer time period than is usually used
for test–retest stability, and it is possible that the MS bowel symptoms had genuinely changed in the
control group. It is known that MS bowel symptoms are variable over time. A repeat of this test–retest
with a shorter time between the completions, and possibly asking participants if they perceive that their
symptoms changed or not, is recommended.
When compared against other bowel symptom scores, such as the NBDS and the Wexner score, a high
correlation was found for most items, suggesting good criterion validity for the new questionnaire. It was
also highly correlated with the EuroQol-5 Dimensions (EQ-5D) quality-of-life score, but not the EuroQol
Visual Analogue Scale (EQ-VAS). NBIS was strongly correlated with the primary outcome measure NBDS.
As the new questionnaire was developed after extensive qualitative work with people with NBD, including
those with MS, this lends credibility to both scores. However, neither score showed a significant difference
between our intervention and control groups, so there is no evidence that one is more responsive to
change that the other. Further work is needed to determine which score patients find better reflects what
is important to them. As our trial found no significant difference between groups, we are not able to
recommend either score as being more or less sensitive to change. We did not find anything to suggest
an advantage to either questionnaire and both had similar completion rates.
However, some questions within the NBDS (primary outcome) were difficult for some patients to fully
understand (e.g. digital stimulation, use of drops), whereas in the new questionnaire, the language was
better but the whole questionnaire was felt to be too long.
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Chapter 4 Health economic evaluation
Economic evaluation
The aim of the AMBER trial was to determine the clinical effectiveness and cost-effectiveness of abdominal
massage (intervention) as part of an adjunct to the control of optimised bowel care in PwMS who have
NBD. This chapter gives the results of a formal economic evaluation of the AMBER trial intervention
compared with control from a NHS and patient cost perspective. Health-related quality-of-life (HRQoL)
data and health-care resource-use data were used to examine the following:
l the cost of delivery for the patient groups
l the health-care costs for participants in both trial groups
l HRQoL through calculation of utility values using the EQ-5D-5L.
Using the above information, we calculated an incremental cost-effectiveness ratio (ICER) and the
probability of the intervention being cost-effective at different thresholds of willingness to pay (WTP) per
QALY gained.
Data related to the economic analysis
Abdominal massage costs
The intervention is described in Chapter 2. In this chapter, only costs that would be observed if the
intervention was delivered in practice will be considered; trial-related costs are not part of the analysis.
In terms of the materials used for the training of the patients, it was estimated that the DVD production
and the training materials provided would cost approximately £1 per patient. Research staff involved in the
AMBER trial confirmed that the training of patients would take approximately 30–45 minutes. If abdominal
massage becomes an established intervention in the NHS, it is expected that NHS staff involved in training
patients would usually be at a NHS pay grade of 5, 6 or 7 (and could also be non-nursing staff).
For the purpose of this economic evaluation, and based on the above information, an ongoing cost of
£90 per patient was calculated for the intervention and £0 costs were assumed for the controls. For the
intervention, this is calculated assuming a hospital-based grade-6 nurse would provide this service for
50 minutes, which comes at £89 cost per patient contact, since contact will typically take < 50 minutes
and this service can be provided by lower pay-grade staff and non-nursing staff. Duration of contact was
not recorded in the trial. Therefore, the exact duration of these appointments could not be determined
with certainty, and so the longest possible duration (50 minutes) was chosen for our baseline analysis. It
was assumed that standard care involved no additional costs other than resource use; therefore, zero was
taken as the baseline cost for the control group, even though, in practice, NBD patients would have access
to services, which would involve some costs for the NHS. Moreover, in this trial, the control group did get
follow-up calls and they were aware of the potential to be offered abdominal massage in the future.
These calls were considered to be trial-only costs and were not included in the cost-effectiveness analysis.
Health-care resource-use data
Resources used by the participants were recorded in the outcome questionnaires at baseline and
weeks 6 and 24. Participants were asked to record use of NHS services and all contacts (not just those they
directly associated with bowel problems) with HCPs throughout the trial period. These are presented in
Appendix 7.
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Health-care costs
The information on resource use was combined with the unit cost of each resource to estimate the total cost
of NHS resources used. Health service unit costs were valued using the most recent Department of Health
and Social Care resource cost data, at 2015–16 UK prices.41 The NHS resources that were included, and their
unit costs, are shown in Appendix 8, along with the source of cost information. The cost of drugs consumed
by participants only includes drugs prescribed by the participant’s GP (this is not shown in the Appendix 8).
The British National Formulary42 was consulted for the unit cost of individual drugs prescribed to participants.
The NHS resource-use costs were calculated using unit costs, as shown in Appendix 8. Hospitalisation
refers to the cost of an average inpatient stay in a hospital in England and Wales, as estimated in the
Personal Social Services Research Unit (PSSRU). Patients did not report length of stay; they only reported if
they had been admitted to hospital. Therefore, we assumed that, on average, patients stayed in hospital
for the average duration of stay in England and Wales and we applied the cost of £1609 to each reported
case of hospitalisation. The total resource-use-related costs for the NHS in each trial group at each time
point are also shown in Appendix 8.
Between the two groups, NHS resource use and associated costs were not statistically different. Reported
resource use suggests that there was little difference between the groups in terms of NHS costs related to
resource use. The impact of the costs at weeks 6 and 24 is investigated further in the cost-effectiveness
analysis. Costs at week 6 include all resource use from baseline up to the week-6 follow-up point. Costs at
week 24 include all resource use from the week-6 follow-up point to the end of the trial at week 24. Baseline
costs are not included in the cost-effectiveness analysis because they take place before the trial started, but
they are used to show that there is no statistical difference between the two groups at baseline. As standard
practice, and as part of the economic evaluation for this trial, we collected information on NHS resource
use, prescribed medication costs and out-of-pocket costs. For reasons unknown, completion of prescribed
medications and out-of-pocket costs was poor, resulting in many missing observations. Participants did have
the option of reporting zero costs in these questions, but most did not respond. Given that the reported
medication and out-of-pocket costs were very low, and similar between the two groups, we decided to use
only intervention costs and NHS resource-use costs in the economic evaluation that follows, and excluded
other costs. In general, few participants reported drug-related costs, resulting in many missing observations.
These costs are not taken into account in the cost-effectiveness analysis that follows, because of the low
numbers of participants who responded to these questions. Drug prescription costs in the intervention group
were driven by one participant who was prescribed very expensive medicinal cannabis-based drugs. For
example, if we remove this participant from the calculations below, the mean £187.25 cost per participant
decreases to £18 cost per participant. This participant reported a cost of £1372 in the period between 6 and
24 weeks follow-up, vastly inflating the reported mean cost of £187.25 at week 24 in Table 20. Testing the
equality of means at weeks 6 and 24 using t-tests (t = 1.16 and t = 0.79, respectively) suggests that there is
no significant difference between the patients who responded to these questions on drug-related costs.
TABLE 20 Prescribed medication by trial group per-patient spending
Time point
Trial group, per-participant cost (£)
Intervention Control
At baseline 3.20 (0.00) 5.08 (0.19)
At week 6 11.17 (6.00) 22.83 (21.59)
Up to week 24, excluding baseline 187.25 (169.33) 52.48 (52.48)
Notes
Data include all participants who responded to questions on prescribed medication in the trial. One participant in the intervention
group and seven participants in the control group reported drug costs at baseline. Five participants in the intervention group and
10 participants in the control group reported drug costs at week 6. Eight participants in the intervention group and 19 in the
control group reported drug costs at week 24.
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Patient costs
Information on out-of-pocket expenses was collected in the questionnaires. At each follow-up, participants
were asked if they had bought medicines or other equipment related to their condition. They reported
out-of-pocket expenses for medicines and the majority of participants who responded reported costs related
to their NBD needs. The most common items reported were laxatives, suppositories and incontinence
pads. The out-of-pocket expenses for incontinence pads and other items are summarised in Table 21.
In terms of average out-of-pocket cost per participant, there is a very small difference between the two
groups; the higher spending costs seen in the control group were driven by one individual only. We report
only total costs for the two groups and a mean cost calculated by dividing by the number of participants
who reported costs in each group. Overall, out-of-pocket spending reported per participant was very small
in both groups and, again, because of the low numbers that responded to these questions, these costs were
not taken into account in the cost-effectiveness analysis that follows.
EuroQol-5 Dimensions, five-level version, data
The EQ-5D-5L data were collected via participant-completed questionnaires at baseline, week 6 and week 24.
The EQ-5D-5L responses were given in the two sections of the EQ-5D-5L questionnaire: the EQ-VAS and the
EQ-5D Descriptive System.43 The EQ-5D-5L Descriptive System was scored using the UK tariffs.44 Table 4
provides a summary of the EQ-VAS and EQ-5D Descriptive System index score. Higher scores represent better
quality of life. In the cost-effectiveness analysis that follows, HRQoL, as measured by the EQ-5D-5L index
scores in Table 4, is combined with resource-use costs as shown in Appendix 8 and intervention costs (which
were described in Abdominal massage costs and calculated as £90), and assigned to each participant in the
intervention group.
Economic evaluation of abdominal massage (intervention) versus
standard care (control)
The raw data indicate that there is little difference between the two groups in this trial both in HRQoL
outcomes and costs. However, there were fewer quality-of-life data to analyse than the number of
recorded participant withdrawals or losses to follow-up. Missing data occur frequently in RCTs as
participants may withdraw, questionnaires may be unreturned and responses to individual questionnaire
items may be impossible to use. In the AMBER trial, one reason for the differing numbers was the fact
that, in some instances when missing outcome data were chased, participants said that they had already
completed the outcomes and returned them by post, but these were never received (previously discussed
in Chapter 3).
TABLE 21 Total reported patient out-of-pocket costs (£), by trial group
Time point
Trial group, out-of-pocket costs (£)
Intervention Control
Baseline to week 6 244.96 409.98
Week 6 to week 24 148.93 541.10
Total 393.89 951.08
Mean, per patient through to week 24 6.57 11.46
Notes
Data include all participants who responded to these questions. Five participants responded in the intervention group and
11 participants in the control group at baseline. Six participants responded in the intervention group and 4 participants in
the control group at week 6. Five participants responded in the intervention group and 19 participants in the control group
at week 24. Total costs include all reported out-of-pocket costs.
DOI: 10.3310/hta22580 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 58
© Queen’s Printer and Controller of HMSO 2018. This work was produced by McClurg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
At the end of the trial, 58 participants in the intervention group and 83 participants in the control group
had EQ-5D-5L data to analyse. To account for the missing data, and the highly imbalanced nature of
the two groups that resulted in more missing values in the intervention group, the following statistical
approaches45 were used: EQ-5D-5L data were analysed (Table 22) and then MI was performed. The imputed
data sets were then bootstrapped to perform a cost-effectiveness analysis including NHS resource-use costs
and interventions costs. In the economic evaluation that follows, NHS resource use included all costs related
to both bowel issues and other health issues as reported in Appendix 9.
The results in Table 22 are not adjusted for missing values. The economic analysis of the AMBER trial data
employed methods described in another study to handle missing data by MI (to reduce bias and ensure
that missing data are handled appropriately).46 The economic evaluation, therefore, also included
participants with only partial data. For the cost-effectiveness analysis, QALYs and total patient costs were
calculated for the 6 months that the trial lasted. The imputation was run 60 times, resulting in 60 different
data sets to be used in the cost-effectiveness analysis. The imputation was implemented separately for the
intervention and control groups to account for differences in the missing values between the two groups.
Multiple imputation was performed using predictive mean matching.47 The MI model uses baseline
covariates (EQ-5D index scores, age, sex, time since diagnosis of MS and severity of MS symptoms),
costs and QALYs at each follow-up to impute unobserved costs and QALYs, so that, for example, missing
costs at week 24 are imputed using data on baseline covariates, costs at baseline and week 6 (if available)
and QALYs between baseline and week 6 (if available). QALYs were imputed using EQ-5D index scores.
One thousand bootstrap samples were drawn from each of the 60 multiply imputed data sets, analysed
and the difference in net benefit between the treatment groups in each bootstrap sample was estimated
(at a given threshold for cost per QALY). The proportion of bootstrap samples in which the net benefit is
positive represents the probability that the treatment is cost-effective for each multiply imputed data set.
This probability is then averaged across all multiply imputed data sets.
Tables 23 and 24 show resource-use spending at 24 weeks before and after imputation. As expected,
resource use remains not statistically significantly different between the two groups after imputation. Table 25
shows the estimates of costs and QALYs per patient in the MI models. These costs include intervention costs
and resource-use costs as shown in Table 25. QALYs were calculated from EQ-5D index score, taking into
account the fact that the trial lasted only 6 months.
Table 26 shows the average incremental costs and QALYs for every participant obtained from the multiply
imputed sample and the bootstrapping. The ICER based on these data is negative at –£24,149 because
the model estimates a negative incremental QALY.
This method accounts for the uncertainty around the mean estimates of both costs and QALYs; to make
conclusions about the cost-effectiveness of abdominal massage compared with control, the probability
of cost-effectiveness at the WTP threshold of £20,000 per QALY is calculated at 31.3%. That probability
increases to 34.2% for a WTP threshold of £30,000 per QALY.
To test if the results were affected by the imputation or the bootstrapping processes, two extra models
were estimated. First, it was estimated that a seemingly unrelated regression model was applied on the
imputed data sets.48 Second, a mixed model was employed using maximum likelihood estimation.44,49
The mixed model did not require an imputation step; this approach is a good check to see if imputation
affected the results. The results of the seemingly unrelated regression model and the mixed model are
shown in Appendix 7.
These results are similar to the bootstrapping model, and all three methods predict a probability of
cost-effectiveness that is < 50% at the WTP threshold of £20,000 per QALY gained. Both imputation models
predict a negative QALY gain after controlling for baseline HRQoL in these models. For this reason, the ICER
of these models is negative, making straightforward comparisons rather difficult. The mixed model also
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TABLE 22 The EQ-5D-5L index scores and effect size
EQ-5D-5L index
scores
Trial group
Effect size (95% CI)aIntervention Control
Baseline
(n= 90)
Week 6
(n= 60)
Week 24
(n= 58)
Baseline
(n= 99)
Week 6
(n= 84)
Week 24
(n= 83) Week 6 Week 24
Mean (SD) 0.545 (0.246) 0.520 (0.290) 0.536 (0.276) 0.498 (0.281) 0.481 (0.271) 0.458 (0.277) 0.004
(–0.061 to 0.068)
0.017
(–0.047 to 0.081)
p-value
Median (range) 0.615
(–0.183 to 1.000)
0.570
(–0.245 to 1.000)
0.592
(–0.245 to 1.000)
0.555
(–0.467 to 1.000)
0.527
(–0.213 to 1.000)
0.548
(–0.130 to 1.000)
0.916 0.605
a Adjusted for centre, sex, disability and baseline. Bootstrapped 100 times.
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TABLE 23 Resource-use NHS costs per participant, by trial group, excluding baseline
Summary statistics
Trial group (£)
Intervention Control
Mean cost per participant 416.40 487.01
Standard error 130.70 83.84
SD 986.79 768.39
95% CI 154.57 to 678.23 320.26 to 653.76
t-test on the equality of means 0.47
Notes
Data include all patients who participated in the trial. There were 58 participants in the treatment group and 83 in the
control group at week 24. Reported contact with NHS services from baseline to 24 weeks.
TABLE 24 Resource-use NHS costs per participant, by trial group, excluding baseline after imputation
Summary statistics
Trial group (£)
Intervention Control
Mean cost per participant 427.49 500.46
Standard error 83.79 71.42
SD 794.87 710.64
95% CI 261.01 to 593.98 358.72 to 642.19
t-test on the equality of means 0.67
Notes
Data include all patients who participated in the trial. There were 90 participants in the intervention group and 99 in the
control group at baseline. Reported contact with NHS services from baseline to 24 weeks after imputation. Average
resource-use costs from 60 imputed samples. See Table 31 for NHS services included in these calculations.
TABLE 25 Multiple imputation estimates
Summary statistics
Trial group (£)
Intervention Control
Mean costs per participant 590.44 540.65
Standard error 127.44 96.28
Mean QALYs per patient 0.230 0.216
Standard error 0.015 0.012
Notes
Data include all patients who participated in the trial. There were 90 participants in the intervention group and 99 in the
control group. Costs exclude baseline and include resource-use NHS costs and intervention costs when applicable.
TABLE 26 Mean incremental costs and QALYs per participant
Summary statistics Estimate Standard error 95% CI
QALYs –0.002 0.009 –0.029 to 0.027
Costs 56.50 116.99 –372.62 to 415.68
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controlled for baseline HRQoL but the estimate on incremental QALYs and the ICER of this model was
positive. In all three estimated models, the impact on quality of life is close to zero, with relatively large
standard errors reflecting the uncertainty around patient utility scores. The mixed-model point estimate of
the ICER is at £28,722, which is over the £20,000 WTP threshold.
In sensitivity testing, patient characteristics (age, sex, time since diagnosis of MS and severity of MS
symptoms) were further controlled for, along with baseline HRQoL, in the three models, but this did not
significantly change the results. In another sensitivity test, unit costs were varied by 20%, but this did
not have a significant impact on the probability of cost-effectiveness, possibly because of similar resource
use between the two groups. In a final sensitivity test, the impact of changing the intervention cost was
explored. All three models were ran with the intervention halved and doubled. The results do appear
sensitive to the intervention cost, as the probability of cost-effectiveness at the WTP threshold of £20,000
per QALY gained ranges from 21% for high intervention costs of £180 per patient to 55% probability
of cost-effectiveness for low costs of £45 per patient. Notably, the point estimate of the ICER drops to
between £6000 and £7000, which is in the cost-effective range given a WTP threshold of £20,000 per
QALY gained. As described earlier, it is more likely that the intervention costs will be < £90 per patient
than > £90, and the results in Appendix 7 should be considered as conservative. However, it should be
noted that given the negative QALY increment, the control was bound to dominate as long as the mean
cost was higher in the intervention group.
The economic evaluation results show that abdominal massage is less likely to be a cost-effective alternative
to standard care than the other way around. However, all models predicted a probability of cost-effectiveness
of > 30% and, in the mixed model, close to 47%. In the sensitivity analysis, this probability was > 55%
assuming a low intervention cost per participant. The probability of cost-effectiveness can be seen as the
probability that an individual (random) patient will have a positive individual incremental net benefit. It can
also be seen as the proportion of all patients in the population who have positive individual incremental net
benefits; therefore, it is reasonable to assume that our results suggest that there is a subset of patients who
had a positive incremental net benefit from abdominal massage.50 If there were no patients with a positive
net incremental benefit, then the likelihood of cost-effectiveness would have been close to zero. Further
research is needed to establish the type of patient that may have benefited from abdominal massage
(discussed further in Chapter 6).
This economic evaluation has certain limitations. First, excluded drug costs and out-of-pocket costs were
excluded because very few participants responded to these questions. The participants who responded
reported very low costs per patient and it is not expected that inclusion of these would have a large impact
on our results. Second, subgroup analysis, by estimating these models on a subset of participants, was
not performed. This was decided against because regression results (available on request) did not show
a statistically significant impact of participant characteristics, such as age and sex, on costs and QALYs
gained. Finally, the results were not extrapolated over a horizon longer than 6 months. The results suggest
that the impact of the intervention on quality of life as measured by the EQ-5D-5L is small and significant
differences in the probability of cost-effectiveness are not expected if the trial lasted for a longer period.
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Chapter 5 Process evaluation
Introduction
The AMBER trial included a process evaluation, in line with advice from the Medical Research Council
guidance for evaluating complex interventions.51,52 This was informed by realist evaluation methodology,
which goes beyond the evaluation question ‘What works?’ to ‘What works, for whom and in what
context?’53 The aim of this approach is to situate and explain outcomes within the contexts in which they
are achieved in order to explain potential discrepancies between expected and observed outcomes, and to
assess fidelity to implementation processes. Furthermore, results of the process evaluation also provide
data to inform the optimisation of the intervention and seek to explore potential routes to sustainable
implementation. The process evaluation follows a longitudinal case study design.54,55
The objectives of the process evaluation are to explore:
l fidelity to processes of implementation of the trial intervention
l implementation contexts (including settings, demographics and implementation processes, delivery and
take up of the intervention, and adherence and non-completion)
l intervention optimisation and sustainability beyond the life of the funded project.
This chapter presents the research methods for the process evaluation, the results of the analysis of
data from interviews, bowel diaries and telephone support recordings. The chapter ends with practice
recommendations.
Methods
Recruitment and sampling
People with multiple sclerosis
A total of 20 PwMS taking part in the trial, and randomised to the intervention group, were selected via
convenience sampling.56 The small numbers recruited into the trial from each site meant that our intended
purposive sampling strategy was not feasible. However, as Figure 1 illustrates, the sample achieved a
variation in terms of geographical location, age, MS type and different stages of the disease progression.
This sample variation facilitated the exploration of hypothesised context–mechanism–outcome (CMO)
configurations. We did not adhere rigidly to definitions of ‘contexts’ or ‘mechanisms,’ since previous
experience of using this approach informed us that contexts can become active mechanisms that promote
change in some instances and, at other times, mechanisms of action can be better conceptualised as
contexts.57,58 For instance, sampling reflected the following hypotheses: that there could be sex differences
in the acceptability of massage, severity of MS might have an impact on ability to do the massage and
length of time living with MS may also contribute to attitudes towards self-care. This sample is reflective of
the characteristics of trial participants as a whole, with those aged > 50 years and women being the most
prominent. The mean age for the intervention group participants was 52.2 years (51.3 years for those in
the control group); 84.4% of intervention participants were female (78.8% for the control group). Of the
interview participants, 16 lived in the north of England, reflecting the fact that half of the 12 sites involved
in the study were located in that part of the UK. Table 27 provides further details on the characteristics of
those interviewed. Figure 10 shows the flow chart for the process evaluation.
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TABLE 27 Characteristics of interviewed participants
Characteristic Number of participants
Age range (years)
< 21 0
21–30 0
31–40 1
41–50 4
51–60 7
> 60 8
Sex
Male 1
Female 19
Employment status
Unemployed 2
Employed 3
Business owner 1
Retired (on ill-health basis) 12
Retired (reached retirement age) 2
Geographical location
West Scotland 3
North-west England 10
North-east England 6
South-east England 1
Type of MS
Benign 0
Relapsing–remitting 11
Secondary progressive 8
Primary progressive 1
Years with MSa
< 5 3
5–10 3
11–20 6
21–30 3
> 30 6
a This is estimated, as a number of participants reported living with MS symptoms for years.
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Declined because of illness, lack of time
or no response to further contact
(n = 13)
No response or unavailable
(n = 2)
No response or lack of availability
(n = 9)
Stakeholders interviewed
(n = 6)
Information given to stakeholders about the interviews
(n = 15)
Interviews conducted with HCPs at end of recruitment
(n = 19)
HCPs are contacted at the end of trial recruitment
(n = 21)
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20 participants interviewed at two stages
(n = 40)
Information given to HCPs at the 12 sites about the
interview substudy during the first stage
(n = 23)
Information given to trial participants in the
intervention group about the interview substudy
(n = 33)
• Interviews conducted, n = 23
FIGURE 10 Flow chart for the process evaluation.
DOI: 10.3310/hta22580 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 58
© Queen’s Printer and Controller of HMSO 2018. This work was produced by McClurg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
By the time of the first interview, participants had been enrolled in the trial for ≈4 weeks. All those who
took part in a first interview agreed to participate in a second interview. A total of 20 PwMS were
interviewed twice, giving a total of 40 interviews.
Health-care professionals
Forty-two interviews were conducted with 25 different HCPs. One or two people involved in delivering
the AMBER trial from each of the 12 sites were recruited to interviews. The range of involvement in the
trial varied from those who delivered the massage training and/or the participant follow-up to the local
principal investigators, whose role centred on identifying suitable patients for the trial. Appendix 10
documents the roles of the HCPs interviewed and the number of interviews. This sample was also
designed to reflect the realist evaluation approach.
Initial interviews with HCPs were usually conducted within a few weeks of recruiting their first intervention
participant. Owing to variation in site initiation and trial recruitment, initial interviews took place between
January 2015 and March 2016. During this first stage, 23 staff members were interviewed.
Second interviews were sought with staff members who were actively involved in patient training and
follow-up, in order to explore any problems that may have arisen since the first stage of interviewing.
In a small number of cases, a different staff member who had since become more involved in the trial or
delivery of the treatment was selected for interview at the second stage. Nineteen staff members were
interviewed in the second stage of interviews.
Stakeholders
Six interviews were carried out with stakeholders purposefully selected for their expertise in neurological and
incontinence treatment provision, policy-making and service development. The process of identifying suitable
interviewees began with research into neurological and incontinence services throughout the UK. Snowball
sampling was also used, meaning those interviewed recommended other potential interviewees. Appendix 10
illustrates the types of organisations that stakeholders came from and the number of interviews.
Fifteen potential interviewees were contacted and six people were interviewed after giving informed consent.
The interviews took place from early to mid-2016, in order to capture their knowledge and insights into recent
policy and clinical developments related to the treatment of MS.
Data collection
Interviews
Data collection consisted of qualitative semistructured interviews, allowing the views and ‘lived experiences’
of participants to be explored.59 Interviews drew on topic guides (see Appendix 11), taking an iterative
approach to allow unanticipated themes to be explored in subsequent interviews.59 All interviews were
conducted by telephone to save on travel costs, as interviewees lived in locations throughout the UK.
The purpose of the interviews with trial participants was to explore experiences of living with MS and
bowel problems, as well as experiences of taking part in the trial. The second stage of interviews focused
on exploring any change in symptoms, any adaptations that they had made to the massage, further
thoughts on taking part in the trial and whether or not they intended to continue with abdominal massage
at the end of the trial. Appendix 11 details the main topics covered in each stage of interviews and
Appendix 12 details the interview schedules and site questionnaires.
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The aim of the interviews with HCPs was to explore any issues with the training processes (both their
own training in massage as well as delivering massage training to trial participants), trial delivery and
implementation. The first stage of interviews aimed to detect any problems faced in delivering the trial and
anything that worked well. The original interview transcripts were used to write the topic guide for the
second stage of HCP interviewing. Second stage interviews gathered an overview of staff members’ experiences
in participant recruitment, the delivery of massage training and advice and participant follow-up. Appendix 11
gives an indication of the topics explored during both stages of interviews with HCPs.
Stakeholder interviews explored ways to implement the abdominal massage intervention on a larger scale
and any potential challenges to doing so. Background research was conducted into the organisations for
which the interviewees worked. Current neurological and incontinence policy developments at local,
regional and national levels were also extensively researched to ensure that appropriate, targeted questions
were asked during the interviews. Although wider policy developments and trends were acknowledged
during interviews, the focus remained on those that may facilitate or hinder the possible implementation
of abdominal massage treatment. Appendix 11 gives an indication of the range of topics covered in
stakeholder interviews; although this varied in accordance with the expertise of each organisation
and interviewee.
Data analysis
Interview recordings were transcribed verbatim. Data were analysed by drawing on an adapted framework
approach.60 This followed an initial categorising and coding process similar to thematic analysis, using
the qualitative data analysis software NVivo version 10 (QSR International, Warrington, UK). Coding and all
further stages of analysis were conducted by Selina Doran (SD) and checked for consistency by Fiona Harris (FH).
Analysis was conducted continuously with interviewing, contributing to the iterative process, allowing emerging
themes of interest to be explored further in future interviews. The initial coding was then transferred into
framework matrices for the three categories of interviewees. These summary tables explored within-case
issues, in which each trial site was considered as a case, that is, the unit for analysis. During the analysis,
attention was paid to any contextual differences that could have an impact on outcomes. Cross-case
comparison then identified higher-level themes that explored facilitating contexts and mechanisms, and any
barriers to successful implementation. The matrices also tracked the process of change over time, taking
account of the longitudinal aspect of interviews. Interviews with PwMS also retained attention to case study
sites to ensure that analyses were sensitive to any contextual variations. However, given the small numbers
recruited from each site, participants have not been identified by recruitment location. Identifiers in quotes
simply read as, for example, PwMS1 or HCP1. When second interviews were conducted with the same
person, the identifier illustrates this by the additional number so that, for instance, the second interview
with PwMS 1 would be identified as PwMS1_2. Bowel diaries were also analysed for those participants who
reported either no improvement or only a temporary improvement in bowel symptoms. To ensure validity
and reliability of the analyses, these tables were deliberated within the process evaluation team (SD and FH),
and received further clinical input from the wider study team.
Results
This section presents the analysis of interviews with trial participants alongside bowel diary analysis, and
analysis of interviews with HCPs and higher-level stakeholders. The within-case descriptive data informed
the beginning of Chapter 5; here the focus is on presenting experiences of trial participation and a
cross-case comparison of implementation issues drawn from interviews with HCPs.
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Bowel dysfunction and treatment
We begin this section by exploring the experiences of interviewees, who provided some powerful
narratives of how living with NBD affects their everyday lives. This is followed by views from HCPs and
stakeholders on current treatments and the delivery of care for constipation.
Living with bowel dysfunction
Trial participants revealed the extent to which quality of life is impeded by severe constipation, which
might range from passing a stool four times per week to passing a stool once a fortnight. Bowel problems,
coupled with their impact on other symptoms, had a negative impact on the quality of their lives:
My whole life is ruled by my bowels – that’s all I think about every day, 24/7.
PwMS20_1
One person explained that they felt thus:
I can go for days without having to go to the toilet, it can be, like, a week, and of course my stomach
ends up bloated away out to here and then you get worried that if you go out somewhere, that
you’re going to have to make a quick dash to the toilet, and then when you’re there you can be there
for ages. So if you’re out with friends and you disappear to the toilet, you’re stressed ‘cause you think,
‘God, they’re going to wonder where I am, what’s happened?’ and it becomes embarrassing then,
and I have, on maybe two occasions, actually had an accident when I’ve been out and it’s just been
an absolute nightmare, so you’ve got to try and plan ahead, you know, to work round it.
PwMS11_1
This sometimes resulted in taking extreme measures to cope with symptoms. For instance, some
participants avoided eating at certain times because of the uncertainty of when they would next pass
a stool:
I can’t eat because I’m scared, I can’t eat because I don’t know when I . . . if we’re going on holiday
I can’t eat because I don’t know when I can go to the toilet again or what the toilet facilities are when
you go away and things like that. And when I went [on holiday] . . . I only ate [for] 2 of those 6 days
and I managed, even though I was really, really hungry.
PwMS20_1
Constipation was linked to laxative usage, which could also result in negative side effects. Interviewees
reported that taking laxatives caused pain, sleeplessness, cramps and diarrhoea. The unpredictability of
passing a stool when taking laxatives meant that a number of patients became very concerned about
their potential for bowel accidents, sometimes not leaving home for days because of the lack of control.
For some people, this can lead to social isolation:
At the moment it’s absolutely disastrous, like today I won’t even answer the doorbell if the doorbell
rings. . . . That’s what happens when I have a day that I know I’m going to spend it hanging around,
hovering, trying to go to the toilet, I can’t even answer the door, I can’t leave the toilet ‘cause I’m
scared I’ll have an accident, . . . I have no control whatsoever.
PwMS20_1
Current delivery of care for constipation
Health-care professional and stakeholder interviews revealed consistent views that abdominal massage
could provide a useful addition to current treatments that commonly involve oral therapies. Abdominal
massage has a number of positive attributes as a form of treatment: it is cheap, low technology, simple,
non-invasive and can be used anywhere.
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However, stakeholder interviews revealed that most patients are underinformed about bowel matters. They
stated that people do not fully understand constipation; thus, in some cases, they do not report it as an
issue until it is quite advanced. Furthermore, HCPs reported that constipation is not discussed enough, and
patients may not connect this to their MS. There is also a lack of evidence and education around treatment
for bowel problems. In addition, the huge workloads of MS nurses have led to increasing numbers of MS
patients being managed by general nurses (Stakeholder 1 and Stakeholder 4). As one stakeholder put it:
Excellence in continence care comes from a degree of specialists, who would be able to make better
decisions and better treatment plans at a local level.
Stakeholder 6
Ten out of the 12 sites did not currently use abdominal massage as a form of treatment for bowel
problems. Although one site had a bowel specialist who offered some form of abdominal massage,
MS patients were only referred to her when their bowel problem was at a critical stage. The other site
currently using abdominal massage offered specialist bowel clinics as part of a community service. This
meant that this site struggled to find PwMS who had not used abdominal massage before to recruit
into the trial. One further site had previously used abdominal massage as part of the continence service;
however, only one member of staff had been trained in it and had since left, so massage treatment was
no longer offered.
Experiencing and delivering the intervention
In this section, we explore how the intervention was experienced by participants, and issues around
implementation. Interviews gathered data on various aspects of trial experience and delivery that may inform
any future implementation of abdominal massage as a treatment for PwMS. This included experiences of
massage training, supporting materials and telephone support. This is briefly reported in the following sections.
Recruitment and retention
By the end of recruitment, four sites had recruited to or exceeded their targets. The main reasons for
failing to meet recruitment targets centred on understaffing and time constraints. At one site, recruitment
was entirely reliant on one research nurse, who was also working on 15 other trials. This meant that
she did not have the time to repeatedly chase patients and was sometimes not available to see them in
clinic. The incorporation of the AMBER trial into the existing workloads of staff members also proved
troublesome in some cases, with an already limited staff capacity further stretched unexpectedly by
sickness absence or resignations.
Sites that did not meet their recruitment targets were, nevertheless, usually successful in retaining those
that were enrolled in the trial. Retention was affected by being patient-centred in approach during
baseline appointments. In one site, both staff members involved attended every baseline appointment:
one demonstrated the massage technique while the other checked the paperwork. These were also all
home visits, because that was more convenient for the participants. Another site that conducted home
visits reported the unexpected benefit of establishing a better understanding of patients’ home contexts:
It helped to see them at home because you had an idea about their home set-up – how chaotic their
lives were.
HCP19_2
Probably the most important contributor to retention was the relationships established between those
delivering the trial and the participants. For some sites, this was facilitated by the fact that participants
already knew the staff members involved. One way of enhancing the rapport with participants was to have
the same staff member carrying out the weekly calls:
I think it’s just getting to know me and feeling comfortable with giving me information.
HCP21_2
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Being supportive and offering advice during the first appointment and follow-up also appeared to
enhance retention.
Massage training
Delivery of massage training by health-care professionals
The massage training delivered to participants during the baseline appointment was a critical component
of the trial. Staff members had a variety of techniques: showing participants how to position their hands
during the massage, administering the technique on them to give them an idea about pressure, watching
participants do the massage themselves and commenting on it. A problem that arose during this initial
training was that some people preferred the massage to be administered over their clothes or on body
parts other than their stomach. This may have affected how the staff member was able to deliver the
training, since the massage should be administered on the abdomen in order to allow them to gauge
pressure. As per the AMBER trial protocol, the staff member advised that a carer or spouse could administer
or assist with the massage, or that they could use their fist as opposed to a flat hand in order to provide
more pressure.
Trial participants
All 20 trial participants agreed that the massage training and follow-up materials were very useful.
For most participants the training comprised being given the AMBER trial DVD, having the massage
demonstrated on them and then engaging in supervised practice. One-quarter of interviewees had their
partner present at the baseline appointment to receive the training:
If there’s a day where I’m not capable of doing it or can’t remember a bit, then I’m covered.
PwMS3_1
Most interviewees were very positive about the massage video:
The DVD is brilliant. It is so simple and easy to understand.
PwMS12_1
Engagement with the DVD was enhanced by the woman demonstrating the massage in the video, who
appeared to normalise the technique:
She’s a real person . . . when I saw her I immediately relaxed and felt I could do it.
PwMS3_1
Feedback on the video was positive and, after initial viewings, most people used the quick reference
guides as aids during the administration of the massage. The quick reference guides were found to be
helpful, clear, portable and ideal to use while administering the massage. The few negative comments
about the DVD were related to the format, as some participants found that their copy of the DVD would
not work on their DVD players and had to seek alternative copies. Others preferred to use the information
leaflet as it was easier to carry around and refer to.
Experiences of doing the massage
The frequency of administering the massage varied, with participants fitting the massage around their daily
routines. A number stated a preference for administering the massage last thing at night, as part of their
bedtime routine:
It’s part of my ritual now, before I go to bed.
PwMS15_2
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However, all participants adjusted the frequency and timing of their massage routine based on their
stamina levels and personal circumstances. Circumstances that interfered with the massage routine
included grandchildren visiting, a house refurbishment, family bereavement and festive periods, such as
Christmas. Health problems that affected adherence included diarrhoea, vomiting and bladder infections.
Physical weakness and numbness in fingers, hands and arms caused by the MS posed another challenge,
which led to several participants adapting the massage technique to suit their abilities or enlisting the help
of a partner. Adaptations included administering the massage first thing in the morning (when feeling
stronger), using one hand to guide the other and asking a partner to assist with parts or the whole of the
massage routine.
As Table 28 illustrates, these results were drawn on to establish some key CMO configurations that might
impede or facilitate positive impacts. Those contextual factors that might facilitate positive outcomes are
linked to the adaptability of participants, with those who demonstrate an ability to adapt either the
massage techniques or the massage oil to suit their own capabilities and preferences.
Supporting and experiencing the trial
Site staff made weekly calls to participants, in both the intervention and the control groups, for a period of
6 weeks and then again at the 24-week stage. Fourteen of these calls were audio-recorded from 8 out of
the 12 sites in order to check fidelity to the AMBER trial support call protocol. Calls were not recorded at
the remaining sites because of the timing of patient calls, the site not completing the calls (the AMBER trial
office took over this task for one site) or the availability of the recording equipment. In the sample of recorded
calls, one was in week 24 and the remainder took place in weeks 1–6. The support calls were structured by a
CRF guide of questions and, at the 24-week stage, questions were asked about issues relating to the primary
outcome measure. Questions covered the following three areas:
1. participant experience – changes to bowel habits, health condition and personal circumstances;
self-administration of the massage (if applicable)
2. managing symptoms – usage of medication and laxatives; any changes to diet, fluid, exercise and
positioning on the toilet seat
3. delivery of the trial – more practical aspects, such as time and staffing arrangements for weekly calls
and completing and returning paperwork.
However, from the 18 recordings it was identified that, in some instances, these calls were not as
supportive in discussing the lifestyle changes and/or the massage as had been anticipated and were
more of a tick-box exercise. In an effort to improve the quality of support, the control and intervention
participant calls completed by one site, which were deemed by the AMBER trial office to be exemplary,
were transcribed, anonymised and circulated to all sites as a good practice guide.
Further review of these transcripts highlighted a number of strategies that may have enhanced participant
engagement in the trial. Some HCPs referred to the results from the previous call or information in
participants’ forms, highlighting the value of providing information about their condition. Callers gave
TABLE 28 Context–mechanism–outcome configuration: adaptability and capability
Context Mechanism/action Outcome
Severity of MS Ability to do massage Impedes adherence or effective massage
technique, unless administered by a carer
Physical weakness/mobility issues/fatigue Adaptability and commitment
to continue
Achieves adherence via adaptations to
massage technique or enlisting help
Greasy massage oil leads to increased time
involved (e.g. showering after massage);
may reduce adherence
Adaptability and commitment
to continue: use alternative
massage products
Continued adherence; no lubricant being
used may lead to poor massage technique
and negative outcomes
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positive reinforcement to encourage positive lifestyle change, explored diet and fluid intake and advised
on massage technique. Some of the callers reminded participants to complete and return paperwork and
advised on how to complete the questionnaire.
The weekly telephone calls from sites were positively received by participants. The additional support
available from staff members seemed to be the main attraction, as one person stated:
It’s nice to think there’s somebody out there that’s listening and helping.
PwMS2_1
Participants found the advice useful and supportive; this may have been one of the reasons that trial
retention was high within the control group. The only minor points of criticism came from a few trial
participants who became anxious over missed calls and one person was initially given the wrong dates,
which led to waiting in for calls that never came:
We had a wee bit of a hiccup with the first one, I was sitting waiting because it was written down as
the 19th and it was written down as a Monday and I remember her saying about a Monday and I sat
for about an hour and nobody phoned.
PwMS13_1
However, this initial mix up with dates was sorted out and subsequent calls were received when expected.
Participants’ reactions to the trial paperwork were mixed. Although some participants found the
paperwork tiring and burdensome, a number of people felt that completing the bowel diary was
invaluable for keeping track of progress and may have encouraged adherence to the massage:
You forget and think ‘did I go or did I not go?’ and then you have a look back and you’re like ‘oh,
yeah, I did’.
PwMS9_1
During the second stage of interviews, some people said that they would have liked to have continued
completing the bowel diaries, as this acted as a record.
The consensus from HCPs was that the paperwork was fairly straightforward for participants to complete,
with the exception of one person who had severe visual impairment. In this case, a staff member completed
the paperwork during the baseline appointment and the participant developed their own bowel diary.
This issue may have been mitigated by large print materials for visually impaired participants.
A number of suggestions were made by HCPs to improve the bowel diaries. These included being more
explicit about when they should be started and picking up an error in the reporting of stool frequency,
which added up to > 100%. It was also reported that bowel diaries did not fully capture bowel habits; for
instance, although it recorded the number of attempts to pass a stool, it did not record how many times
this led to a bowel movement. Another area of confusion was the options for laxative usage of ‘usual,’
‘less’ and ‘more’, and the lack of a category for no laxatives.
For whom does abdominal massage work?
Positive improvements related to massage
Three-quarters of those interviewed (n = 15) reported improvements in their bowels as a result of the
massage. The main benefit seemed to be a feeling of empowerment and control over their bowel habits:
I know when I get to the toilet I’m going to have a bowel movement.
PwMS17_1
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By the time of the second-stage interviews, one participant said:
I have to make myself look back to see how bad things were because there’s a terrific improvement.
PwMS1_2
This was the case for many people in the second stage of interviewing, with them passing the ‘ideal types’
of stools (type 3 or 4) more frequently, and with less pain. For example, one participant who mainly passed
stool types 1 or 2 every 3 to 4 days or longer before the trial stated:
It was just awful. I’d sit on the toilet for ages and ages and ages just knowing that I had to do
something and it was painful.
PwMS17_2
However, by the second interview, she had a bowel movement of stool type 3 or 4 every day. Others
reported being able to stop taking laxatives and an increased frequency of bowel movements or, as one
person reported, the time spent trying to pass a stool changed from 3 hours to only 5 minutes.
Although improvements were not so dramatic for others, one of the consequences of even small
improvements was, for instance, a reduction in anxiety about potential impaction and hospitalisation.
Notably, when participants stopped doing the massage because of personal circumstances, any
improvements in symptoms were lost:
In some ways that was a positive thing because it proves that while I wasn’t doing it [the massage]
things deteriorated.
PwMS3_2
Other reported benefits from doing the massage included feeling less bloated, clothing becoming looser
and a decrease in sluggishness, which reduced fatigue levels. As one person reported:
I don‘t think I’ve been tired since I’ve been on this [trial].
PwMS14_1
Some participants were also able to stop or reduce laxative usage, which was reported to disrupt sleep
patterns. Improved diet was also noted by some participants, which was particularly important for those
who ate very little because of their bowel problems. One person, who had a diminished appetite at the
beginning of the trial, stated that by the end:
It’s weird to say I feel hungry, even saying the word starving.
PwMS12_1
At the second stage of interviews, all 15 people who had reported some improvements agreed that
participating in the trial had been worthwhile.
Exploring reasons for no improvement
Five interviewees reported no improvement arising from the massage. A complete set of bowel diaries
for these participants was analysed alongside their interview data in order to determine whether or
not this captured any changes in bowel habits, and to explore potential explanations for the lack
of improvement.
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A higher severity of MS and body numbness may well have interfered with the ability to administer the
massage effectively. Indeed, one stakeholder interviewee reported that effectiveness of abdominal
massage is likely to vary:
Some people find it beneficial and some people don’t find it that effective. I think it depends on how
advanced the MS is.
Stakeholder 3
Furthermore, when delivering the massage training, one HCP expressed doubts as to the likely
effectiveness of the massage, attributable to the reduced physical dexterity of some participants:
Some of them, when you’re watching them doing it and you’re thinking ‘how effective is that going
to be?’
HCP19_2
Another person who found no improvement experienced a worsening of their MS during the course of
the trial, perhaps impeding the potential to show improvement. Although bowel diary data support the
reported lack of improvement, the interview data reveals that in fact this person, unlike before the massage,
now had sensation and was able to feel the urge to pass a stool. This was perceived as a positive change
related to the massage that, nevertheless, would not have been captured by trial outcome measures.
Unfortunately, this person’s condition worsened during the course of the trial and they reported the impact
of worsening symptoms thus:
I find now I’ve sort of got quite a bit worse and I find if I get down and do these massages I can’t get
up again, I have real trouble getting up. So I’ve had to stop doing them which was a shame really.
PwMS5_2
Two further participants showed no improvement on the main indicators for constipation and consistently
responded ‘no’ to the question ‘Do you feel you have emptied your bowel?’ However, both of these
participants reported ‘ideal stool types’ at baseline, indicating that the severity of constipation was not
significant enough to demonstrate any improvement.
Another participant felt that, although the treatment worked initially, this effect was not sustained:
It started to work a little bit, that was really good; unfortunately, it didn’t last.
PwMS16_2
The initial benefit was improved control over when bowel movements happened, which in her case
meant that she no longer remained at home for 3 days at a time in fear of bowel accidents. Her bowel
diaries revealed that she only ever passed type 1 stools and that there was no noticeable improvement in
frequency, stool type or amount of time spent passing stool throughout the course of the trial. As this
participant was wheelchair bound, mobility issues may well have played a part in her ability to effectively
administer the massage.
Despite a perceived lack of impact, these five participants remained in the trial. This may be attributable to
their overall trial experience being positive. Indeed, perhaps a ‘positive outlook’ could explain why three
of these participants expressed the intention to continue with the massage after the trial, in case it did
eventually work.
A coding matrix was applied to all interview transcripts from trial participants to explore attributes, such as
severity of MS, severity of constipation and massage adherence. This revealed contextual factors that
affected outcomes, as illustrated in Table 29.
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Further analysis was undertaken to explore whether or not expectations of the trial might have been linked
to perceived impact, as a means of exploring whether or not ‘hopefulness’ might have an association with
subsequent outcomes. The majority of those interviewed had no previous knowledge about abdominal
massage and were unsure of what to expect. As a result of this, around two-thirds of participants initially
felt doubt about whether or not the massage would help them. This was especially true for those for
whom other forms of treatment had failed:
Because nothing else had worked like the Senna tablets and stuff, I was a bit like ‘well, I wonder if it is
going to work?’
PwMS15_2
Although frequency data must be approached with extreme caution when reporting on such a small
sample, Table 30 serves to illustrate the likelihood that there was no association between expectations and
trial outcomes.
Contextualising the trial primary outcome
One further piece of analysis was conducted in order to explore the discrepancy between the statistical
analysis of the NBD total score and self-reported outcomes of the trial. The NBD total scores for all
interviewees were matched up with data from interviews. Table 31 illustrates the discrepancies found by
comparing these data. Although 15 interviewees reported some improvements related to the massage,
only seven participants recorded an improved NBD score between baseline and week 24, six participants
showed no change and seven worsened over the course of the trial. However, of those seven participants
who showed improved NBDSs, two of these interviewees self-reported as not having experienced any
improvement in their symptoms. There are several potential explanations for these discrepancies. First, both
the interview and the NBDS questionnaire captured snapshots of participant experience tied into particular
weeks. Although interviews roughly followed the same time point as the trial measures, they were within
the same month rather than completed at the same time as the trial measures. Second, and perhaps more
importantly, the NBDS questionnaire did not necessarily explore those aspects of participant experience
that affected quality of life more generally, hence the discrepancy between self-reported outcomes and
those measured by the NBD questionnaire.
TABLE 30 Participant expectations and trial outcomes
Expectation (n)
Hopeful of improvement Sceptical/no expectation of improvement
Positive impact No impact Positive impact No impact
6 2 9 3
TABLE 29 Contextualising participant outcomes
Context Mechanism/impact Outcome
High severity of MS: reduced mobility,
fatigue, severe constipation, numbness and
lack of sensation
Reduced ability to massage effectively or apply
correct pressure unless carer administers the
massage; high severity of bowel problem means
it is difficult to show an improvement
No improvement
(n= 5)
Bowel diary reports show ideal stool type,
reasonable frequency and duration on toilet
Bowel diary cannot demonstrate improvement as
baseline recorded as ‘ideal’ with no capacity to
demonstrate benefit
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TABLE 31 Neurogenic Bowel Dysfunction Scores compared with self-reported outcomes
Identification Type of MS NBDS total score
Adherence to massage reported in
interviews Perceived impact
PwMS6 Relapsing–remitting Baseline, n = 13 l Mixed
l Some weeks this was daily; other times
no massage
No perceived impact. Continuing to take laxatives. Bowel diary shows ideal
stool type and frequency of three or four stools per week
Week 6, n= 7
Week 24, n= 8
PwMS16 Relapsing–remitting Baseline, n = 6 Daily for 18 weeks then stopped l No perceived impact
l It initially worked and then no positive changes. Began taking opiates
that affected appetite; has poor mobility and bowel diary shows lack
of improvement
Week 6, n= 13
Week 24, n= 9
PwMS18 Secondary
progressive
Baseline, n = 5 Sporadic. A few times a week up to week 6 No perceived improvement. On medication for bladder problems; bowel
diary shows ideal stool, regular frequency but not feeling full evacuation
Week 6, n= 5
Week 24, n= 5
PwMS20 Secondary
progressive
Baseline, n = 12 Daily No perceived improvement. High severity of MS and body numbness
means massage likely not to be effective; does not seek help with massage
Week 6, n= 21
Week 24, n= 24
PwMS5 Secondary
progressive
Baseline, n = 3 Sporadic. Had problems with the massage oil
and administering the massage
l No perceived improvement but now has urge to pass and feels gas
moving after massage
l Started taking an oral solution to treat constipation and feels that has
worked. MS worsened during trial
Week 6, n= NR
Week 24, n= 3
PwMS8 Secondary
progressive
Baseline, n = 14 Two or three times a week Slight improvement. It still takes a long time to pass a stool but massage
seems to help and she has reduced stomach pain
Week 6, n= 19
Week 24, n= 13
PwMS1 Primary progressive Baseline, n = 16 Daily (carer assistance) Improved: passing a stool daily. Decreased laxative usage. Better sleep
Week 6, n= 8
Week 24, n= 2
PwMS2 Secondary
progressive
Baseline, n = 1 Two or three times a day l Improved: stools feel more solid. Bowels are ‘functioning better.’
Improved appetite
l Longer on toilet, but greater emptyingWeek 6, n= NR
Week 24, n= 8
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Identification Type of MS NBDS total score
Adherence to massage reported in
interviews Perceived impact
PwMS3 Relapsing–remitting Baseline, n = 7 Five times a week Improved. Passes a stool every 2 or 3 days with ‘less bother.’ When
stopped massage, improvements disappeared
Week 6, n= 7
Week 24, n= 7
PwMS4 Relapsing–remitting Baseline, n = 1 Daily Improved. Passes a stool every 2 or 3 days and she has managed to stop
taking laxatives. Improved appetite
Week 6, n= 6
Week 24, n= NR
PwMS7 Relapsing–remitting Baseline, n = 5 Daily Improved. Feels that if she starts to feel constipation, the massage clears it.
Managed to stop taking oral constipation solution
Week 6, n= 6
Week 24, n= 5
PwMS9 Relapsing–remitting Baseline, n = 5 Every second day Improved. Passes stool three times a week and has stopped taking
laxatives. Without massage, there is no movement at all
Week 6, n= NR
Week 24, n= 3
PwMS10 Secondary
progressive
Baseline, n = 5 Daily Improved. Passes stool every second day. Greater sensation of emptying,
less bloating, improved appetite and energy levels
Week 6, n= 11
Week 24, n= 3
PwMS11 Relapsing–remitting Baseline, n = 3 Daily Improved. Feels it is easier to pass a stool
Week 6, n= 11
Week 24, n= 8
PwMS12 Relapsing–remitting Baseline, n = 11 Daily l Improved. Passes a stool daily and it is the ideal type
l Improved appetite, less bloating and reduced abdominal pain
Week 6, n= 13
Week 24, n= 11
PwMS13 Secondary
progressive
Baseline, n = 21 Five times a week Improved. Passes a stool once a week with more ease and it takes less
time (reduced from 3 hours to 5 minutes). Has lost weight since being on
the trial (regarded as positive)Week 6, n= 13
Week 24, n= 8
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TABLE 31 Neurogenic Bowel Dysfunction Scores compared with self-reported outcomes (continued )
Identification Type of MS NBDS total score
Adherence to massage reported in
interviews Perceived impact
PwMS14 Relapsing–remitting Baseline, n = 11 Every second day Improved. Passes a stool three or four times a week. Stopped massage
during trial because of bladder infections but plans to resume as felt
that it workedWeek 6, n= 7
Week 24, n= 14
PwMS15 Secondary
progressive
Baseline, n = 3 Daily l Improved. Passes a stool four times a week with less pain
l Stopping laxatives. Less bloating and feels full evacuation
Week 6, n= 11
Week 24, n= 7
PwMS17 Relapsing–remitting Baseline, n = 7 Three times a week Improved. Passes a stool every day with more ease and stopped laxatives.
Feels lighter
Week 6, n= 0
Week 24, n= 4
PwMS19 Relapsing–remitting Baseline, n = 7 Daily (carer-led massage) Improved. Passes a stool every 6 days and has reduced abdominal pain,
less bloating
Week 6, n= NR
Week 24, n= 14
NR, not reported.
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Post-trial intentions
From discussions with participants during second-stage interviews, it appeared that all but two of them
intended to continue with the massage. This is either because it worked for them or they hoped that it
would work in the future. The massage seemed to have been incorporated seamlessly into their routines.
Views on potential future implementation
This section explores the views of both HCPs and stakeholders regarding the potential to implement the
intervention within the NHS. These data are situated within the larger body of work conducted by the
process evaluation team, and interviews were done on the premise that the intervention may demonstrate
effectiveness and were carried out before the results of the trial were known.
Health-care professionals in the majority of sites reported issues related to staff capacity, which represents
a potential barrier to future implementation of abdominal self-massage within the NHS.
Across all services in NHS England and Scotland, there are threats to the specialist nurse role and other
positions through despecialisation, redundancy and not replacing staff members when they leave. At one
site, there was a problem with staff recruitment and retention, which resulted in a reliance on agency staff
to deliver the service.
To successfully implement abdominal massage as a form of treatment, staff members would require
reassurance regarding workload and capacity. There was a perception that this would require additional
resources, although in many cases this might replace more invasive, time-consuming treatments and could
reduce the ‘revolving door’ of hospital admission or attendance for severe constipation. There were also
concerns that if massage training was extended to other patient groups, there could be a resulting marked
increase in referrals:
We could potentially be inundated with patients.
HCP16_2
There was also some debate about which staff members would be best placed to deliver the massage
training. It was suggested that massage training could be offered by the colorectal and continence team in
hospitals, or built into existing MS or continence clinics. This could be coupled with the DVD and written
training materials to assist people in learning the technique. Furthermore, it was suggested that the
massage could possibly benefit patients on bed rest or in nursing homes:
That could be something we teach them, to look after more progressive patients.
HCP18_2
It was suggested by some sites that community and district nurses could become involved in training
people in massage in their homes. Indeed, there were indications that abdominal massage could be
introduced to a wider population in a range of health-care and community settings.
Enthusiasm for abdominal massage was such that a number of sites indicated a willingness to incorporate
it into current services. For instance, a HCP from one site who had set up a bowel clinic during the trial
said that, since the staff members who delivered the AMBER trial were already trained in the massage, this
could be rolled out more widely. Interest was also expressed in distributing training materials and engaging
in additional training.
Stakeholders indicated that there are a number of policy and capacity issues affecting the potential for
abdominal massage to be successfully implemented within the NHS. Evidence of clinical effectiveness is
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required in order to convince commissioners and other services to support this new treatment option.
Moreover, in the current NHS environment, health boards and trusts are ‘just looking for a short-term gain
from cost savings’ (Stakeholder 6), thus evidence of cost-effectiveness is also important.
The case for abdominal massage needs to be persuasive to convince Clinical Commissioning Groups, HCPs
and other services to adopt this intervention if it was found to be clinically effective. This might highlight,
for instance, the potential for abdominal massage to free up capacity within GP, continence and MS
services by dealing with bowel problems before they deteriorate (Stakeholder 4 and Stakeholder 5).
Training in the massage could be framed as upskilling staff members:
It should be career-enhancing rather than career-threatening for those involved.
Stakeholder 6
It could also reduce the costs and capacity issues associated with long-term bowel damage: unplanned
hospital admissions, bed occupancy and the prescribing of medications/other forms of treatment
(Stakeholder 1, Stakeholder 2 and Stakeholder 6). Secondly, there would be the potential to improve
quality of life for patients:
It’s the cost to the patient of the indignity of having bowel management such as a suppository.
Stakeholder 2
A potential barrier to implementation is the challenge of ‘getting something from best practice to common
practice’ (Stakeholder 4). First, massage treatment would probably be most useful if administered at an
early stage in the development of constipation problems, rather than when patients are at crisis point
(Stakeholder 3). GPs are integral to this process:
They see the whole person and spot potential issues around bowel dysfunction at a much
earlier stage.
Stakeholder 6
A health-care assessment for each individual needs to be carried out to determine what is causing the
constipation and to ensure that abdominal massage is the right treatment for them (Stakeholder 2).
Furthermore, one stakeholder suggested that abdominal massage should be part of an individual’s
self-management programme, supplemented by advice around fluid intake, changes to diet and exercise
suggestions (Stakeholder 5). The use of tracking tools like bowel diaries can help demonstrate how things
have progressed (Stakeholder 2 and Stakeholder 3).
Stakeholders felt that abdominal massage could be taught by community nurses or other HCPs, such as general
nurses, physiotherapists and continence advisors (Stakeholder 3). They also suggested that consideration should
be given as to how this treatment could be taught to those who are severely disabled and unlikely to be able to
self-massage (e.g. those in care homes). As reported by HCPs above, this suggests the need for staff members
at care homes to be trained in the carer-led massage.
Stakeholder interviewees suggested ways of disseminating the massage training materials to reach the
people who matter most: those with NBD and HCPs dealing with these issues. To that end, PwMS would
need to be given access to videos and other training resources, and HCPs would need to be trained in the
intervention and how to teach it. Stakeholders suggested that a number of key organisations should be
included in approaches to dissemination of training and, when appropriate, training materials could be
hosted on their websites:
l National Institute for Health and Care Excellence (NICE)
l NHS England
l Royal College of Nursing
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l Association for Continence Advice
l MS Society
l MS Trust
l Association of British Neurologists
l UK MS Nurse Association.
Process evaluation discussion
The experiences of PwMS provide powerful illustrations of how constipation can have a wide-ranging,
negative effect on their everyday lives. Quality of life is severely impaired, to the extent that some people
are afraid to leave their homes and may end up socially isolated, anxious and in pain. Interviews revealed
the vicious cycle of symptoms, such as reducing food intake and disturbed sleep as a result of laxative use,
and the fatigue commonly associated with MS17 was exacerbated by constipation. Despite the symptom
burden, there are few evidence-based treatments available and the cost to the NHS of dealing with
constipation is substantial.61
The findings from the process evaluation demonstrate the potential for abdominal massage to be adopted
as a bowel management technique more widely within the NHS. Seventy-five per cent of interviewees
(n = 15) experienced improvements in their symptoms, and we were able to offer possible explanations for
the lack of improvement in others. In some instances, it would be more appropriate to report that there
were only minor improvements rather than none, but these minor improvements were not detectable
via primary and secondary outcome measures in the main trial. It seemed that only the more dramatic
improvements were able to be captured. The training focused on supporting patients to administer the
massage themselves and, although the AMBER trial protocol did include the option for carer-/partner-
administered massage, this option may have been missed by those unaware at the outset that they did
not have the physical dexterity to perform the massage effectively.
Most of the sites involved in the trial were not currently using abdominal massage as a form of treatment
and the consensus, from both HCPs and stakeholders, was that bowel problems in PwMS had to be
better managed. The interviews revealed that most participants intended to continue with the massage,
demonstrating the acceptability of this noninvasive treatment.
The process evaluation presents results of an approach that draws on longitudinal interviews. Following both
trial participants and trial delivery over time allowed us to track processes of change and offer explanations
for trial outcomes. The finer nuance achieved by bringing together interviewee experiences with bowel
diary data offered insights that suggest that the outcomes may actually be more positive than the statistical
analysis suggests. Furthermore, arguably, the AMBER trial achieved greater value by incorporating insights
on trial processes. While being mindful of the need to protect trial equipoise, the process evaluation team
worked closely with the trial team to establish a feedback loop to report anything that could be easily
addressed without affecting the intervention itself. For instance, the time burden associated with compiling
information packs was reported back to the trial team and they subsequently changed the format of
recruitment packs to address this. This ensured that HCPs within the sites felt listened to and it encouraged
them to reflect on the trial and share their feedback with us.
Capacity issues at sites mainly affected recruitment levels in the trial. Understaffing, part-time contracts
and hectic workloads meant that staff members were limited in the amount of time that they could spend
on the trial. As some sites were already offering massage, this also meant that there were few eligible
participants to recruit. Interestingly, it was reported across all sites that participants randomised to the
control group of the trial were disappointed, but the retention rate was higher in this group. This may be
because the control group had a greater incentive to remain in the trial until the end, when they would be
offered the opportunity to learn the massage technique. Control group retention may also have been
positively affected by the telephone support offered by site staff. This may also have contributed to
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fewer differences between intervention and control group outcomes, because site staff gave advice on
medications as well as lifestyle.
What may be extrapolated from our process evaluation is that there is the potential for massage to improve
the symptoms of NBD; this in turn may then lead to reduced hospitalisations, reduced prescriptions, amount
of time HCP spend with patients and improved quality of life for PwMS. The main macrolevel changes from
the massage are said, by interviewees, to be freeing up staff capacity in the long term and greater quality of
life for PwMS. The argument would need to be made that the short-term work and costs associated with
implementing massage training would save money in the long term.
Health-care professional and stakeholder interviewees expressed interest in implementing abdominal
massage in the longer term. A number of sites were willing to adopt abdominal massage as a form of
treatment and many of these interviewees felt that there was potential to roll this out to wider population
groups, in a range of health and community settings. Finally, the words of our trial participants are
worth repeating:
It made a terrific difference, in fact I have to make myself look back to see how bad things were
because there’s a terrific improvement, yes. It’s made an awful lot of difference to me ‘cause things
were really bad to start with, but they’re a lot better now.
PwMS1_2
There are some strengths and limitations to the process evaluation. Strengths include the fact that although
we were unable to purposively sample, nevertheless the convenience sample yielded a participant mix that
reflected our initial hypotheses regarding time since diagnosis, severity of symptoms and sex. This enabled
us to capture robust data from which to explore potential variations in the experiences of trial participation
(PwMS), trial delivery (HCPs) and to reflect on issues of potential future implementation and sustainability.
The HCP interviews all included at least one staff member involved in delivering the trial at each site. This
allowed the researcher to identify any challenges around recruitment or other trial processes that could be
fed back to the trial management team. Another strength was the longitudinal nature of the research, thus
facilitating scope for follow-up on any problems raised during the original interviews and exploration of the
longer-term impact of abdominal massage. This is a methodological innovation rarely accomplished within
process evaluations and is a major strength of the AMBER trial. Similarly, interviewing HCPs in two stages
provided an opportunity to talk to additional staff members who had become involved in the trial later on,
allowing for the exploration of contextual factors, such as change in capacity over time, that might have
negatively affected trial delivery and implementation.
There are, however, some limitations to the process evaluation study. Owing to limited resources, only
those in the intervention group were recruited for interview; therefore, we could not explore any contexts
experienced by control group participants that might also have had an effect on outcomes. Another potential
limitation was that those who agreed to be interviewed were likely to have had a higher level of engagement
with the trial; thus, they may have been both more likely to fully participate in the intervention and to remain
in the trial until its completion. However, our analysis of bowel diaries linked to interview participants revealed
that they had variable levels of adherence to the massage. Although all interviewees remained in the trial,
interviews with those that did withdraw would have been informative. Finally, participants’ expectations of
the trial were not associated with positive or negative outcomes, suggesting that our conclusions regarding
their trial experiences and outcomes can be used to interpret wider trial outcomes. As only 12 sites (hospitals
in Scotland and England) were involved in the trial, and our stakeholder interview numbers were small, the
results cannot be seen to be representative of health-care services across the whole of the UK.
PROCESS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Chapter 6 Discussion
Neurogenic bowel dysfunction in PwMS has a significant impact on quality of life as demonstrated bythis quotation:
My whole life is ruled by my bowels – that’s all I think about every day, 24/7.
PwMS20
Despite this, it remains a topic that is often not discussed by patient or clinician and is perceived as an area
with few evidence-based treatment options.16
This is the first large RCT looking at the short- and long-term effects of a supported programme of advice
on lifestyle and training in abdominal massage compared with lifestyle advice only. Moreover, this research
adds to the evidence on the impact of NBD on quality of life, and identifies the most frequent symptoms
and possible mechanisms; it also facilitates the triangulation of information from the quantitative and
process evaluation substudies.
Overall, the study recruited to statistical target sample size; the 20% dropout rate was in alignment with
that expected in our sample size calculation. The increment in the primary outcome measure, the NBDS,31
favoured the intervention group but was small and did not show a statistically significantly different
change between groups at any time point, but we believe that findings of trials should not be described
as ‘negative’ on the simplistic metric of whether the p-value is strictly < 0.05. There is a small effect
(–1.64 units) that is around two-fifths of the specified MCID (4.21, as specified in the power calculation).
We estimated with good precision (i.e. we have narrow 95% CIs) a treatment effect on the primary
outcome that was around half the magnitude that we declared as being the estimated MCID, and we
found a p-value of 0.0558 for this difference. The bulk of the 95% CI (–3.32 to 0.04) is in favour of the
intervention, making benefit a more likely outcome than harm. Our lower 95% CI, at 3.32, rules out
our original suggested MCID of 4.21. It would, therefore, seem appropriate to say that we have weak
evidence of a small effect (< 2 units on the NBD measure) and our study has been able to rule out the
larger MCID of 4.21. The conclusion could then boil down to a CI that is mostly in favour of benefit, but
an effect that is smaller than the one the trial was designed to detect. Frequency of defaecation and
feeling of more complete emptying are two secondary outcomes specifically mentioned as being of great
importance in our interviews, and in both we did demonstrate statistically significant improvement in those
that undertook the massage, with similar benefits being reported by the bowel diary and specific questions
within the questionnaires.
As identified in Chapter 5, there does, however, appear to be some disparity between the quantitative
and qualitative findings. This may be attributable to the questionnaires being insensitive in this population
or could perhaps be a result of interviewees wishing to please the interviewer, or a mixture of the two.
The NBDS31 is only validated for NBD in spinal cord-injured patients. We used this as our primary outcome
measure because spinal cord-injury and MS patients have relatively similar NBD symptoms, the differences
being that only some symptoms in PwMS correspond to the level of the spinal cord lesions, can fluctuate
between constipation and faecal incontinence and may involve slow transit and/or pelvic floor dyssynergia.
However, there are also some differences in the pathophysiology of the diseases and approaches
to treatment.
Once stabilised and rehabilitated, spinal cord-injury patients tend to establish a bowel care routine often
established while in hospital. Their ‘disease’ does not progress and the bowel symptoms relate to the level
of injury. PwMS, on the other hand, have an ultimately progressive disease with many symptoms that
can fluctuate in nature and severity. In addition, we do not know all the physiological implications of the
disease on the bowel itself or on the neural control of the bowel. For this reason, the NBDS may not have
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been sensitive enough to detect changes in the symptoms that we have identified as mattering most to
the patient, that is, empowerment and control:
I know when I get to the toilet I’m going to have a bowel movement.
PwMS17
Our other symptom questionnaire, the CSS,32 is validated in those with chronic but non-neurological
constipation and, like the NBDS, uses terms that have been shown to be unfamiliar to the general public,
such as defaecation, use of drops for evacuation, evacuation, digital stimulation, evacuation of the rectum,
constipation, FI, flatus incontinence and perianal skin problems. A recent study has suggested that many of
these terms are unrecognised by the public62 and this aligns with some of our incomplete questionnaires
in which questions, for example, about digital stimulation were left incomplete, either because the patient
did not know what this was or were too embarrassed to answer (information gleaned from nurses’
calls). There were also some participants who stated that completing the questionnaires was very tiring,
especially the length of the NBIS questionnaire, which we were hoping to validate; this again may have
attributed to poor or indeed inaccurate completion. Moreover, the EQ-5D-5L35 results indicated that, in
both groups, MS symptoms worsened over the study period and this may have made it difficult to improve
one symptom significantly. Following on from our analyses of the NBIS questionnaires’ repeatability and
criterion reliability, further work is needed to determine which questions truly reflect what is important to
PwMS who have NBD.
Throughout the quantitative results, there is evidence of greater improvement in the intervention group
when compared with the control group in the symptoms of incomplete evacuation, infrequency and
reduced laxative use (and, therefore, side effects), which were also identified in the interviews. The sensation
of incomplete evacuation is a symptom that is rated as very common and causes a lot of distress with
> 90% of participants indicating that they were distressed:
Sometimes it would get so bad that I could hardly sit down because I was so bagged up and just
couldn’t go.
PwMS13
Data from the bowel diary indicated a significant benefit in this outcome [incomplete evacuation (mean
change 1.08, 95% CI 0.41 to 1.76; p = 0.002, see Table 19)]. The response to the individual question in the
CSS also indicated a benefit in this symptom (the percentage of participants in the intervention group who
never felt incomplete evacuation increased from 6.7% at baseline to 15.5% at week 24, and in the control
group this percentage decreased from 9.1% at baseline to 8.4% at week 24 (i.e. more participants in the
intervention group improved). Those in the intervention group who always felt that there was incomplete
evacuation decreased from 21.3% at baseline to 3.4% at week 24; in the control group, this percentage
decreased from 20.2% at baseline to 10.8% at week 24. Moreover, the results of the transit study test
identified that the markers in the intervention group moved more quickly to the distal colon, and so, if
not triggering voiding, could potentially aid evacuation once defaecation was started. Change in stool type
could also indicate a possible decrease in transit time with a move towards normal stool types 3 and 4.
For example, one participant who mainly passed stool types 1 or 2 before the trial every 3 to 4 days or
more stated:
It was just awful. I’d sit on the toilet for ages and ages and ages just knowing that I had to do
something and it was painful.
PwMS17
By the second stage of interviews, however, she had a bowel movement of stool type 3 or 4 every day:
It’s back to what it used to be years ago before the MS . . . really, really quite consistent.
PwMS17
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The results of stool consistency in the main study as recorded in the bowel diary also indicated a greater
percentage in the intervention group passing stool type 3 or 4 at week 6, as well as reporting less total
constipation at both weeks 6 and 24 (see Table 13).
An increase in stool frequency was evident from the responses in the NBDS, the CSS score and from the
bowel diary. This bowel diary outcome was significant (p = 0.039) and indicated an increase of 0.7 stools
per week [adjusted change from pre treatment versus week 6 was 0.5 stools per week (SD 1.55 stools per
week) in the intervention group and –0.2 stools per week (SD 1.64 stools per week) in the control group;
pre treatment versus week 24 in the intervention group was 0.4 stools per week (SD 1.79 stools per week)
and in the control group it was 0.2 stools per week (SD 1.62 stools per week)]. In addition, within the
repeated-measures analysis, the change in frequency of defaecation was significant at week 6 (OR 0.56,
95% CI 0.03 to 1.10; p = 0.039); although this effect was decreased at week 24. It is, however, worth
noting that at baseline the frequency of defaecation in the bowel diary was not that severe, with a mean
of 3.9 times a week (SD 1.71) and the NBD mean score of 8.2 (SD 5.2), indicating low to medium levels of
constipation; this was also supported in the CSS.
An episode of FI can have a devastating impact on a person’s self-esteem and confidence, creating a
reluctance to leave the house, and was described by one participant as an ‘absolute nightmare’ when it
happens, especially if out of the house. FI may be frank and unexpected or may be attributable to the
urgency created by the use of laxatives. There was no change in the frequency of FI episodes in the
quantitative data, but participants in our qualitative study reported decreased episodes of FI and more
confidence in leaving the house. Other reported benefits from doing the massage included feeling less
bloated, clothing becoming looser and a decrease in sluggishness with reduced fatigue levels.
Adherence
According to the self-completed diary, which recorded the frequency of undertaking the massage,
adherence to the massage intervention was good; 75% of participants administered the massage five
times per week, although, interestingly, the vast majority were undertaking self-massage. At week 24,
66% of participants were continuing with the massage at least three times per week. In the qualitative
interviews, participants reported that they practised the massage when it fitted into their routine and
altered it according to effect, that is they did not necessarily do it every day. In fact, one person felt it
to be too effective if undertaken every day.
The adherence to changing lifestyle, such as diet and exercise, was slightly greater in the control group,
with 30% (20% in the intervention group) saying that they had made at least one lifestyle change. Such
changes may have facilitated the changes reported within the control group. The overall uptake of the
suggested modifications, supported and discussed at the weekly telephone calls, was perhaps lower than
expected and is in contrast to what was reported in the qualitative interviews in which the participants said
that they found the information to be helpful. To that end, discussing it with the nurse should have aided
implementation in both groups. However, those in the control group were not interviewed (a limitation of
the study), so there is no feedback as to how they felt about the delivery of the advice. It is a recognised
feature that for some PwMS, the processing of such information is difficult and requires frequent,
spaced reinforcement.
Who benefits and why?
Abdominal massage is thought to work by stimulating the bowel and decreasing the overall transit time;
thus facilitating defaecation by the stronger propulsion of stools that are less hard and difficult to evacuate.
Within our anorectal substudy, it was identified that 60% of this subgroup demonstrated slow transit; if we
could extend this frequency of slow transit to the whole study group then it may, to some extent, explain why
DOI: 10.3310/hta22580 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 58
© Queen’s Printer and Controller of HMSO 2018. This work was produced by McClurg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
the response was varied and less than expected. Patients may also have anorectal dyssynergia, which can
make it difficult to pass stool; if this was the primary reason for their constipation, then abdominal massage
would have little effect. However, slow transit and dyssynergia often coexist and, unfortunately, owing
to poor uptake of the follow-up anorectal outcomes, we can only speculate and identify this as an area
requiring further investigation. Given the small improvement in the primary outcome but not in terms of
QALYs, a low-cost version of the intervention might be considered worthwhile by some patients. For example,
it could be a part of a supported self-management pathway for NBD in PwMS.
Our data indicate consistently that the male participants reported better outcomes from the intervention.
Although only a small group (n = 14 in the intervention group and n = 21 in the control group), the
reasons behind these findings are unclear (see Tables 18 and 19). It may be that the male participants
were stronger and less fatigued and undertook the massage more effectively. To date, we do not know
the amount of force that is needed to be effective in stimulating the bowel. Within our qualitative study,
a theme emerged around the adaptations made as a result of fatigue and difficulties actually doing the
massage; yet there was also a theme that this was something PwMS wanted to do themselves, so as not
to increase care burden, and a way of improving symptoms without taking medications. The amount of
pressure and an assistive device to help with self-massage are potentially other avenues that should be
explored. There was also some evidence that those with a slightly higher BMI, those who were slightly
older, those who were less cognitively impaired and those with relapsing–remitting MS improved with the
abdominal massage more than those with a lower BMI, who were younger, more cognitively impaired
and did not have relapsing–remitting MS. Potentially, the older participants may be retired and have more
time; however, why the slightly heavier people should improve more is difficult to explain.
Medication
Constipation was linked to laxative usage, which could also result in negative side effects. Interviewees
reported that taking laxatives caused pain, sleeplessness, cramps and diarrhoea. The unpredictability of
passing a stool when taking laxatives meant that a number of patients were afraid to leave the house once
they had taken laxatives. From the analysis of laxative use, it would seem that those in the intervention
group were more likely to reduce their laxative use. Participants’ overall medication change was monitored
and the number of medications seemed to change more in the control group; however, this was difficult
to analyse as several participants had multiple changes and, in one instance, suppositories were individually
mentioned. It was, however, interesting to see the history of the prescribing of laxatives, where it seemed
to be the norm to increase the dose as well as prescribing additional laxatives within a short space of time.
This is an intervention for which we found no evidence of harm and which does not require extensive
resources or training. There were a small number of AEs, none of which could be directly attributable to
the massage. Moreover, this is the first time that the reduced training, to both clinicians and participants,
was rolled out. In our earlier studies, those teaching the massage to the participants were experienced
continence clinicians and the participants received weekly follow-up visits for support. In this trial, some of
the clinicians had no experience of treating either bladder or NBD and only one had pre-trial experience
with the massage. Feedback from clinicians was very supportive of the intervention and our recruitment is
testimony to this. Some reported that further training may have been helpful and this is understandable
if a ‘hands-on’ concept was new and also the lifestyle information was not within their usual scope
(clinicians comprised MS nurses, continence nurses, a research nurse and one research assistant). However,
as shown in our secondary and sensitivity analyses (see Tables 18 and 19), results were not significantly
dependent on sites and the experience of the researchers.
If this intervention was to roll out within the NHS, then we suspect that it would depend on local services
to facilitate staff training; yet, where these staff sit (e.g. the continence service or the MS nurse service) is
undecided at the moment. Remarkably, there was no feedback from participants that they would have
preferred more training or support with the massage. The interviews did highlight that, during the initial
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training, some people preferred the massage to be administered over their clothes or on body parts other
than their stomach. This may have affected how the staff member was able to deliver training, because
the massage should be administered on the abdomen in order to allow the patient to gauge pressure. The
clinicians interviewed all remained enthusiastic about the intervention, which influenced the mainly positive
feedback participants were giving to them. Those used to treating PwMS recognised that interventions
to treat the symptoms of NBD are scarce and that this could be a part of their ‘toolkit’, as an adjunct or
perhaps instead of, for instance, laxatives, rectal irrigation, biofeedback, none of which is evidence based.
Stakeholders also recognised that there was a definite need for additional treatment modalities and that
this is a relatively cheap intervention if, after appropriate assessment and training, it is undertaken by the
patient themselves or a carer. Additional resources may, however, be required should NHS employees be
required to administer the massage routinely.
Limitations
There are several limitations in this study. The differential numbers recruited to our two groups (attributable
to minimisation by centre) coupled with the additional numbers in the intervention group who failed to
complete the study meant that we ended up with a smaller number in the intervention group than we had
hoped. The extent of missing data and the reasons behind it have been explored but do not seem to be
related to any predictable factors. One site, UCH, London, which undertook the anorectal physiology tests,
had a slightly lower retention rate (76.9%); this may have been because of the invasive nature of these tests
and the unwillingness of participants to return for follow-up. Royal Preston and the Walton Centre both had
a retention rate of 81%, but no specific pattern for loss to follow-up could be identified as reasons were
varied and appeared unconnected to the intervention (e.g. family illness, moving location).
It may also have been better to use more stringent inclusion/exclusion criteria, such as Rome III,63 as some
participants were not severely affected (according to the primary outcome measure) by their constipation
and, therefore, had limited capacity to improve. These criteria had been used in a previous study by the
authors, but were felt to be too stringent, focusing, as they do, on a clinical expert definition rather than
a patient-based or a combined clinician–patient definition of constipation. Indeed, the suitability of the
Rome III criteria for assessing symptoms of constipation has been challenged, as studies show that many
patients who report constipation symptoms do not fulfil the Rome III criteria.64–66 Patients’ perception of
‘bothersomeness’ seemed to fit better. A large number of participants undertook the massage themselves,
but because of their weakness and fatigue the effectiveness may have been reduced. Several participants
in our qualitative study stated some difficulty self-massaging because of fatigue, but tried to work out a
way around it by, for example, taking rests. However, for some participants, the massage was probably
undertaken at a suboptimal level. Within our process evaluation study, owing to financial constraints, the
interviews were only conducted with those who were undertaking the abdominal massage, which poses a
limitation on our knowledge of the uptake of the advice and perceptions of taking part in the trial as part
of the control group. The limitations in the economic evaluation have already been discussed in Chapter 4.
Future research
It would seem from the results of the RCT, the qualitative study and the health economic component that,
similar to other studies, abdominal massage is effective on some patients. Most likely, these would be
patients who have primarily slow transit (potentially 60% in this study). Therefore, future research should
focus on identifying those with slow transit, which, as our anorectal substudy showed, is not easy to
do using invasive tests. There have been attempts to validate questionnaires (e.g. Kess Questionnaire66)
that may indicate which type of constipation a person has, that is slow transit and/or dyssynergia, and
these should first be validated in a MS population and then used for possible screening of those with
predominant slow transit constipation. In addition, the optimum frequency and, importantly, intensity of
massage should be explored with use of pressure-sensitive devices and massage devices.
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The following is a list of recommendations for future research:
l further mechanistic evaluation of NBD and ways of identifying those with predominantly slow transit
l further validation of the NBIS questionnaire
l development of a treatment algorithm that would aid clinicians in the treatment of NBD
l development and evaluation of a device to aid abdominal self-massage
l development and clinical trials of other interventions that may help with the symptoms of constipation/
FI, for example the superfruit baobab, which has recently been developed into a drink, Baotic (Hippo &
Hedgehog Ltd, Glasgow, UK).
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Chapter 7 Conclusion
The benefits of using abdominal massage for the relief of symptoms in PwMS and NBD are not clearlydemonstrated by the results of this methodologically high-quality trial. Moreover, there is uncertainty
around cost estimates with domination by the control group. The research identified that, although the
increment in the primary outcome favoured the intervention, it was not statistically significant. The analysis
of the process evaluation component identified that most (15/20) participants reported benefit and felt it
an attractive option as it was non-pharmacological and non-invasive. Feedback from clinicians teaching the
massage was also positive, although in a few cases they expressed concern around the capability of the
participant to do the massage effectively. Budget holders, albeit before the results of the trial were known,
thought that the infrastructure and training required to introduce abdominal massage as an additional
treatment option in this group of patients was implementable.
Based on the results of this programme of work, we believe that there are some PwMS and NBD who may
benefit from undertaking abdominal massage as a low-cost, self-management intervention; the challenge
is to identify these individuals and introduce it as part of a self-management bowel care pathway. Bowel
dysfunction is not widely researched; there are fewer than 30 RCTs (n = 1300 participants)16 published
relating to all neurogenic bowel conditions.
Work such as this should be used to develop a treatment algorithm to facilitate better management of FI
and/or constipation, thus improving the lives of patients and their carers.
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Appendix 1 Massage training materials
The ideal position of the participant is supine with appropriate head and knee support, and in
a relaxed atmosphere. Adaptations to this position may be required depending on the patient’s
disability.
There are 4 basic strokes with the massage lasting about 10 minutes. 
1. Stroking commences from the small of the back, over the iliac crests, and down both 
sides of the pelvis towards the groin.
2. Effleurage follows the direction of the ascending colon across the transverse colon 
and down the descending colon. This is also repeated several times with increasing 
pressure
3. Palmar Kneading tracks down the descending colon, up the ascending colon, and 
down the descending colon once again. Effleurage is repeated and continued with a 
relaxing transverse stroke over the abdomen. 
4. Vibration over the abdominal wall to relieve flatus concludes the massage session. 
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Appendix 2 Data Monitoring and Ethics
Committee charter
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Appendix 3 Site and recruitment information
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Site Type of facility Governing body Target, n
Participants
recruited,
n (% met)
Retention,
n (%)
Trial group, n (%)
HCPs involved
Current bowel treatments
offered
Abdominal
massage
Standard
care
Anne Rowling
Clinic, Edinburgh
Neurological
research facility
NHS Lothian
Health Board
10 9 (90) 9 (100.0) 4 (4.4) 5 (5.1) Consultant neurologist None. This site is focused more on
advancing MS research
John Radcliffe
Hospital, Oxford
Tertiary teaching
and research
hospital
Oxford University
Hospitals NHS
Foundation Trust
20 17 (85) 15 (88.2) 9 (10.0) 8 (8.1) MS specialist nurse
and research nurse
Bowel problems are
underrecognised and only referred
to the bowel specialist nurse
when explicitly raised
St Mary’s
Hospital, Leeds
Community
health-care
service
Leeds Community
Healthcare NHS
Trust
10 10 (100) 10 (100.0) 4 (4.4) 6 (6.1) Bowel specialist nurse
and research nurse
Specialised bowel clinics and
home visits for those with
constipation, FI and irritable bowel
dysfunction
Lincoln County
Hospital, Lincoln
District general
hospital
United Lincolnshire
Hospitals NHS
Trust
10 13
(exceeded
by n= 3)
13 (100.0) 7 (7.8) 6 (6.1) Consultant neurologist
and research nurses
Advice from a MS specialist nurse
Northampton
General
Hospital,
Northampton
General,
specialist and
teaching hospital
Northampton
General Hospital
NHS Trust
20 14 (70) 12 (85.7) 7 (7.8) 7 (7.1) Research and
Development team,
research nurse and MS
nurse specialist
Home visits and a bladder and
bowel clinic, with bladder
specialist nurse and bowel
specialist nurse
Royal
Hallamshire
Hospital,
Sheffield
Clinical research
facility
Sheffield Teaching
Hospitals NHS
Trust
10 17
(exceeded
by n= 7)
16 (94.1) 8 (8.9) 9 (9.1) Research sister, clinical
research nurse and
consultant neurologist
Laxatives and diet advice in
neurology department
Royal Preston
Hospital, Preston
District general
hospital
Lancashire
Teaching Hospitals
NHS Foundation
Trust
20 22
(exceeded
by n= 2)
18 (81.0) 10 (11.1) 12 (12.1) Senior research nurse
and neurologist
Laxatives, digital stimulation,
medication and self-administration
of enemas
Royal Victoria
Infirmary,
Newcastle upon
Tyne
Tertiary teaching
hospital
Newcastle upon
Tyne NHS
Foundation Trust
20 17 (85) 16 (94.1) 8 (8.9) 9 (9.1) Consultant (50%
neurology, 50% MS)
and research nurse
MS patients only get to see the
bowel specialist in Newcastle
upon Tyne if there is a significant
problem
Salford Royal
Hospital, Salford
General,
specialist and
teaching hospital
Salford Royal
Hospital NHS
Foundation Trust
20 15 (75) 14 (93.3) 7 (7.8) 8 (8.1) Research officer and
senior research nurse
Dietary advice from MS specialist
nurses. If bowel problems
continue, they refer PwMS to
colorectal specialists
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Site Type of facility Governing body Target, n
Participants
recruited,
n (% met)
Retention,
n (%)
Trial group, n (%)
HCPs involved
Current bowel treatments
offered
Abdominal
massage
Standard
care
Southern
General
Hospital,
Glasgow
Tertiary referral
centre
NHS Greater
Glasgow and
Clyde Health Board
20 20 (100) 18 (90.0) 10 (11.1) 10 (10.1) Health-care support
worker, MS nurse and
consultant neurologist
with specialist interest
in MS
MS team can refer to
gastroenterology department for
them to investigate the problem
and offer medication
The Walton
Centre, Liverpool
Neuroscience
centre
The Walton Centre
NHS Foundation
Trust
20 11 (55) 9 (81.8) 5 (5.6) 6 (6.1) Consultant neurologist
and research nurse
Bowel issues are discussed in
multidisciplinary clinic and bowel
management advice is given
UCH, London National referral
and teaching
hospital
University College
London Hospitals
NHS Foundation
Trust
30 26 (87) 20 (76.9) 11 (12.2) 13 (13.1) Bowel management
specialist nurse and
gastroenterologist
consultant
This is a specialist bowel centre.
Sustainable provision for those
with lower bowel conditions:
irrigation feedback, pelvic floor
physiotherapy, tailored drug
regimes, irrigation therapy,
surgery and diet advice
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Appendix 4 Differences in characteristics of
missing Neurogenic Bowel Dysfunction Score at
24 weeks compared with complete data
Variable
NBDS at week 24, n (%)
Total, n (%)Present Not present
Intervention
Abdominal massage 72 (44.4) 18 (66.7) 90 (47.6)
Standard care 90 (55.6) 9 (33.3) 99 (52.4)
Total 162 (100.0) 27 (100.0) 189 (100.0)
Centre
Southern General Hospital, Glasgow 18 (11.1) 2 (7.4) 20 (10.6)
Royal Victoria Hospital, Newcastle upon Tyne 15 (9.3) 2 (7.4) 17 (9.0)
UCH, London 18 (11.1) 6 (22.2) 24 (12.7)
Royal Preston Hospital, Preston 14 (8.6) 8 (29.6) 22 (11.6)
The Walton Centre, Liverpool 9 (5.6) 2 (7.4) 11 (5.8)
John Radcliffe Hospital, Oxford 15 (9.3) 2 (7.4) 17 (9.0)
St Mary’s Hospital, Leeds 10 (6.2) 0 (0.0) 10 (5.3)
Lincoln Community Hospital, Lincoln 13 (8.0) 0 (0.0) 13 (6.9)
Salford Royal Hospital, Salford 14 (8.6) 1 (3.7) 15 (7.9)
Royal Hallamshire Hospital, Sheffield 16 (9.9) 1 (3.7) 17 (9.0)
Northampton General Hospital 11 (6.8) 3 (11.1) 14 (7.4)
Anne Rowling Centre, Edinburgh 9 (5.6) 0 (0.0) 9 (4.8)
Total 162 (100.0) 27 (100.0) 189 (100.0)
Minimisation criterion
Walking unaided 66 (40.7) 13 (48.1) 79 (41.8)
Aided walking 76 (46.9) 13 (48.1) 89 (47.1)
Wheelchair bound 20 (12.3) 1 (3.7) 21 (11.1)
Total 162 (100.0) 27 (100.0) 189 (100.0)
Sex
Male 31 (19.1) 4 (14.8) 35 (18.5)
Female 131 (80.9) 23 (85.2) 154 (81.5)
Total 162 (100.0) 27 (100.0) 189 (100.0)
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Differences in continuous characteristics of missing Neurogenic Bowel
Dysfunction Score at 24 weeks compared with complete data
Variable
NBDS at week 24
TotalPresent Not present
Total NBDS at baseline
Complete, n 155 25 180
Missing, n 7 2 9
Mean (SD) 8.1 (5.1) 8.3 (6.0) 8.2 (5.2)
Median (minimum, maximum) 8.0 (0, 22) 6.0 (1, 22) 7.5 (0, 22)
Age (years)
n 162 27 189
Missing, n 0 0 0
Mean (SD) 52.8 (10.7) 49.4 (11.3) 52.3 (10.8)
Median (minimum, maximum) 52.0 (26, 79) 48.0 (32, 70) 51.0 (26, 79)
Time since diagnosis of MS (years)
n 162 27 189
Missing, n 0 0 0
Mean (SD) 14.4 (9.4) 14.1 (8.1) 14.3 (9.2)
Median (minimum, maximum) 13.0 (0, 51) 14.0 (1, 32) 13.0 (0, 51)
BMI
n 157 25 182
Missing, n 5 2 7
Mean (SD) 26.7 (5.9) 27.3 (5.8) 26.8 (5.9)
Median (minimum, maximum) 25.8 (14.7, 48.8) 26.5 (19.8, 43.9) 25.9 (14.7, 48.8)
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Appendix 5 Summary of stool type
(Bristol stool chart information)
Time point
Trial group (%)
Intervention Control
Baseline
No stool 39.8 40.1
Types 1 and 2 21.8 18.9
% constipated 61.6 59.0
Types 3 and 4 20.2 17.5
Types 5, 6 and 7 16.0 19.6
Missing 2.3 3.8
Week 6
No stool 35.0 38.8
Types 1 and 2 22.4 19.0
% constipated 57.4 58.2
Types 3 and 4 29.9 23.6
Types 5, 6 and 7 11.4 14.6
Missing 0.9 2.4
Week 24
No stool 32.0 41.4
Types 1 and 2 23.4 17.5
% constipated 55.4 58.9
Types 3 and 4 23.9 22.8
Types 5, 6 and 7 15.5 12.0
Missing 5.0 5.7
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Appendix 6 Summary of all adverse events
Variable
Trial group, n (%)
Total, n (%)Intervention Control
Severity
Mild 10 (35.7) 26 (46.4) 36 (42.9)
Moderate 14 (50.0) 23 (41.1) 37 (44.0)
Severe (not serious) 4 (14.3) 7 (12.5) 11 (13.1)
Total 28 (100.0) 56 (100.0) 84 (100.0)
Causality
Unrelated 25 (89.3) 54 (96.4) 79 (94.0)
Possibly related 3 (10.7) 2 (3.6) 5 (6.0)
Total 28 (100.0) 56 (100.0) 84 (100.0)
Action taken
None 14 (50.0) 22 (39.3) 36 (42.9)
Hospitalisation 2 (7.1) 4 (7.1) 6 (7.1)
Medication(s) commenced 6 (21.4) 23 (41.1) 29 (34.5)
Other 2 (7.1) 2 (3.6) 4 (4.8)
Hospitalisation/medication(s) commenced 1 (3.6) 3 (5.4) 4 (4.8)
Intervention reduced/other 1 (3.6) 0 (0.0) 1 (1.2)
Medication(s) commenced/other 2 (7.1) 0 (0.0) 2 (2.4)
None/other 0 (0.0) 2 (3.6) 2 (2.4)
Total 28 (100.0) 56 (100.0) 84 (100.0)
Outcome
Recovered 17 (60.7) 37 (66.1) 54 (64.3)
Ongoing 11 (39.3) 19 (33.9) 30 (35.7)
Total 28 (100) 56 (100) 84 (100.0)
Summary of serious adverse events
SAE
Trial group (n)
Total (n)Intervention Control
Breast cancer 1 0 1
Cholecystitis 0 1 1
Fall 1 0 1
Femoral neck fracture 0 1 1
Localised infection 0 1 1
MS relapse 1 1 2
Myocardial infarction 0 1 1
UTI 0 1 1
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Appendix 7 Cost-effectiveness analysis of
abdominal massage versus standard care
Measurement
MI with a seemingly
unrelated regression model Mixed model
Difference in costs (£)
Mean 50.02 77.54
SE 156.84 143.8
Difference in QALYs
Mean –0.002 0.0026
SE 0.012 0.011
ICER (£ per QALY) –19,392.89 28,722.05
Probability of cost-effectiveness at £20,000 per QALY gained (%) 37 46.6
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Appendix 8 Frequency of health-care contacts,
by trial group, at baseline
Service used
Trial group (n)
Intervention group Control group
BR HR BR HR
GP at surgery 0 5 0 6
Nurse at surgery 0 2 0 0
GP on the telephone 0 1 1 4
Nurse on the telephone 0 0 1 2
GP at home 0 0 0 0
Nurse at home 3 0 1 0
Out-of-hours clinic 0 0 0 0
Outpatient department 1 3 2 6
Admitted to hospital 0 0 0 0
A&E visit 0 0 0 0
Allied Health Professionals 0 8 0 9
Continence Service 0 0 1 1
A&E, accident and emergency; BR, resource use for bowel problems; HR, resource use for health problems other than
bowel problems.
Note
Data include all participants who participated in the trial at baseline. There are 90 participants in the intervention group and
99 in the control group.
Frequency of health-care contacts, by trial group, recorded at week 6
Service used
Trial group (n)
Intervention group Control group
BR HR BR HR
GP at surgery 1 15 1
Nurse at surgery 0 7 0
GP on the telephone 1 7 1
Nurse on the telephone 6 7 11 4
GP at home 0 0 0 1
Nurse at home 10 2 5 0
Out-of-hours clinic 0 0 0 2
Outpatient department 4 13 1
Admitted to hospital 0 2 1 5
A&E visit 0 0 0 1
Allied Health Professionals 2 41 0
Continence Service 3 2 0 2
A&E, accident and emergency; BR, resource use for bowel problems; HR, resource use for health problems other than
bowel problems.
Note
Data include all participants who participated in the trial at week 6. There were 60 participants in the intervention group
and 84 in the control group.
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Frequency of health-care contacts, by trial group, recorded at week 24
Service used
Trial group (n)
Intervention group Control group
BR HR BR HR
GP at surgery 7 29 7 42
Nurse at surgery 4 15 1 27
GP on the telephone 7 18 2 20
Nurse on the telephone 12 0 3 9
GP at home 1 2 1 9
Nurse at home 6 7 14 10
Out-of-hours clinic 0 0 0 3
Outpatient department 3 20 4 40
Admitted to hospital 1 6 1 8
A&E visit 1 1 0 4
Allied Health Professionals 8 27 14 73
Continence Service 3 3 5 7
A&E, accident and emergency; BR, resource use for bowel problems; HR, resource use for health problems other than
bowel problems.
Note
Data include all participants who participated in the trial at week 24. There were 58 participants in the intervention group
and 83 in the control group.
Total frequency of health-care contacts, by trial group, excluding baseline
Service used
Trial group (n)
Intervention group Control group
BR HR BR HR
GP at surgery 8 44 8 60
Nurse at surgery 4 22 1 42
GP on the telephone 8 25 3 32
Nurse on the telephone 18 7 14 13
GP at home 1 2 1 10
Nurse at home 16 9 19 10
Out-of-hours clinic 0 0 0 5
Outpatient department 7 33 5 67
Admitted to hospital 1 8 2 13
A&E visit 1 1 0 5
Allied Health Professionals 10 68 14 117
Continence Service 6 5 5 9
A&E, accident and emergency; BR, resource use for bowel problems; HR, resource use for health problems other than
bowel problems.
Note
Data include all participants who participated in the trial excluding baseline. There were 60 participants in the intervention
group and 84 in the control group.
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Appendix 9 NHS unit costs
Service Unit cost (£) Reference
GP at surgery 44 PSSRU
Nurse at surgery 16 PSSRU
GP on the telephone 27 PSSRU
Nurse on the telephone 5 PSSRU
GP at home 114 PSSRU
Nurse at home 47 PSSRU
Out-of-hours clinic 66 PSSRU
Outpatient department 117 DHSC reference costs41
Admitted to hospital 1609 DHSC reference costs41
A&E visit 138 DHSC reference costs41
Allied Health Professionals 24 PSSRU
Continence (Hospital) Service 108 PSSRU
A&E, accident and emergency; DHSC, Department of Health and Social Care; PSSRU, Personal Social Services Research Unit.
Notes
Admitted to hospital refers to the cost of an average impatient stay as estimated in the PSSRU. The cost of £1609 was
applied to each case of hospitalisation assuming an average inpatient stay.
Resource-use NHS costs per participant, by trial group, at baseline
Summary statistics
Trial group (£)
Intervention Control
Mean cost per participant 14.59 17.73
Standard error 4.12 5.12
SD 35.41 48.82
95% CI 6.39 to 22.80 7.56 to 27.89
t-test on the equality of means 0.46
Notes
Data include all participants who participated in the trial. There were 90 participants in the intervention group and 99 in the
control group at baseline. See Table 31 for NHS services included in these calculations.
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Resource-use NHS costs per participant, by trial group, at 6 weeks
Summary statistics
Trial group (£)
Intervention Control
Mean cost per participant 120.65 186.78
Standard error 38.01 52.36
SD 299.29 485.60
95% CI 82.67 to 290.89 82.67 to 290.89
t-test on the equality of means 0.95
Notes
Data include all participants who participated in the trial. There were 60 participants in the intervention group and 84 in
the control group at week 6. Reported contact with NHS services from baseline to 6 weeks. See Table 31 for NHS services
included in these calculations.
Resource-use NHS costs per participant, by trial group, at 24 weeks
Summary statistics
Trial group (£)
Intervention Control
Mean cost per participant 312.14 313.18
Standard error 104.45 65.90
SD 795.49 600.41
95% CI 102.98 to 521.30 182.08 to 444.28
t-test on the equality of means 0.01
Notes
Data include all participants who participated in the trial. There were 58 participants in the intervention group and 83 in
the control group at week 24. Reported contact with NHS services from 6 weeks to 24 weeks. See Table 31 for NHS
services included in these calculations.
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Appendix 10 Roles of health-care
professionals interviewed
Type of interviewee
Interviewees in
total (n)
Interviewed in first
stage (n)
Interviewed in second
stage (n)
Principal investigator 6 6 2
Research nurse (including those in senior positions) 7 6 6
General nurse 1 1 1
MS specialist nurse 3 3 3
Health-care support worker 1 0 1
Bowel management specialist nurse 2 2 2
Research co-ordinator/officer/assistant 5 5 4
Stakeholders selected for interview
Type of organisation Aim of organisation Interviewees (n) Expertise of interviewees
MS charities Support and resources for PwMS 2 Policy and research
Incontinence foundations Supporting people with continence
problems; developing educational
and commissioning guidelines
3 Continence service provision;
commissioning
NHS Specialist Commissioner Commissioning support for
neurology services in the NHS
1 Neurology expertise; policy
and research
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Appendix 11 Topics discussed during interviews
Intervention group
First stage at week 4 Second stage at end of study
Personal experiences with MS and bowel problems Issues faced during first stage
Recruitment into trial Trial paperwork
Massage training Weekly nurse calls
Weekly nurse calls Any other challenges to lifestyle
Trial paperwork Impact of massage on bowel problems
Administering massage Unexpected health benefits of massage
Initial impact of massage on bowel problems Post-trial intentions with the massage
Any problems Any problems
Advice for other participants/staff members Advice for other participants/staff members
Health-care professionals
First stage Second stage
Training delivered by the AMBER trial team Issues faced in first stage
Recruiting participants Participant recruitment (target met or not)
Training participants in massage Training participants in massage
Dealing with control group participants Dealing with control group participants
Participant follow-up (weekly calls) Participant follow-up (weekly calls)
Current treatment options at the site Any problems faced/advice for other sites
Other policy and clinical developments at the site Implementing the treatment long term
Any problems faced/advice for other sites Any problems faced/advice for other sites
Stakeholders
l The organisation’s role in neurological and/or incontinence services.
l Current policy developments in this area (local, regional and national).
l Current treatment options for bowel problems, particularly neurogenic ones.
l Whether or not there is a need for an additional treatment option.
l The long-term implementation of abdominal massage and any challenges involved.
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Appendix 12 Process evaluation interview
schedules and site questionnaire
Includes:
l draft interview schedule – participant interviews (first stage)
l interview schedule – participant interviews (second stage)
l interview schedule – stakeholder interviews
l draft interview schedule – HCP site interviews (first stage)
l draft interview schedule – HCP site interviews (second stage)
l six-month site-tracking questionnaire.
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Draft Interview Schedule: Participant Interviews (First Stage)
Introduction to the project
1.I’d like to start by finding out a little bit about you (sets context). 
Please could you tell me about your life:
Where do you live? Who do you live with? 
Are you employed, unemployed or retired? If unemployed or retired, what was your previous
occupation? 
2.I would now like to move on to discuss your health. 
Could you tell me a little about your health: 
How long ago were you first diagnosed with MS? Which type of MS do you have and has 
this always been the case (i.e. it might have progressed into another type)? What impact does
this have on you physically (mobility issues, visual, bowel/bladder, fatigue, numbness) and 
emotionally (cognitive issues, depression, mood swings)?
How do you manage your symptoms (e.g. gentle exercise, sleep patterns, diet, medication, 
bladder/bowel strengthening exercises)? Have you ever used any non-abdominal form of
massage? If so, did this elevate your symptoms and how was this treatment administered
(self, carer, nurse)? If not, why not, and would they consider having any non-abdominal
massagespost-AMBER? 
Do you go to any support groups (charities, community groups, friends) relating to MS?
If any experience with bowel problems: You mentioned earlier that you had problems with
your bowel – could you expand on this, explaining the difficulties you face and the impact
this has on your life?
3.I would like to explore your previous knowledge of abdominal massage
Before you signed up to the AMBER trial, what did you know about abdominal massage as a 
form of treatment for bowel problems and have you ever used it before the AMBER trial?
If little knowledge and experience, then what are your thoughts on it as a way of managing
bowel problems? Is this preferable over alternative forms of treatment (e.g laxatives)?
If knowledge but no experience, then why did you never use it as a form of treatment – 
perhaps alternative methods were used? 
If knowledge and experience, how has AMBER differed from previous massages? Did you
find the other abdominal massages worked and, if so, what encouraged you to sign up for 
AMBER? 
4.Now I would like to find out a bit about your experience of taking part in AMBER. 
Let’s start from the beginning. How did you find the process of recruitment? How did you 
feel about the treatment before attending your baseline appointment? Did anyone (e.g. 
relative, friend) attend the baseline appointment with you? Was everything clearly explained 
to you at the baseline appointment? Is there any way this could be improved?
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How was the AMBER training administered and by whom? How do you feel the training 
went – was everything clearly explained and did you feel you had a clear understanding by 
the end of it? Is there any way this could be improved?
Will you be administering the massage yourself at home or will someone else? If yourself,
how confident were you after the baseline appointment – has this changed at all? If someone
else, did they attend the massage training? If yes, do they feel confident after the training? 
Did they have any suggestions for improvement? 
5.I now would like to look at expectations of AMBER when agreeing to take part in the trial.
Why did you sign up for the AMBER study (i.e. expectations about outcomes)? Was
anything different to what you expected? Did these outcomes change at any point during the 
study (baseline appointment, training, after that)?
6.Could we now discuss how you have been getting on with the abdominal massage. 
[Based on response to question 4 about who is administering it]: how often have you/they
been do this? Do you/they do this at a set time or whenever is convenient? How long does the 
massage and setting up/winding down take? Is this similar to your other forms of symptom 
management (i.e. has it been incorporated into a daily routine or is it burdensome)? 
Have you altered the massage at all to suit your needs (e.g. using fists to combat fatigue)? Do
you feel you/they have a good grasp of the technique? How motivated are you to carry out
the massage? Do you have any support when doing the massage or to chat to people about the 
massage (e.g. local support groups, carer)?
7.May we now discuss whether you have experienced any benefits of doing the massage? 
Have you seen an improvement in your bowel functions? If so, in what way (passing stools 
more frequently and easily)? If not, why do you think this is the case (.e.g. massage not
administered correctly, diet, medication, any other factors)? 
Have there been any other unexpected benefits (e.g. decreased use of laxatives, more
confidence, other physical symptoms)? What impact has this had on your life (e.g. able to go
out more, able to eat more, able to engage in another activity like exercise without feeling 
bloated)? 
8.Have you experienced any problems in doing the massage? 
[Based on response to question 7 about their success so far with the massage] Have you/they
encountered any problems when carrying out the massage? If so, what was the main issue 
(e.g. pressure to apply, fatigue (if themselves), timing of steps, confusion about massage)?
Did you/they devise any solutions to deal with this? 
If not, did you believe there would be any problems (e.g. see those above) before undertaking 
the treatment and, if so, what were related to? Why do you think this has problem has not 
arisen (e.g. good grasp/adaption of technique, found the right amount of pressure, etc.)?
Would you recommend that intervention staff at other sites adopt this lesson in their training?
9.We hope that if AMBER works well for patients, that we might roll this out more widely to
help others. Based on your experience so far, is there anything that we could do better? 
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You have summarised your experience with AMBER so far, is there anything that could be
done differently to improve it (e.g. information leaflets provided, training with intervention 
team, DVD and other training materials, providing more support during the process – 
telephone calls with nurses in particular, provisions for visual problems and other 
disabilities)? 
Do you think there is anything in particular that could improve the experience for patients 
who are of a similar age group, as well as the same gender and employment status, as
yourself? [Captures demographic details – perhaps there will be different requirements for 
younger employed females, for instance, compared to older, retired males]
10.Lastly, is there anything that we could do to encourage more MS patients to take part in
AMBER?
Earlier we discussed why you were motivated to sign up for AMBER – do you think those 
reasons would encourage other people with MS to do the same? If not, why not? Do you 
think there is a way to tackle this issue (e.g. be clearer about what the study involves, provide
more incentives to take part)?
[If they stated they keep in touch with other MS patients in their answer to question two] Did 
you tell your friends/group members about your participation in AMVBER? If so, what were
their thoughts about it? Did you try to encourage them to sign up? If not/they declined, why 
was this the case (do not meet criteria, not enough support in place, unsure about study)? 
What about motivation during the study: did you feel engaged and motivated throughout the 
process? If not, why not (e.g. not enough support, difficulties with massage, etc.)? If this was 
the case, why did you refrain from dropping out? What would you suggest to encourage 
completion from other MS patients?
For those interviewed who have ‘dropped out’/not completed:
Ask questions 1-5 (modifying as appropriate to their responses) then follow with: 
11.I understand that you withdrew early from the study. We would like to learn from you 
what might have put you off and what we might be able to do better.
Could you please explain why you dropped out the study (e.g. personal reasons, lack of time, 
problems with study)? If personal/unrelated to study, is there anything AMBER could have
done to help you with this? Have you got adequate support in place to deal with this issue? 
[This is where a recommendation to a support centre for advice might come in] 
If directly related to the study, follow up on why they did not feel motivated and engaged 
with the process: What would have helped with your motivation? How could the level of
support provided been improved? What would you recommend to avoid making the same
mistakes with future patients of AMBER?
Thank you for your time – we value your input. 
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Interview Schedule: Stakeholder Interviews
Introduction
1. I’d like to start by finding out a little bit about you. Please could you tell me about your 
role as [insert role]? 
I’d like to find out more about the current projects you are involved with [add details 
based on background research and tailor questions around these.] 
2. [Check how much she knows about AMBER beforehand] What do you think the 
potential might be for self-led abdominal massage to help MS patients with bowel 
problems? How does this compare to other forms of treatment for bowel problems?
-What kind of savings could be made by patients using self-led abdominal massage (i.e. in
terms of not having to see a more expensive staff members like a GP or consultant, reducing 
nurse contact with patient and chances of hospitalisation)? 
Some people with MS are not under the care of an MS service – impact on them? 
3. If AMBER proves to be effective for managing bowel problems in MS patients, we
would like to take this forward to implement the intervention within NHS contexts. Do
you have any thoughts on what might help or hinder that? 
Implementing massage
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-Could details for the massage be detailed in existing resources, such as guide to bowel
problems or ‘Making Sense of MS’ booklet provided to newly diagnosed patients? 
-Which stakeholders/NHS gatekeepers would need to be engaged/involved in the process?
[Scottish MS Register, British Neurologists, third sector organsiations?] 
-Sustainability: would this be a long-term initative?
-Would it be implemented in MS Trust educational training, e.g. ‘MS Nurse Support 
Programme.’
4. Can you tell us anything about current or forthcoming policies related to the treatment of
MS patients that might have a bearing on the rollout of AMBER in the future? 
[Add details based on background research pertaining to neurology/continence services based 
on expertise of interviewee.] 
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Draft Interview Schedule: Health Care Professional Site Interviews (Second Stage)
1. Recruitment 
The [add name of site] has currently recruited [add number of participants at time of second
stage interview]. Do you think the site will reach its target of [insert number] participants
and, if so, do you think it will be able to recruit over this? What advice would you give to
other teams in order to recruit successfully? 
[Add details of recruitment and any problems faced during first stage of interviewing, 
including information discovered from interviews with other HCPs at this site.]
There has been [add number] potential withdrawal (check this). Why do you think the site has 
been so successful/struggled [delete as appropriate] with retention? Have there been any 
particular problems with patient recruitment and/or retention during the AMBER trial?
[Only ask to those actively involved in recruitment] In the last interview, you were the one 
been dealing with recruiting patients (e.g. sending out packs, arranging appointments, etc.) – 
did this continue during the trial or did another member of staff get involved in this? 
2. Delivering intervention 
Since we spoke last year, were there any difficulties during the process of administering the 
massage. If so, what impact do you think this would have had on the effectiveness of the 
massage? If not, did this improve patients’ understandings of the pressure required? Did 
patients have any other questions/concerns about performing the massage themselves? Since 
you have been carrying out the follow-up calls, how have patients reacted to the intervention 
treatment?
[Any anecdotes or details mentioned during first stage.] 
How has this compared to the reaction of those in the control group? Are you still planning to
show the ones in the control group the massage at the end of the trial?
Did patients find the rest of the materials provided (DVD, training manual, guide and leaflet)
to be helpful and informative? Have patients had any issues playing the DVD or accessing 
the videos online? 
[Any information provided during first stage.] 
Last time we spoke, you said some patients were a bit concerned about completing their 
bowel diaries properly. Did this continue or what were the reactions of the four other patients 
you have recruited since then? 
How did you get on with the 24 week calls? 
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I will now move onto any larger changes that may have affected the delivery of the trial.
Have there been any changes in staff involved in delivering AMBER in the past six months
(e.g. staff leaving or joining the AMBER team)?
What impact, if any, have these changes had on the delivery of the AMBER trial?
Has there been any substantial funding or other changes to your organisation since we last
spoke?
3. Problems mentioned during first stage 
Mention any problems discussed during the first stage of interviewing – were these resolved? 
Are there any other ways to improve the AMBER trial, particularly thinking in terms of an
implementation study?
4. Implementing AMBER long-term 
Considering your experience with AMBER, do you think it would be possible to implement
this as a form of treatment in your centre in the long-term? If not, why not? If so, what
additional resources would be needed (staffing, funding, liaisons with external stakeholders)?
Overall, based on your experience of delivering the trial how do you feel about the process of
implementing AMBER in the Walton Centre (i.e. challenges involved, what was successful)?
DOI: 10.3310/hta22580 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 58
© Queen’s Printer and Controller of HMSO 2018. This work was produced by McClurg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
APPENDIX 12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
DOI: 10.3310/hta22580 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 58
© Queen’s Printer and Controller of HMSO 2018. This work was produced by McClurg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131
APPENDIX 12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Appendix 13 Summary of ‘yes’ responses to
questions asked during the weekly telephone call
(weeks 1 and 24)
Outcome
Time point, trial group (% of yes responses)
Week 1 Week 24
Intervention Control Intervention Control
Diet changed 13.4 19.1 13.1 18.1
Fluid intake changed 20.4 27.7 15.5 25.1
Defaecation position changed 25.3 27.7 9.1 8.5
More exercise 15.1 18.1 12.9 18.8
Concomitant medication(s) changed 5.7 9.6 15.6 14.9
Use of laxatives changed 13.8 16.0 9.1 15.4
Bowel habits changed 49.4 38.3 42.9 30.9
Bowel habits (more often) 35.6 24.5 29.9 19.1
Bowel habits (less time) 6.9 4.3 18.2 6.4
Bowel habits (less hard stool) 20.7 5.3 20.8 14.9
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